var title_f36_15_37104="Vitamin A and vitamin D: Drug information";
var content_f36_15_37104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin A and vitamin D: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F14852066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F14852067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/23/371?source=see_link\">",
"       Vitamin A and vitamin D (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/21/13650?source=see_link\">",
"       Vitamin A and vitamin D (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Gordons-Vite A External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 unit (120 mL): $7.60",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10310 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-2CE9AB38EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37104=[""].join("\n");
var outline_f36_15_37104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/23/371?source=related_link\">",
"      Vitamin A and vitamin D (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/21/13650?source=related_link\">",
"      Vitamin A and vitamin D (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37105="Patient information: Heat stroke (The Basics)";
var content_f36_15_37105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16341\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heat stroke (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heat-stroke-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11692947\">",
"      <span class=\"h1\">",
"       What is heat stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Heat stroke is a condition that can happen when people&rsquo;s bodies get too hot. Most often, heat stroke happens when people exercise in very hot and humid weather without drinking enough fluids. But heat stroke can also happen in people who are not exercising.",
"     </p>",
"     <p>",
"      Heat stroke is a medical emergency that needs to be treated quickly. That&rsquo;s because heat stroke can lead to death if it is not treated quickly.",
"     </p>",
"     <p>",
"      When people get too hot, they can also get &ldquo;heat cramps&rdquo; and &ldquo;heat exhaustion.&rdquo; These conditions are not as serious as heat stroke, but they can lead to heat stroke if they aren&rsquo;t treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11692962\">",
"      <span class=\"h1\">",
"       What are the symptoms of heat stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with heat stroke have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A body temperature of 104&deg;F (40&deg;C) or higher",
"       </li>",
"       <li>",
"        Brain symptoms &ndash; These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Confusion or trouble thinking clearly",
"       </li>",
"       <li>",
"        Seeing or hearing things that aren&rsquo;t real (called &ldquo;hallucinating&rdquo;)",
"       </li>",
"       <li>",
"        Trouble walking",
"       </li>",
"       <li>",
"        Seizures",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Heat stroke can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fast breathing or a fast heartbeat",
"       </li>",
"       <li>",
"        Skin redness and warmth",
"       </li>",
"       <li>",
"        Vomiting or diarrhea",
"       </li>",
"       <li>",
"        Muscle cramps or weakness",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11692977\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you or someone you are with has heat stroke, get medical help right away. In the US, you should",
"      <strong>",
"       call 9-1-1",
"      </strong>",
"      for an ambulance.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11692992\">",
"      <span class=\"h1\">",
"       Is there a test for heat stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will do an exam and take your temperature. He or she will probably do other tests to check if the heat stroke hurt other organs in your body. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Chest X-ray",
"       </li>",
"       <li>",
"        Electrocardiogram (ECG or EKG) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"mobipreview.htm?6/63/7154\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11693014\">",
"      <span class=\"h1\">",
"       How is heat stroke treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment involves cooling your body down. Your doctor can do this in the hospital in different ways.",
"     </p>",
"     <p>",
"      Your doctor will also treat any other problems the heat stroke has caused.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11693029\">",
"      <span class=\"h1\">",
"       Can heat stroke be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. When it is hot or humid out, you can do the following things to prevent heat stroke:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Try not to be too active, and take breaks when you exercise.",
"       </li>",
"       <li>",
"        Drink plenty of fluids, especially water or sports drinks.",
"       </li>",
"       <li>",
"        Do any exercise early in the day, before it gets too hot out.",
"       </li>",
"       <li>",
"        Wear loose, light-weight clothes. Don&rsquo;t wear too many layers.",
"       </li>",
"       <li>",
"        Avoid being in a hot car.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also watch for symptoms of heat cramps or heat exhaustion. Heat cramps cause painful muscle cramps. Heat exhaustion can cause headaches, dizziness, nausea, or vomiting. It can also make people thirsty or tired.",
"     </p>",
"     <p>",
"      If you have symptoms of heat cramps or heat exhaustion, you should cool your body down right away to avoid getting heat stroke.",
"     </p>",
"     <p>",
"      To cool your body down, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Move into the shade, or go into an air-conditioned building or car.",
"       </li>",
"       <li>",
"        Take a cool shower or bath.",
"       </li>",
"       <li>",
"        Drink water or a sports drink. Do NOT have a drink with alcohol or caffeine.",
"       </li>",
"       <li>",
"        Take off any extra clothing you are wearing.",
"       </li>",
"       <li>",
"        Put a cold pack or cool cloth on your neck or armpit.",
"       </li>",
"       <li>",
"        Spray yourself with cool water and then sit in front of a fan.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11006194\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/15/37105?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16341 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37105=[""].join("\n");
var outline_f36_15_37105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11692947\">",
"      What is heat stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11692962\">",
"      What are the symptoms of heat stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11692977\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11692992\">",
"      Is there a test for heat stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11693014\">",
"      How is heat stroke treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11693029\">",
"      Can heat stroke be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11006194\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37106="Patient information: Electroconvulsive therapy (ECT) (The Basics)";
var content_f36_15_37106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/5/4178\">",
"         Patient information: Bipolar disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/55/39796\">",
"         Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/21/29013\">",
"         Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/50/37664\">",
"         Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Electroconvulsive therapy (ECT) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/electroconvulsive-therapy-ect-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1568333\">",
"      <span class=\"h1\">",
"       What is ECT?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Electroconvulsive therapy (ECT) is a safe and effective treatment for severe depression. It is also sometimes used to treat other forms of mental illness.",
"     </p>",
"     <p>",
"      During ECT, a small amount of electricity (called an &ldquo;electrical current&rdquo;) is passed through the brain. The current causes a seizure that affects the whole brain. This causes chemical changes in the brain that relieve severe depression.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568340\">",
"      <span class=\"h1\">",
"       How do I know ECT is safe?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before giving you ECT, your doctor will make sure ECT is safe for you. He or she will give you an exam, ask you about your medical history, and run tests. For example, you will probably have blood tests and a test called an \"electrocardiogram\" (ECG) to make sure that your heart is healthy enough for the treatment. These tests will also help the doctor make sure that there is no other medical problem causing your depression.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568347\">",
"      <span class=\"h1\">",
"       How many times will I need to be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Every person is different, but most people need a total of 6 to 12 treatments. (Some people need fewer. Other people need more.) The treatments usually happen 3 times a week &mdash; Monday, Wednesday, and Friday.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568354\">",
"      <span class=\"h1\">",
"       What should I do to prepare for each session?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You must not eat or drink anything after midnight the night before each treatment. If you smoke, do not smoke the morning of your treatment, because smoking before the treatment could cause problems during the treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568361\">",
"      <span class=\"h1\">",
"       What happens during the ECT treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you get the treatment, a doctor or nurse will put a needle into a vein in your arm (IV). That way, the medical team can easily give you the medicines you need before and during the treatment.",
"     </p>",
"     <p>",
"      You will be asleep during the treatment. But the medical team will start getting you ready for treatment while you are still awake. The team will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Place devices called &ldquo;electrodes&rdquo; on your head, so that they can measure the electrical activity in your brain. To do this, they will use a device called an EEG, or \"electroencephalogram.\"",
"       </li>",
"       <li>",
"        Place electrodes on your chest, so that they can measure the electrical activity in your heart. To do this, they will use a device called an ECG, or \"electrocardiogram.\"",
"       </li>",
"       <li>",
"        Wrap a blood pressure cuff around your arm, so that they can check your blood pressure during the procedure.",
"       </li>",
"       <li>",
"        Put a small device on 1 of your fingers called a \"pulse oximeter,\" which measures the amount of oxygen in your blood. This will tell them if you are breathing normally.",
"       </li>",
"       <li>",
"        Give you oxygen through a mask or a tube that rests below your nose. You will get oxygen throughout the whole procedure, until you wake up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When everything is connected, the medical team will test the ECT machine to make sure that it is set properly for you. Next, a doctor or nurse will give you a medicine that will make you go to sleep for 5 to 10 minutes. When you are asleep, you will get another medicine to relax your muscles. This will keep you from moving during the treatment.",
"     </p>",
"     <p>",
"      When your medical team is sure that you are deeply asleep and that your muscles are completely relaxed, they will give you the ECT treatment. You will be asleep, so you won&rsquo;t feel any pain, and you won&rsquo;t feel the current or the seizure. If you could watch yourself getting the treatment, you would see your toes wiggle or other parts of your body move a little&mdash;but not much else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568368\">",
"      <span class=\"h1\">",
"       What happens after the treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you wake up after treatment, you might feel confused. This is partly due to the medicines you got and partly due to the treatment. In most people, the confusion goes away within an hour. You might also have a headache the day of the treatment, but you can take a pain reliever, if you need it. Other side effects, such as nausea, usually last only for a few hours.",
"     </p>",
"     <p>",
"      You might have trouble remembering things while you are in treatment. This memory loss should slowly get better by itself over the course of several weeks. But you might never remember many things that happened to you shortly before, during, or soon after your treatment.",
"     </p>",
"     <p>",
"      To help improve your memory, use your brain. Read, ask questions, and follow stories on TV. This is the best way to help your brain get back to normal.",
"     </p>",
"     <p>",
"      Because of the way that ECT affects memory, you should avoid making any major decisions until a week or 2 after the ECT treatment is finished. You should also not drive during your course of ECT.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568375\">",
"      <span class=\"h1\">",
"       When will my depression lift?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people start to feel a little better after 1 to 4 treatments. But many do not get the full benefit of ECT until they have more treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568382\">",
"      <span class=\"h1\">",
"       Does ECT have any risks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Like any medical procedure, ECT has some risks. In rare cases, ECT can disrupt the heart&rsquo;s rhythm or cause other problems. People who already have heart disease are more likely to have these problems. If you have a heart condition, your doctor will take special care to monitor your heart. He or she will also take other steps to make sure the treatment is as safe as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1568509\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       Patient information: Bipolar disorder (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/50/37664?source=see_link\">",
"       Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/21/29013?source=see_link\">",
"       Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/15/37106?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16272 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37106=[""].join("\n");
var outline_f36_15_37106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568333\">",
"      What is ECT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568340\">",
"      How do I know ECT is safe?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568347\">",
"      How many times will I need to be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568354\">",
"      What should I do to prepare for each session?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568361\">",
"      What happens during the ECT treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568368\">",
"      What happens after the treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568375\">",
"      When will my depression lift?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568382\">",
"      Does ECT have any risks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568509\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/50/37664?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37107="Mycoplasma pneumonia CT";
var content_f36_15_37107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Mycoplasma pneumonia with patchy ground-glass opacities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) High-resolution computed tomography (HRCT) section at the level of the middle lobe bronchus demonstrates ground-glass opacification of the right lung and superior segment of the left lower lobe in a patient who had proven Mycoplasma pneumonia.",
"    <br>",
"     (B) Follow-up HRCT at the same level as in (A) shows only minimal residual ground-glass opacification.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Infections. In: High-Resolution CT of the Lung, 4th Ed, Webb WR, M&uuml;ller NL, Naidich DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37107=[""].join("\n");
var outline_f36_15_37107=null;
var title_f36_15_37108="Cetrorelix: Patient drug information";
var content_f36_15_37108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cetrorelix: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/3/22580?source=see_link\">",
"     see \"Cetrorelix: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetrotide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cetrotide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10014620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug if you are pregnant. A pregnancy test will be done to show that you are NOT pregnant before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cetrorelix or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor kidney function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store vials in carton.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store 0.25 mg vials in a refrigerator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699326",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store 3 mg vials at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11966 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37108=[""].join("\n");
var outline_f36_15_37108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148948\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014620\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014622\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014621\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014626\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014627\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014629\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014624\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014625\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014630\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014631\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/3/22580?source=related_link\">",
"      Cetrorelix: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37109="Carvedilol: Patient drug information";
var content_f36_15_37109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carvedilol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     see \"Carvedilol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/63/40952?source=see_link\">",
"     see \"Carvedilol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coreg CR&reg;;",
"     </li>",
"     <li>",
"      Coreg&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Carvedilol&reg;;",
"     </li>",
"     <li>",
"      Ava-Carvedilol;",
"     </li>",
"     <li>",
"      Dom-Carvedilol;",
"     </li>",
"     <li>",
"      JAMP-Carvedilol;",
"     </li>",
"     <li>",
"      Mylan-Carvedilol;",
"     </li>",
"     <li>",
"      Novo-Carvedilol;",
"     </li>",
"     <li>",
"      PMS-Carvedilol;",
"     </li>",
"     <li>",
"      RAN&trade;-Carvedilol;",
"     </li>",
"     <li>",
"      ratio-Carvedilol;",
"     </li>",
"     <li>",
"      ZYM-Carvedilol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701731",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carvedilol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very bad liver disease, slow heartbeat without a working pacemaker, or wheezing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having cataract surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry eyes. Using artificial tears may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11802 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37109=[""].join("\n");
var outline_f36_15_37109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146697\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146698\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021811\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021813\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021812\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021817\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021818\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021820\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021815\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021816\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021821\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021822\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=related_link\">",
"      Carvedilol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/63/40952?source=related_link\">",
"      Carvedilol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37110="Iliopsoas bursitis CT and MRI";
var content_f36_15_37110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Computed tomography and magnetic resonance imaging of iliopsoas bursitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 398px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGOAkcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUchYho2Ofnbv0A4oA9W/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6uK+F3wc+FvxJ0y8vNB1HxhCLSYQyw3ctskgyuVbCxsNp5xz/CeK+YdrYztOPpQB9p/wDDVfgf/oFeJP8AwHg/+PUf8NV+B/8AoFeJP/AeD/49XxXSUAfav/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8VU4Kx6KT+FAH2n/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49Xxpa2F1duEtreWVj2RSx/Suy0X4a6tcqk2q7dLtD/y0uQQT9EHzH9KAPpoftU+CGOBpPiUn2toP/j1a2jftDaBrcwi0rwz4sumP/PO1gx+J87ArwLT/AAz4c0fYILKfVbkdZrz93D9VQcn/AIEa07rVr4KiicQbBhI7dQiqPp0/GgD324+NWm24HneGvEKZ9Wss/wDpRVV/jzoqY3+HvEQ4zyLTp/4EV83X7XBTJuGcPyrF91LJ5cmmoscyLOr/ADNI2QR3x7CgD6Jj/aE8PyH5PD3iZu3EVt/8fq3H8ctKkQOnhnxMVPQ7LX/5Ir55i1HT40jjS5lEaD5wVA8w+tNF7bKF2XTG2zvVH4w3oR3HvQB9FP8AHDS4498nhjxMi/7aWin8jcU2X456TEQJPDPiUf8AAbTH/pRXj9t4jjaG0X7OszREM0wG5sdOnb6Vhz6pdzSSbIrx0aVm+WI8AdBjsKAPer747aPYxJJd+G/EkaOcLlbQn8hcZqpD+0P4dmz5WgeJGxzxHa//AB+vCXhuIJBcTIYZC2Skylu3cVnSXccsrLcQRoqfMT5fl5HrigD6Hk/aG8PxnD+HfFA4z/qLfp/3/q9a/HHS7vT/ALfB4X8UNZ/89THagfrPXzLJqVgLZZILN58Hl/MI2/UelWrbxPezwpCllLJZRHDRpK2WzQB9GxfHfRpWZYvDviJnXqgFpu/AfaMmsS8/ae8IWUzQ3eh+KYZR1WS1hU/+jq4IeEY7pLaeGCWITrkx7gdoI9fWuQ8S6XqOkv5Wr6eL3Tj8oMh3qvsD1WgD2X/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+f/wDhA9H1ZEktJ59Mkc48uQiVQfTsaRvg1qb82uq6bKp7szR/zFAH0D/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fOz/B/WVOP7Q0gn0Fz39Pu1A/wo1aNgHvtOBIzxKTx+AoA+kP+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq+f7D4MateR701C1C5xny35+nFXo/gVqbE51a0XHXMT9fT60Ae5f8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1eFXPwM1aMkRalaSkDoFIrK1f4Q6zp8CSC6tZS38HzKR+lAH0V/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fIOr+HdU0kk3tq6oP41+ZfzFZNAH2p/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB+knxQ+IGlfDjQLfV9ct76e2multFWzRGcOyOwJDMoxhD39K8w/wCGq/A//QK8Sf8AgPB/8eo/bW/5JZpX/Yai/wDRE9eJfDH4d+ENW+EOueNvF9xr6ppl8bZotLeEFk2w4IEinJ3Sn+IDA/MA9t/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMerkPCPwQ+HfiTXL/R1k8b6dqVlBFcyQ3k9mcxyDKMGiV15HYkH2r5ZoA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4rAzWvoPhvVteukt9KsZ7mVjgCNCaAPr3/hqvwR/wBArxJ/4Dwf/HqfH+1N4LkP7vR/EzfS2g/+PV5j4M/Zp1m8WOfxDdQadGeTGf3kn5DivXtD+AfhHT41F215eyDr8/lqfwFAFdf2mvCbDjQ/FH/gNB/8epD+034SHXQ/FH/gNB/8ers7X4XeCrYAJ4etXI7yEsf51bHgPwhHwvh3TQB/0yoA4A/tOeEgMnQ/E/8A4DQf/Hqhb9qXwYn3tH8Tj/t2g/8Aj1eiSeAfB8y4k8O6af8AtniqFz8KvA1wMP4etFJ7oSp/nQBw5/aq8EDrpXiX/wAB4P8A49R/w1X4I/6BXiX/AMB4P/j1bOpfAbwHeBtthcQMehjmPH51x2r/ALMnh+YMdO1a8t2xwJEDDNAGx/w1X4I/6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49Xk/iD9mrX7RXfSdQtL1R0Ukox/OvLfEvw+8T+HGb+1dIuY0H/LRV3J+YoA+qv+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq+K2BU4IINJQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8h+DdAufFPirStDsR+/vrhYQ3XYCfmY+wGSfYVufGLwYfAXxB1PRE8xrNGE1o7nJeFxlcnuRypPqpoA+/wDwF4rsfG/hOx8Q6VFcw2V55nlpcqqyDZIyHIUkdVPfpRXFfsuf8kJ8M/8Ab1/6VS0UAYv7W2mPrHgLQ7GORI2l1pPnc4AxbXDH+Vcl8KvBusX/AMCvF/hTw3fWcd1c6wYJLm4Lqgia3tmkxhSSSpK49zyK9T+NyxtbeEhMqtH/AG0chun/AB5XWK8+vtC0C9uDcXujaVNO+A0k1pG7sAMDkjJwAPwoA7XwJ8MtQ8D/ABCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXhfguz07UND0WJ9Nhk/0OPdIqoS7BBnj1z613C+EvDhfKeH9HIAww/s+L9PlqHW7O00m1t7/TYYYJLQqojjQKuzptxxxigDHufhZ4d1FvtF7ayWjNzthdR+OBxSr8IfDCkC2idwOpkckn8K7bTryC/sYbi2njeKQZ+XoPUfWrS7lODtXuDmgDyPXvA2maEqySaRbyQk4V8MQT/dbng1StU0qHYU8PWS/MFy0GRj1yTXqPjWJJPDlzFOyoHwu/dt2mvPNJt3h/cSOtyZ2CxuX+UY6n60Abd3cSWNpDPamCGORtoht4xCWI/iyOtQa+NH/smK5n1lG1V3yEUFmUehHatTxjbJe2bz3TRebHEI1WFtwjx1JxXM3mkSxJY/2bYmeeQZmliYN9M56fjQBUsdBmv7fcLjLlshBy5HrjtT5vBt+hbZaRqzAYeZ8H9a9J8M6SunwK80RkuZOTISCR7U/wAT31rBABPAZTnBixk49f8A69AHmdh4N1fzAENsMHgq4bBpB4XluNWTTr97AMylisOSwP4dPWo9a1PVLi+ms7CI2SRHKi2Yglf97vU/he6n8LvcX0unyTyzqFYuwJHfhvegDaj+GNrOB9pvpBGoARY1w/vkmrsXhHQtP1CNfsodWBkLzEuWPp6DFYtz8UpUBS20Xax+7JLLnB+gri/EGv67q9y/27fGrnBjjUqlAHrcOpeG7G087zLWCEv5bHGNj+h9OlV7LxFos9/9pTUYUnmYRxr5oBdeg+X1zXB2mlu+m3EFlYS3AjKm4kuvl3sQMbR1+lUbDR7axju7rVrO4WLlYFVSZFb+97DPegD3Fhyg8sFu+Pm/OoLuxtb9HS8t4mUjq6jOa8Ts/FOvaXFDJBd3H2cE7RMmdw+pHSnaz8RNd1OxNqTbwKww8kS4cj2Pb8KAOs8VWllpdsH03SFAkyrTZxjnpj3rkLuNtPnV7ZDAkiZLIdw3EdR/tCtrwtqLaroM4u189rGPDhmOGToCc96wpHZxcuxkEIPCu3zZB449KAPY/CeoQ6lpVnunMksSBHjHVWA/r1zWb4xg1Q6bMY4RdQkg/KBvUd85/pzXCaSNSWC3mHnRAtkMvyjGep/p3Ner6TcyXMA88GTYNrF1+8R7UAeQW8iLOiQW80MjMEbnncf5D3rtLrXZ7rTIrS5WFEtiPMljTiQjoMnrXc3Fjaz2xEsarngYGwZPpispvA9lZTA3Ml0tzGQyo2NoPUcHrQBjRwqunCW4Ntd3NwvFt9wjPT8cVzNvCulavDbTqYkd8yo8m7YPcV2JsilrNpk6NcNt82O9Y7XOW6e2K0NN0CytELtCjyv8ztJ8xHsPSgDYimjEMawFfIVQQUPUe1K0wYHC7VU4xxxVOSztHKsYiWUBVKsRt9hiluXkit3wHmVFysIIDP8Aj/jQBHqWpxWDW0Kr5k9w/lxxIwBbuT9B3rF1rRNau7wT6fq8VifZN2eeQR3FcxYXN0fiCl7d2MkIWMQqjuNsKt3r0J5nZ1YEMvs2f5UAc9qPhU3tkqNOs2orkmbGFJ916EfWvKvF/wAOwpJkij066P3Z1P8Ao059D/zzb8x9K918xnYouVXPUjG4U+dba5ha3uIopoG4KSLkfrQB8Z6pp11pd29tfQtDMnVW7j1B6Ee4qnX0l478GwTWZS5L3GlrzHOo3T2RPoB96P8A2a8C8RaJdaFqDWt4o5AeORfuyoejKfQ/p0NAH2B+2t/ySzSv+w1F/wCiJ64/4DeGbzxl+zP4u0DS5beK8vdWZY3uGZYwVS2Y5Kgnop7Guw/bW/5JZpX/AGGov/RE9fFVAH6BfDf4f6l4d8Z3WtTW+j6NYSabHY/2Xo8jPFNKrAm4kJjjAfAxwvQ9fX8/aKKACiirNnY3V5JstYJJW9FUmgCtRXX6b8PtcvQrG38lCQMycV1dj8MLK2wNY1CRpuvlW6Z/MmgDyapIreaU4iidz/sjNfTngj4UmfQtN1W38MaBcR3tvFdR/bNXmLBXUMAQLcgHB5wTXZfDu/8ADmrabYyWmjWlhNNbpN5WwEDcoOA2BnrXHhcww2MlKNCak4726b/5MqUHHc+TNP8AB3iHUCv2PR72Xd0IiNdx4e+BHjHVWU3FmljETy1w4XH4V9dwbIlOwhFHQU0XsrtIFDDa2OeRj3rsJPK/BX7PPh/S2SbxBcPqc458pPkj/Hua9r0TTtO0e2FvpFjbWcK8YhQLn8epqvHcN5W/gAjDCqd7qMka/unVW9+lAHUCUY7mjz0Bxk1ywvNQaNCkoy3txV+C3uXIknnYkDovSgDbMquD8+B9aQzRA48xckcc151qravdahLFbQ3Kqp28cCr2m6DqSust1KoYEfLvzkd6AOkv9ZsoYyZJV2A8kHoaW11mxnjkZJVKoAW55FYGoeE7KbyctIGEm6UBuCp6/wBKY3hZbaMxW1yywMPmHVmPqT+VAHTf2natnEy+uSaUXayDCSBsV5Bqg1HTZ5Fu4LhAv3SBuXHrVzw3quoajeR29qxJH3nKkBR6mgD02aSQDGFHes6dwFdZ0EsbHJVhkVHchhlDOc4zn1xWfdXHlaPM0x3SRZOc9fSgDjPGPwx8G+L/ADDHAlhqH/PW2wpz7joa+e/Hnwc8ReF2kmhiOo2A5E1uCSB/tL1FfQVleLdXCqD5LPysg6g119jfvJaKLjlsYLeuKAPgN0ZGKupVhwQRjFNr7S8VeCvDGvt5l/pMLzN1lhGx/wBK881b4HaBKzGxvry19mAcCgD5wor2rUPgJqSfNYarbSr1AkUqa5PV/hT4n03JNtFcKO8MgP6UAcDRWjeaJqVkxFzY3EZHXKGs9gVOGBB96AEooooA6f4feMr7wLrUur6Pb2kmpeQ0EMtwhcQbsZdRkDdjI5yMMeK6v9oTxlfeKPHep2OqW9pv0XULyyt7mJCsjwCYhEfnB24OCAPvHOa8trq/ix/yVPxl/wBhq9/9HvQB9qfsuf8AJCfDP/b1/wClUtFH7Ln/ACQnwz/29f8ApVLRQBc+Nxxb+EiGCn+2jyRn/lyuq4g5BRS6PIW3YUdB/Su2+OGfsvhPapYjWTwMZP8AoV3XnmoahLaeXNcQTW0eQPMUggk9M0Aa4lVSoy49Oao69pb61pz2jzGONudyAbuOlXISWU8hgeclsZ96nKDdnccjpg9aAOR8KW83hq7fSdUlURXDl7aTjt97K9q62a6it0Lpum9ox1Prz0qB9NtV1RdQli33Zj2fMd+1fQDoKbrV5/ZeiahqSRBVtLeScDnHyKWx+lAHKa9Zazq7CTUrXyYl+5EuGUr74/nWLpmjzq13dm1urjR7T9zc3UKh/skh5IC9XCDG8rnGRwcNt7WO71TW71fD9rb3Wm6vIv8Apomi4sYu8ivja+eiY6nk/dYDvtQutL8A+EoY7aA+TCBBaWqH57iU9FyerMcksfdj3r5TOuJVg506GCSqVJ203Vn6dX0+/sb06PNdy0R4Xr2jzWV9baqLuK70lo0kia3bCyjsCOjA+tO1XUI4dl5ZJLp1yxDFlXEc/HQivVNCstEtPC8lmLmx1G/uLxtQvFtFBhgmbqka4+VRgD1OCx5Jpmq6fDqFqIpUhYDlSFG4EenpX1MG3FOSszA5rw74vg1KwIcIt6FOApyrcdjXA6rNP9qF3fXcqXBbZsYk4HoQD0rc1vTNI1DU2TR5YbbUIgBPDgKvB659azfEcUEC20c+8HB/ebcsfXmqAxJ7xUJMUrEODgc+tZcN3MLlsurjGWQZ2gep7UOYkYlJTI4IBZo8g8e1WPKkg06dlH+tPy/JncO+D6e1AFVZ5ZJYkihZ2L4UBckjsAK9X8HaHc21jFPqwSF2GfLKhmQdgT2qPwP4aTRrJNV1FBJqM4DRrwfJyOx9cda3ZDJKd0hLrkcDgg0ATi9tkZQkYZic8jk+/wBaU3qOxD26cEdQCMe9UFiUD92oAJJwRmnFUjiJC4THAHBH070AW5n0+4j8qazEiPwybBgj+grmPEfw/wBK1ffLpuyxuRyFC/K3HQjtW2FDdmIPBJpyMImDgYbqPegDgNB0WbQ7qe0ukEEssDpIjAlZ+4YHvRY6baC+e61SJhBDEPLhDEKc9D7njpXomtWzanpPm7hHcRkkSBSSD3+lecapdrc3slvA3m3axiEhBkOFPBA7e9AGnNey6rbp/Z8iW9tFxvlO0I3fHqRXoGkrZ2Vla2lvIWVUHzNlmY9SeepzXkGm6NezataR3MckNsrgOWAC4z0+pr1e98jTDbOEEa7sH5uAMe3T6UAapjR5FEiEsT1b+npWO3iK4fVLuOa1uZlD7I5l+YPjjaM85/pWj5yvGfs7gswHK1ALCBJFbzZBInQKeAT1oAS1drqWR7tgkiHDLHnA9AKuYViQuRj1NVpriJJkhWGRxISRtUnkdSfapY7mKYBV3eYBkpjbj8KAJABkKH3cZOeAD7UxRvkwMBfbillX5eUYkngbqrTSSReWYYt53DIDdB/WgCnqlhDfzhxb4ntyBHISfyx3FWrdNkQeTgkHOeMVHaSKDcSLkkzNkuelQ2ULQW2yeQSsWL8c4yehz6UAJfXaLbuVZSzfu0Kno5+7WH4QudaihktfFMUomjbEVwqgrKvoSO9bi20OHMUEaxuwY54yaeJmUFNqhl6sen0FAFiFyr/Ku5ZCFVep54xgdzXl3xU8P2n9lahb3DbfIjkurRtnMDqCXjz/AHWwRj+9g16Hb2sK3LXKxsbk8bg5AXHp6H3rl/iRpa3fgTVLi2LtLBG8uA5+6FIYHPUAZNAHa/trf8ks0r/sNRf+iJ6+Kq+1f21f+SWaV/2GYv8A0RPXxVQAVPaW015cJBbRNLK5wqqMkmm20MlxPHDCpeRyFVR1JNfQfg3wvZeB9JivL2NZ9bnXhTzsz2H+NAHMeGfhVHbW63nimcQ5wVtlPJ+pr0bQLPwwlt5aSiyRf+WaLhvzrHuJLm9uy1226Rvugn7n0FVyuDubO1eOnJoA7W6Se80SKTRpkmSFmVzt+ZueD9cVyUjvHcFZy4lzggjBJq9pWtzadbSJEMbuQKzNP8RprPjeDT9Z1C8sNPlHkNNaRwfu5CQEdmkjchSTtOMYyp6ZrKvWVCnKrJNpK+mrGld2Pfvhj/yTXwn/ANgi0/8ARKV438OrvSbDQdCnu47iadbOHnOFGUFe96DpkOi6Hp+lWrSPb2NvHbRtIQWKooUEkADOBzgCvnfXNHtPD/iWPR9A1fU7qx02ERXRujC6b9o2xKVjU5VeWOTyVHrX51wTjKbxmIppNubTWnROW/bdHXiYvlT7Hq82rW11aO1tHvl3YQBvvA96mtr+ztVAuJJ4wwGWXnn3rzzwvMw1BLcFfJkYNuJwFPf863NRXUFv2tbi3bynOQ69APQ1+lHGdtNcuUEVhdI+4ZCyDr+NZltb3v2wfbEKD1zmqdnbSwWcjCQmSFSwU9x6V0toz/YbcXWHO0ESD+L0P5UAXbZCiIUIZCetOvNYitTtL8j0qld3vlWJIxgdCK4PWNVCu2+QA0Addf8Ai1YOnJPQ1lv43I3KGXcO9ecXd887FjIcdPwrKuLtI2YHO49PagD0+XxyFB+ZiT3JqzZeOBIdryg56Zrxya6VgGZjweOaYb5YzvWQjvjPOKAPf7bxXby4WYLtPGDyK1rW7tHU/ZxChYchQBmvm2DW2JURznrwDXU6L4mkiZfOkDDsQaAPWCftGoTJI5Vo9u0f3h3NLdSQiN0kAIfqprAttTTUIVdWxKRwQeeamETGTcz5z0zQBk38FtaTiZVIIOVVO/0FTQ6y8D7Dbhc/xMaj1dhGywwEmduDIfU9hXMT2E9uZgZmcnIGTnHvQB1UmsRuwUTxvITwq8VE87tc7JZG2kfKK4ddLuopimxUVhvLu+NlM1fXTva1sp/MkZVSS46dOy/40Addrt5KdOZdOdZbpeAu/Bx6CvPLqe9SZhdNcRTE5IZj+lZ7BfM3BmWQ8hlkO7NPmu7iRBFLcmdRjBfr9M0ALLdTyIwlnYhR1YZwBWenh59YnVH0+C4RzksU8s/ge9dV4b0/R9RhSZr0zR7iJLdjgxuOdv0qLxTqN0NdVbWURrAoEUcQwFB/mcUAcH4i+Fk6q8uiM7SAnNpMMNx12nvXmVzBLbTvDcRtFKh2sjjBBr3Nta1W4kieS5LSRZMYxg+9J4m0Kz8f2MslnGlt4jto92OgnX0/+vQB4RRVl7K4S/8AsbxMt15nleW3BDZxjn3r0z/hnz4n/wDQs/8Ak/a//HKAPqr9lz/khPhn/t6/9KpaKt/s5afdaR8HtF03UIvJvbOa9t549wbZIl3MrDIJBwQRkHFFAC/G7/j38Jf9ho/+kV1XEahardLHHdRho1cEoy8E123xvG618Jjj/kMnr/15XVcdG7NdLGuTHGuXCjoT04NADrCFIrdURNwXP+8KknL24RbZGeU8heoIrnJtQv7XxC2mwRiUXZ8xHc8QqOpI7V1EcYs7XcZG9ck5DGgCXcZE/eQAk8kKSP5Vi+NY1fwrqcKkjzojDtfOTvOzn25qS41KQ5QlYVzwAck/U1S13+0L3STFZ+VLOJoZY1uJCI/klRzkgEjhT0BqKnNyPl3BHs+BknAye9eM+PStz46ex8VgJHcxGHRQko8vaQPMPqJieOQBtAC5+bOjfSeI9UXfqWuvDbSAFINJX7Op9jIS0mfdWWq+n6La6bbTS6Ylrb30ilWuGj3yMf8AakbLH8Sa+F4a4WxGXYhYrESje1rbtX89En9+mh1Vq6muVGV4H8PT6J5tw0pBkBUwHnKg8Hd610V7q9laW00rzRoyAkoSQfpjvTrYkxo7yLHhQMhsBj3OKo32lS67q9oIrGa9hAImkhiJHtz2NfenKeM+bcvfyXEEBfz5Tsw20k56GvTXjuta0e2truwiTj53OMxn2rvbfwRdoFMdlaQ4OQzFc/p3rSg8GTXEobVLnZCCCY4HJaTHYt2H60AeYL4DFvogv3jxEj4LBtoPYfnVDw9oX2nXhdX1uot7SICNC25c+o9DXb/HDXY7WGy8PWOBKsYupIUT5QmdqD+ZxVTRLAafolvbhtsrjc5yOWPJ60AF1cpNJ8gbC8LGvP61X3EnAjZs9M+tXwkZB+Uk9CcgflSbULAlvYsw6fSgCkR97zEYSf3d3A/EUIFGCoAJHU8nNXFhcH5hIRj0zj3pwjO4tvUlerMOP/10AUQh642rnkHrSc5BLqhJ/i/pV1o1ZgNz57OaUKFYlpCGxjIXcQP8+lAEVijtBcKVATGMnqD3JrzrULiy0DXoLiCxc2sB/fTBgXI7sB6V6ZbgmJ484yuAQScn3rN1jTLHWNOSzuosSDB+XCnPp6nNAHdXnhqLU9Nt7vSLmGSKeNJlWRMLKCMhgw6Gsz/hBLy4uFa5lhAC4yX3AewFVfhv4ji0zUk8H6lMiELv015HHzA9Yfw6r69K6nxhql9plvJ9jXLkKU4xx0YZ9fagDA0/wPqsV9dNLJYxwyNmMxsScY7jFaM3hG/UfJPbOo6KMpn656muXk8azlDGLqUEHEyOwBU+xNdZ4Re7vXW8W/eS2jO2QSDO4Yzt9j0oA5qTSb21bF4lzaybywBGVcdhuqsJInBWWMxzbsAbxk++a9ZtZZZYA08BgY8GJmDY/GkaytJCS1nbMT1JiFAHj0kswcKksbFSQ2Rzz2zSG2unniddoROu7ktXq0ugaRICrafboCMZjyhH0I715z4g0iXRtVkjtbz7Rbn5l3ABlB/hbHp60AYOsLdWdpcXekWyzXMQLNG5PzgdvrTPC2o3GqaPHd39vHFcMxzGOg9K3obyOTEbbVY9s8GqDwLZXLTRnZBKfnCj+L2FAD55RGuZMsevC/0oWUEIwHXuop7udjBR5e7gHbkn61Q062FvGVQvKcndk8ZoAteZ+8cF2cj+HJA+grG8Zlv+EM8QAgf8g+4OAOn7tq2JWZQz4jXjk5xgVg+MN7+CNbYcKbC4PB4P7tqAOm/bV/5JZpX/AGGYv/RE9fFVfav7av8AySzSv+wzF/6Inr4vtYmnuIokGWdgo/GgD0z4JaDHLqNxrl+n+i2KkpkcF8cflXd397Jf3ZvJwShOEA7D0rW03Rv7P8IW2l2OxHKbnL8Bsfez9TxVAwwWvlDUz5yIcrDAfvfU/WgBlqjNcZdlhP3tudzt7VBdIUY79wYtwG9KsxapDbXXn29iiMORuOSKuk2V4imd/LupV3bz92P2oAwQzblAxk9KfH4etZbi5MIWZZ4ykzyHCYPWrHiGGHRokxKspYZZ/XPQCufVmufluXZUJ3GMNhR6KRQB6fpvxSk0rwdNo810lz4mgxbWU7Dck0ZB2zt67Ap3epVf74rlIoIra1iFtK8ueZpGOWlkY5Lk+pJJP1rndyrcA4A25AKjsccfTgflVh73+zZknCsIvvSRHkOM9R+NebgMpw2XzqToRs5u7/yXlv8AeXOpKdk+h0Yt5FJSeUQBjtAHOT/nFdDdeJNRtIktvtKubUKhJGd+O5rz641/T4ZT51zJIgO4CIbiSfU1qtqS6lMn2PzJl2L8wQj869Ig9i0nVLXVbAXEJVJ3XDxk/dPf6itCCeOPTUjYj5AVHPT0rzCwW4TRpreBJRNvDxuRj6/hVi3l1UII5ztTPJJoA3NT1vNlNG0gCqS5B9D2riY/O1CSS7nPl2ynaM9W9qtOkmo6uLFmzCmGbtn/AOvTfEk5tyltEVWOPjA7mgDIvpQCVX5V9Mdqx72dEGGYkE0t/cNID8/OMADrmsC/82UHLnaO1AGpFdRZ29SB07VX1G6hziMDOOpHQ1z4doGJ3H8aJJXkB5wQetAExuvLbDZb8eQK1NN1JcFXbKdMjtWCW35MgBI9KZFMFYbQPwoA9W8L6jPbSoQ7yQFiN3p7V6TbaoRGFlAwTlW/vV5l4AnT7DOZMMiKNo6nJPWpmu54b9IVlZ45gXCscd8ZFAHcXV/BLqO2NwZFJzntxXO6zqgtnIjIdgNxbt9Kz5LO9WYyxnLvwSfSm6/ZyXu2OxXChQGJHXFAGbe6kLyNQ6tv3b5CX/1vPf2rO1OC4gleWWFohJ8wYcqR2+grOvrmbQ2f7fblX2/u0xxIT79sUQa5Jew/aIpChVVjeKU7h+FADxJtJz0PpUUsg2uyZGFOPbiomvIZ5RHEFjlJGQDlfc1NazRicLHLFJIM4Q9AaAMzw2s8WnyXaSMG88ADoGwOa27u8adw7KA3XKmokMtzDHHFErOhZn2jG8k54H04pt3cQyPuS2aI4A2MMAGgCe2We5kjS3hL3bZKYbhhjnHvTLaaewnt7q1yl1btvH06FT9elbGn6jY6WiXunW589SC0MjdBjkg1nXDm81C5uLSIDeWdoWPKZ5JHrzQBjfGXR4dQfSfEWlx4/tPEMqDjEvbPv2rc+HvwN+IukePvDWpah4e8mys9TtrieT7bbNsjSVWY4EhJwAeACaoeIInuvhrqdkySNPaXiSKpXn5+mPXOayfhl4B8YWfxJ8J3V54T8QQW0GrWkkssumzIkaLMhLMxXAAAJJNAH218NP8AkXLz/sNat/6cbiij4af8i5ef9hrVv/TjcUUAc/8AHB1jtfCbuMqNZJI/7crquNTyre2lnkMp48xvm4x+Pauv+OpUWPhQuAVGtZIP/XldV5B4i1C41knTtFgZ4ukzxuQG9s9KALPhC4TUdevrpT5szkD08tO3/wCqurv9s0ZhjY4U/wAPP4Vn+GLJ9L0kQlUFz5fzFRjn0HrUunWl5qNwIbGCR5T1VeQP8B9aAGxxOqFTGrqRyCAc+9MeCMkhRJjP3QCSD6V3um+BWVVfVbmGMk/6uHkn2JPFbS+HdFhOQ5Vh3MozQBwekoJLcQiN12/3jgqT3FbGl6M2qXjIAY448GScjP4AdCTW7deF7afElhckLkExlvlb8R0NbmnTK6NCIDbvCdrREfqPUH1oAxrxPD/hbT3nnhjyoyPMHmSOe3+cVzH/AAsmS63mzt0hhQcIw+8ey+31xW1r2jf2rqM+mX19bSG4/f28fCywkd+uT9K868VvH4ekW1uBBKqMxUJgFs9SfagC1qvjLxCrLLFcIYypRo4D80YPr2J969L8OS3MHhuO812YiURiSWWRdhC44yPXH515f8IZ013xKx2RrbRqziMYwSOn+9zjrVb4n+OZ31S80yVY1EEpMSb8oy9MsP7x/TtQBR8RQya94/l1cyD7Nd7BGhAykacAZH+etdV5IAP7pmJ4+YdK4/wBpzyzyXJjJllOxYwcpGepA56V6MNOulAIZVwPujnP0NAGSVR2UFfnHyngr+GO9SG1G4mKQuOoXPI/A1rtaOFAlJBHQ460gsWK5DooP8IGc/U0AY5t5UbIiP1zgflTTFk8qzEcZB/WtvyGQYyef7/KinNaqxIICdMHrn6UAYnkMPup8vP3+Me9LtVflB3N6gf1rXmspGkBdQwyc4xnFItpgFVjXHGSeD+tAGR5a4wJGLDj/wCvVfUbQzQ+ZEpWYfdL9D7VvNaO2FCL7A8HNRSWTsWy6lu/p+FAHg/jiyZrl73zpY5oQPMguODHg8FWHOM9K95+H2qXPjD4f2n9psP7ZjjI3seXIHySfUjg+9ebfEHSpY9UsbmC1juRyk0crHBQjG4j2rU+E95/Z7adFdOjRxTvbbxnOxjjI9OooA5O00DxBL4haG5sbuSGSRlkwmTGScBsD3/Ovofwloa6BoNrp24Syx5eWQD78h6mvOrXXdWsvG8vh3WJZBILjbDPGTumQEHlvXBH612XxB1i402K3trY7WuAzO4ODgHGBQB0NzObVQoHm3MjYSPOMn39AKRLSR8NeTtK/XYpwg+lcl8P0nvL671C8ZmeNBEm45Iz/wDWrt6AGCCIDHlrj6VQ1DQdPvoyskPlP2kiOCPw6GtUdaKAPHvE+kyaHeeXOrurjdFKqjY3uPf2NSWbLe2u4qA4GMMfmNek+JNLj1jRri0dQZQPMhJ7OP8AHpXk2hecl/LDJE68EEdSMdyaAB45o5WXciIvQv8AMzVQurieJoImMh8+bywYuijGfwq95LRXd1Md+1j8ql+/0rnDqsOoeJ4NJPmXFxArSyoZcLG393jqcdqANy9YQWjmMh36YC7hmsnxi6jwXraAylv7Pn4PH/LNuta18xiiQLDwzgEZAxWZ44Vf+EP1794nFhP8u7P/ACzagDpP21f+SWaV/wBhmL/0RPXx/wCFwp8Q6fvGV85cj8a+wP21v+SWaV/2Gov/AERPXyF4RRn8S6aqDLGdcD8aAPoPxHds109vGxEUaCIc9e5rIEhMZ3YOB0FOv5Gku5GPVpHIGe2QKjXLYCgEn0oAW2gNzPHEgwnLM5/hUdSa0NLtU1bVUjiwLZAWIb+6PX+dVndre3NpCA1xOR5xB5x2X6VS8S6qdA0v+zbNsajex5nmX/ljH/dHuaAKHiLVLfW9fVNOJ/s2z5DMP9Yw6t9OwqKNgz7UUySMc/KMnFX/AAt4WeazhVxsMq73+h6D8q9D0rQLPTYv3cK7v7x5OaAPPEsdQePMdk23371W1CO9wqXP7heQMrkD8a9eURKMBRzVe8tba5QrLGjA9iKAPGfDuhpqWu29nv2xElnc9ABXvenWNtaIiIqAAYBAHNec3Wkw6Lq0F8AxtVbMqjqAe9dq1wsVktzE26NcMQTxigDeYDHAAHas3XtQisLE/u/NnIwi/wB41p288Txqy424rlLxxJ46hWQbo44yqoem5+v6UAVNOtX0u0XUdTmWW8lffkcKvqo+lcRr2q755WY8sfxAPeug+IWoOZI4UIWNRtAFea3Epd3bqe9AG1Dcee4JkC46n2qC8eBgSGBOeg4xWV9qaIhYwvoc96kCSMCzqM9c9xQBVvmiwVRj+NVIp9oAfrirE8OyQFumM1WuFRhwRkd6AGMSWOOQf1qF1cNu2kU5CF46dsVchTzI2BI45oA6LwNqv2WR1kOEcCP+or0i/wBHOuaWtzprBNSgAlgDfdkx1Q/WvF7YmE/MCFNew/Dy7kfTVR2yQCVY9j2FAGx4bvotV02KbaVZ12lG6ow4Kn6GtJ4liBk2gYFcf4LupG1rVlKgoH89EHBG7r+orodXvpjF5axbMjlj0xQBn61Z2WsWLxX8AeJ+VHce4PY15HPpENrO62l07bWIyw/zk13eoat5aTjf8x4UAfpWPa6b5ylpF3M3zYxwM0Ac7FbLH92YZzjGOtQ3OmKGYRExzLyFU8H6V2UmlRMMFccc4FZ2oaTlcoTu6g0Ac9oGs3Oiaoksg8xCNpDenqPetnVbtr6+FzKRiVQVKjAIFYeqwmSM4XlKdpN689r9kkIPlZePI5HqKANSFSFJHY456VNCEWdWRWBOcANjHH8qXSWia5aKckLIhQHsD2/Wklj2TKD0wMj+dAF9L1JLEWmoyFILqCSLzcHcrL8yHjnII4xzR4BHxgX4heGxqreP20sapbC5a5+2eSYfNXfv3cbduc54xnNZd5Gs1mySSCNFG4PnG30Oe2DXS+HfFGoX3iTwRc6d411UmTVrO3vtNk1uaXzQZ0VvkaQllIPI6YNAH1F8NP8AkXLz/sNat/6cbiij4af8i5ef9hrVv/TjcUUAcb+0jLJB4d8NPA+yT+2goP1tLkH9DXBeE7QaTpphkO+eU72xyBnoBXof7Qys2i+GRGnmN/bOQuM5xZ3R6Vxekzx3UcMsahs8cZXB+lAHV+FNHk1i7cFmW0i/1jDrnso962LvWYYYv7O8KNErZKG5Iwue6qT1PvWP4u1pvD3w1s/7PDQz3kpjkKjkddw/HgVk+CZE1C1Xd8zecuY5DymOjexoA24ItSOuQM809xa3CIJmfqCpwc+/StzWtDmFtMyHiKTcrgklYyORjvzXRxWqeUvGM4OPQ1aYAg5GQRyKAOLsLi8hnh+zKRaSDKrjB2jqST0zXTBTf2g3PJbvg+XNGcOvv9PalMHkEFMs2MLgdB6Ut3GIoS4baw5z7/SgDwH4hWWo+HPE8Wsq+b60lWVCOdzZzu9SGGfzxXpPjvQbPxLpFvrlmypM9uro+Mh0YZA9jzVz4naPDrHhlbp9omhwN4XPyt0/AHn8a5/4PXc93omo+FdWKtcWQL2rOv8AyybIHH+w5/IigDkfg9dWw8Sag1uhZtOsppzPuKqpJ2Ku3uTz+Vcn4vtZZvFU9u0jMREk6bjgnJ5AJ6813vhjw+PDPg7xZcXDvJeXd3FaSb02lFQ549eST+VcJ45Yxazpl0SvlzgRMw+9hWB/kaAPZfh9pyrpfntED1VeOff8a6tYIxgFWz2BHf8ApTtEtFttHs4QQcRqxZeMk85/Wrwi468UAUBGQMeWSvovaj7OM5CLWj5eBwcUpTOM8+4oAzfJ6bskj0NMazQ+xz1rT8odQcH6UuwjjjA70AZYswByu719/wAaRrRXP7zBPoRurU8lckkZJ756Unkg5JP5UAZLWoYcg4x93PApVtmC4dQYweM88VqGHuDx70eTk5xjPU560AeafF8vYeFn1G3RA8IK7cfeB6g47YrznwndS/8ACLWptrIRNJudfLb3+8c9z6V6x8b9kXw01Rpefuge3PavN/D8Qg0awRiu1IV3DPXigD1VZ7S/Xw5rl3blmuERA20ExTZxub26jNP8aeHJ9cv7Ron/ANWhTYTwDnOa4691cWvwyvZo4mA0m8jkUl9gRHP3vYAk16V4Z1H+1NA07UBKkrTwq5dOhNAHOfD6Robm/sZTiRfmC8HocHmu0T77cn6VxElt/wAI943W8kQDTr0sFl67S3UH0wf0ruMY68/1oAcpoPX8aTPPSjjI7+9ACg7TknHf6V45ZrI2rXcwn3xIWONuO5/WvQvGeq/YbBrWDa13Ou3bnlVPU1wTr5VutunXqxx0PpxQBmXitaQzXBVVXO4nqQT9axdH0K4i1i51nUZoVaVBGkUS42L6k+prbuVjuJlgd9xHJQnKnHfn0qXIPG0NjuvP8qAGSWltI0W9zIUORjmsjxwIV8G67hVz/Z8+M4z/AKtq11iKEeXv+UcKTxWN44LHwfrqmM4FhOSQBj/Vt+lAHR/tq/8AJLNK/wCw1F/6Inr5e+FlksuvyX83EGnwtcuf90V9Q/tq/wDJLNK/7DMX/oievC/ANgmneCnkdR9q1idLdc/88QcufyzQB0SpL5enrPxcNErOD1Bb5jUc90lnMCJNgZ+H64HTJ/Or3iMldWunRsIWO32G3FVBYR3LJA8Rk+TOeg/GgDpxb29hEJY41kkcblc8k/jXmetiS718zTgEyMAV9BXXWtvNpjrDHcO9qy4AfkR/Ss7xhaK1hHe2rAvAQzEDt6/gaAPTNEt/Ksg4UBm7e3pUssmHwQfzpug3QvNFtZ8D50G4Ds3cUlypYnGRQBVacbsdgafFJlhk8+tUrhXAJAyD+lT2bfKm/rj0oAXVkWW1kLjIIxg96zNDuA9pc2czgxSRmNST2rS1dljsmI7V5/Z3jR6hvB2RNJgRnt70AepeEbgT6eqyMd0GY3J77e/5YrAivftPiy2nDKd7uf0wP0q1aMdP0/VbqMEKYsr7NjFclpjNFqVqWPzLIF+nagCb4g2c01yj26t/dxj+dcRcW/kR/cJPfNe9S2UV0GWQAGM4zjrxXOahounvI3nKrN1C9hQB41GN8+116fdHtWhk+RtXLE8E+ld9Holg11IsVqoKgkbqpf2Wm4gBQPp1oA4GYyyIYzH14B70y20i5eQ/L8g6kdq7uHwyhm8wyZPJrZs9GS2iLZVg3bHSgDzY+F7ydPNhAK89eCKYNA1G3TLwsOw7163GUt7cRlAxzn6VQbUkDksAFU/dI60AecQaFqMrqzQMEz94+leq+HLE6fo7PKV3BB8w4BxzV3T57a7RGj2F8Z2/0p/ieUW2gyvHjZtwox0JoA43w1eG28UW0uflumeBx9fmH6ium8STDyJVjZeRwa85nkaB7eVXwsU8btjqRkD+tejaxZb1eQDjgj3FAHnLhp9RRSOUBLH1rrLKECJG/wAkVh6gAmoKEUL2x64rdhmBQADtjHvQBIy4JHGDVS4izxjI7exq3Hkk/Nk9zSTDIBbt+lAHG6varHcA8fNxisHSNPkbVpE6CMnJPTFdBrRM94iqPlQ7i3tVSzLJ9oui/wA05IC47UAAkCSJiMeYp42nk1OylpN8hAI5/wDrVtaPYi2t49Su4lVU+4ByQfU+9UJJBcag7eUvlfeJA6e9AFO8hVIFDt5QMe9nyBtI5B547ZrvPBHxY8Tan4itLa68aG43atYWqW3k2Y+0xSzoso+WIMflJ5UjFcReN9sMjOGVVQYI4PGSCPyr0nwn4+8a3Gr2i6h4nu51/tXToGhNpaKjwzzojBisIYHBbkEUAe6/DT/kXLz/ALDWrf8ApxuKKPhp/wAi5ef9hrVv/TjcUUAc98cTttfCRIz/AMTrpnH/AC5XVeZXlxLolybuKB5NPkYeYFcExH1xjOK9E/aBbbpXhU/9Rsdv+nS5rkUd5YflZXBGCGGQR3oA19YaO/8AhtqG6NpLe3uI5sD/AJaB+OD2x1zVH4c2r2Vw0ENxD5MuSryAZA9Cf61Y0a0a58Na7oEBJe4tma0TPPmLyqjP6VxfgbxROR/Z+uxCWGNQEdxskjYHoTQB9FWEivCiq/mEDlgcirdYOlXlogijtEWPzV8yT5ss2BwfxrbjcOiuAQGGcHrQA+sjxNeCz05pWl2ohDOq8kr/AEHvWnMCUPJHqfSssQxTXEMckRcklmk6/gc9jQBn6tPs8E3cs+UW6UeSjDlQ2Nox+tee+BrGVPH+lXcCZdlminCE4EZXkt+IFdz45mbUJrTQ7CIS3TuHfBwIwBxn6dT6VX0vSY/BtpczSTLcalfsEMi5CRIOw74zz7mgCTx/LGvhktbKHSS9y23uwB3H2Oa8L8frPNoHm2xjWO2nV2J4Ze2B616rdSyXvgiZwwD2+rN5ihjgAjj69Qa4XxNZfbdGvo3RnkMTbTuzyORj8qAPX/h3q/8AbngrSL5jmRofLkx/eXj/AArpl5XNfPf7PXiYabqc3hi/kURahi4s33cLNjlP+BD9RX0CpP09QaAJCM0dqO1FACUtHaloASjHNLQOtACAYopTWT4n16z8N6NLqV+flU7Y4xyZXPRR/WgDyj9pbU5JbTSvD9tIgeUm6lUk5PGFHsOprF0RFh0uxEs29jCoPOcnHpXFa9rFvqfi+61fXjJNHK2XZc4jYDhQOuP0rqPA5S48O2s6XKyKzOB5iYZQGIxn2oA7uxtvt3gnxhE0C3Ia0G23K/eYcqT+IriPh/42l8PWrW93Mk0kWESKAYgUDqpP8Tf7teoeDbOK48L69HI5MVyDC5RudpTnn8a8p1jwNeeGL+OdYBPZEEWqwNk57Lg9PcmgD32xutO8T6EkqKJ7K4GGjbgow6g+hFJZ2N7pkaQ2My3VovSO4OJF9g3TFc34QlfRbODT7lP9PmZTKwHyMxHRR7Cu4VvUbT6UARxTOynzLaWM+nBH51k+INal0yNcQrH5mQk0rAjPsB/Wtssqxl3ZUjUZZmOFUepNeS+NdVvNe1yL7AgXSrUFEc43ynPzMFPTPbPagCS6uIWk853aW6cks5JrLuboxW0sqI7BATheC3tzTZHMCFvKcnHAxkn6VHBJdSfPdEx4PEWB8v8AjQBBpjSX9nFch0Uv82HPMZ9D/hU1vNc5ljmlVTGcDaOGHqKkNk0l8l3IG2J1Vdp3nsWHamRyyh/9GRGBPLDpQA4sRjCl2zj5TWD41Qr4R1zcZEP2Cf5RgA/u29ua3kaYn94iIexB5rA8bybvCWuAPuP2GcNvJB/1bdOxoA639s9S/wAMtHUdTrcI/wDIE9eXXNqbHTPD1kF5is5ZCR1DEY/rXs37U1n9v8JeGbbbuEmvwgj2EE5P8q8y8dW7QWWi3UCZYM0LqOpVhn9MUAZOpzR3DJLyrOgLD/aAxWv4OEdzJeWt2ytJHgjHHUdaw4ZlK7ZxujbjIHK+9Rafd/2Z4ijkmhbySMSOv/LTj5SPzoA6nW4VQlkI2DoVHGfeuevJkltZYXj4IKsB3BropEj1FC1lN8w6RnqfWuZ1FBbtsmUqc9xigDW+HOpiNJNKunIZDuiJ/iFdvNET/SvJSRJIktvKEuIDlGXrXU6d43W2VY9YjMbdN4GR9aAOjni+ZhjrVO2jeEbWfe2TtPt6U9PEOj3ce6C8iOOxPNYmp+JrSDKwkSSDoBQBZ8T3QjsdpIDtwAK5/wAL6PJf3k1xKMw7QI89PrVOykm1/USWy1uGw5H8R/uivVtHsVgtlwoGRjaB0oAyPE8K2Hgq6EJwd0a5POctXGq4W6LntKCP++q7z4gwlvCV2qZBBV+O2DXn0akzKAPmYg/rQB6fNKQJt33BGZCfU44rhfthu7gT7zhhkD3rvbu3K2gZhkTRhSPQ7cV51pQMV5NDLEwMRxk96ANRLjyLd5C37w56+hrlLrVGiuNxcmPknH8ql1nUHzKiMS3Qj0HrXIXTsAfNLDeeKAOyg1GeaF5bcDaAOCauQ6sRb4lY4xkYPU1wtmxFv54dlMZ2deGBq5DLIUkcEySYJ2jr7YoA7+3uVuIysbbiRxVea13xx/ICVGG96wNLvRCgkc+WDtGc/nXTxXDPHFPjcGTPy9KAK2lTRw6tFJCcMxAA7fSun8bKP+EcmcLhd6HH41maVpYN/HcEYjQGTp+ldJ4ni3eE7vcOSoYZoA8a1plWzmLYxkAEeuc/0r1yPNxY2rsuGaFTj3wK8m1aJZY7aEYImlUAHrXsOngLaxIMZVAMD2FAHBeJdNImZ4hhs7gPT1rMs75Q+2T5G9+K9G1KzSfJIGccEV594k0CbeWiALA880AXBfxquSyjtkVVv9WiihZtwPHIzXE3EN3DPsIlZ87QoOST6AVoQadcQshvCDKeduc4oAkZpJzL5hA80gyEf3fSrdgiM4MxKxKOgFENsJHVV6E4LE8ZrSuY47MS283ykj7/APdPbPsaALketwSBdP8ALCxuNqtjIBPTNYr3Rsp1hlXL5MbcdcVE0IV5IppGikTpt5zVe5VnuvMaX7Q2MAj9KACWNrpfLjbIc7RuXIx6Edx616D4M8SCfxRZ48IeALf7PqVhEJbbQPKmHnXCR70fzTsZc7gcHkCuDkhlt7KVAwSVhzlsEDuARyM9Miu88HX+h3HlatpPw/ht5IbmOVRP4tvWy8TBo3ZDGVYBgCN2enSgD6F+Gn/IuXn/AGGtW/8ATjcUVS+DV3JqHgRLyaJIZbjUtSmeJH3qha/nJUMQMgZxnAz6CigDnf2i7W5vNB8MwWP/AB8trQ2c46Wl0f6V5z4c1kPP/ZuqxGDUYxyjxkbvoelep/HKYQWnhOQttC611/7crquG1GwsdYijM+FuU5SZGw6n2PWgDWtpzazRTW8WySJgyMfUVD4m8MQay91rnhi0R9Sb57vTs87+8kfqfb/9VQ2kFzBH5U92Zj2IGGI9x/WrMU0kM8csVw8MyHch6Y/GgDn/AAZ4pm07UVjuFmjnU/vRJ9/02kEZGPSveLCUzW0UnB3DJPqa4E3MF/LE3iLTLW8lTlb2PCSj8R1rrrPV9Lit0SCR9ijAG3J/+vQBsn36Vj65qC6TbeVZgPqVx8sEXVv97HoKYdWuL5nh0aBPMUfNLO3CZ6HFS6NpRs5Xu7yVbrUJM7psYCj0X/GgCHwzoY0mKWe6fzdRuBuuJWbO0ddoPp3Jryvxn8ULG4uLmxsw9zaCQKJlXG/B5we1eq+KHvP7Jm+xSiCQA5JIwy45z7V82eILKSfUZY4bRrSfP+sC5ik9+OhNAHqnw8iOp+A9dht428t5vPtlLckgZOT9RWIkExlwUVWPBGPug/zrX+DFveaS0/8AaBkhWdABDIu0IQ3yn0yxz+FO8X6e+n65LEN32dmEsQ3gDae2PrmgDxK50O4stFW+t3Mj2966hejIQ3BB9vSvb/hz8TYdWhhsPEsiWmqAiNZmG1Jj23Z6H3ryzUNOudK8Zw3l3cmPR7y5yxEhIU9cFenP5Vc8VW9hB4qs7u5Bl066UeasfytFg8lW6HjmgD6X5U7TwR1pwNeW+DvGkVleQ6XeyzyaTKM2d7cElkGeFc+leoBjxnoeQQcg+9AD+340vem5pc0AHaikzxVXU9Ss9KtHutQmEMC98ZJPoB3oAnuZ4bW2mubqQRW8KGSSRuiqOprwxfFsGtfEmDWPE4eDw7ZB1tLNxvDHGFZl9ecn8B2q54r8TXHjB2sbeb7Lp+Syqp4Kj+OQ/wAhXnjaJPHDKY7uCZY5QqK+Q20nnIxwD6mgDm/iKh/4SS+nUkR3M8ksShNgWMn5VA9hV3wD4gttNsriz1GSOOPzPNhaXO33Ge3rVzVtOk8Y6839jPAkqqElj/hiUccHuaW88DaVLcyRm6uYrUDYxK7i/HOP1oA+kPB+nyR+EokdhHPeJ55Yc7Q2Nv6Y/Oqcfhq/bVw9/cLdWDEgoCAVH97P6YrN0Px/psGmW1rLFcTPbRJEJYwAsgUAA89OAKfqnjPULq3kj0SFIJWGEmwJHX3GflzQB11xpNjAEum22hQY+0OwBxjHU96x7vxdYQJ5WlhryRRtEjZEY/E8tXl9to2p3F8154g1e51SUHIilfIX04HH5CtO9lghjP2ryoowMYLbf0oAv6pqWoapMBe3LSqDxCigIPoP8aplG2/JaqewG8LiqcNzb+Sq6fZuwONoBxn8aVY7q6z9uZYIxnEETYJH+03+FAEV5qttbTNCpNxcjpDCMsD6E9B+NY8Vx4i1G8H2m1tdNtAeVL+ZKfxHSuotooLdBHaxW6If7q4J+vc05sAlQFX0UHH5UAYUmn3JlR/M3rnJMrkn9OCPrV+CBtgBIPYA5FWVgCszLIyseuW61HJD5g2tJuHbeeB+VACGDGTjLdskYrn/ABnGw8G67l9x+wT8AAgfu2/Ktl0EQwxUHP8ACQQ35Vg+N5VTwjraFnmaSynICxjA/dtySPSgD1v4+KG0vwsCM/8AE5JAPr9iusV5j42w2l2yoBvjkDJ9cYP6V6l8dlDWHhVW/i1kr+JsroCvLPFNvcXum25gAMkbFnXp2xQBxgkfGCuQSMjHP51ajXfGyz2/mRdVx1X6VEBKu8NviI+8CuRSbmVhhmB9QaAM/V9OndPMsbqWOVOVwSrD2zVO21rxBGpt7yx+3oRjMifMPxFbjylujDIHIPeni+uYsKCoAH4UAZ9j4a1fUYWuZLSO3jyBs34fHrTtT0rUbBDFMqXkQ6qwww/GtNLq5nYbmkHP3gcBa0N15F/rZUuIsdJOv4GgDzcWNpcM6Ru1pc4yFk6H2zTtJtI5LlY9QlkjiVgrxgcn6Gu5u7fTbobJ4ck9scj6Gp7Lw7ZXABtZg3/TN/5UAdJoGnWVtbxR6esQh7FTkmujjZFIGSMdq4q30O3syFltrm3A/wCWkDkge9XPsVosRNtrF+G9R82KAOg1gxXOnzwTkKjIRn8K810iOS+liS3IGx9pP0NbN7pOoXls0K6wzRN2kj5NXPCmkx6HGsE7efI5JDL1J+lAHa+X9oQxOwLxAr7E+tcZrFr5Nz9sjjBE2S/1rs4ZSrrmPZJuAKnv71n+I7ZkWZRgAZYEfSgDxzWUklumk27SScsOhrH1VFSINJ9/ICj6V3l2kTqsczhPTA61z15pUMrorsWVicEHODQBz0ys8QU4CkZwvar1lIqsWY9AOVHNXjYwugRDyBjPfAqxo8EFkftNxCbhG/hx0oAo34+0Sxw24Hlnl2ArudAt5IYIEcfKRwT3rlmdU3vtWNZHyg9AT0rr9Cea52Bh8iAAGgDsPJBjUBRu2g4HucVfv7cXNrLASu112nPpUdtANjNISOM5H6Cs+7W9dPnG5FOAwOCR70AeYeLtNh0rVbN5HDQxyZMY7e/0rt9I1SymsFkikj2gfe3jrWdrdtbz3X72MM6rg7umPeufWPTY5Sq2Ijz/AHTwT9KAOtuvEem26lZLje39yMbjXMar4jurtGjsrZLaM8edNy35VSkhSRidvkRdDsHJp8GkmU/6DZ3L/wC2/c+vNAGRb2wimMqySS3BJPmMOffFSXPk2x3Xsm0kdM8mtyTTWtQraheR2qY/1cXzP+dRJcadaZNtYozNz5s5yWoAwZNQg+zsyLKqcY/dn5/pVKfUdU1aSyihs/KS24aVxzJ/vZ/lXbSatezIrRtahE4AMfA+lZ89/vyLiJGzyxTjNAGVPHM8peSVd5UKwT09KgJMTBIAqnPXFaBlsdwYwyKD2Bo+02gXbFEUJ9RQBQWBnXE2dzdS3Vq2/Dt3Ja67ZQxkGOcmORB0Axwfwx+tUoykzlYtzydC2Ogrd0LRvsd19snJaZE/dr15P9f8KAPoH4GY/wCFb2mDkfbtQwf+36eio/gK6v8ADCweNgyNeX5Vh3H22fmigCr8ceLTwn/2Gj2z/wAuV1XEBN3zSSKueuxMH867T47FlsPChRdzf2zwM4z/AKFdVxds+8AmAq3diTj8KAKUuhwzXcd1FNc/aI8hWEh4B6ilstPvLBAi34lh5AjuV3ke24c1pckkF0/LGKcqQqcmQhsYyADQBRj1v7FP9mnzbHtwWRh61JfXa30TrApkPTMTbdvvjvV9o4pIwdpZQesh4/KgRR55iRse2MUAQfD/AFqTwqdQivI7jVftUiyySpKPNQAYACHsOe9egWvjbw3eRlH1H7Mc8rcoYiPxrzrVNO+2wN9mm+zXHGxwN2Mf0rldSi123x9s0a31KJOtwjAEj6UAe8XGreH9Tie3bWbKSE/K8YmAB/H/AAqrb6L4XS4aW2ntFcKFwl2uF98E9a8LsvEOkmU208N1ayuf9XLCFAPsfSpJntH3N9ktriMEKWibeB7cd6APpC3t4Fhijt0iMSYKKhDYx0IxXL/EvQv7R0cXyNJFPYAu20f6yL+JfqOo/GvHINRsdJzMFuoXIxvQnp9c4FU9f8fK2lSWkF5fyO5wIpSdrfXnmgDG8dT/ANrNaxQqYoYVLqshA3N0z+VRaDEb7Tv7Mln84LE80G+QZRh1C46/Sn+EtR07Ubs2usQpKWJ2Fsk59BWVqkEug65MbKZbdll/dmPA2A9j/WgDu9F0XGmXVreSZ81VJj8zd5a9ivOB71veEvGWoeFLoaXfK+qaGuStwJQXhx1C+o9qydAt/tcwW5tJJXVFxK7Y3j1yOCK1W0m2a+MpAMG3YIgeFYnkj3oA9W0jxToWrQrJYapbOGGdkjbHH1BrQk1GyiQvJfWiKBkkzL0/OvEP+Ee0+4v2sbOIC7iT5ELH5vq3r7V52fEujadqLRbby8MLspmiCGJWzghQTlgD34BoA+g/EnxP0PSgI7J21C6dSUEQPl/n3/CvOdW8Y61ql/HItg8s2WjfGGEaEcAD6c1l2msWlxo0mp20kGqWkbbZFS38qa2Y/wB5eev5V1OgalZ6nZJdwLCswGGBXJX6ketAFTw9ZfZ1kVpEIlIL/wB4gdvrWT48ihit5RNIbSF92ZdpO44+VCR6108olhkHlBG8xvmxkbT615p8S7+Z1uIzOXUTrtGSGXA5x2Iz60AWvAupXmn+Br17SxjAjkZ5JGJ3HPQ+47Zrk4dc12+1A/ZCN8rfLEqkqCe2K9h8JW+lz+CLbT7m3kN59nMd0rH5ZVYZ3KO1UPB/hyw0Tz2tWdxuwCX3ZHbAoAl0HRp4bGP+0bhXmYAtApwinrxWrdvHp1r59y32SDPZi2T2AHWob3UM3ZstNihuL/G59zf6lf7x9fpTrXT8QRpf3L3kwO4yMNvPsPQUAYk2oa1qkxt9JgOnQk4N5c4Ib3UetadjocViyyzM9/d/x3Ez79x9cdBVy5hifhV6/wASkgg0yCztoDkyzM56l270ATs8ioQCOvTp+tOADqWViT3Apy7kIx06AHpUcoVnxInHsc5oAQjcDmFXUehx+ZprIoAwoX/ZOT+tBcKwVQT2Ax0pkkrL8oiBHrnj6UAKyRnHBVj3PNQXVgk+BLJLgcsiPgH61Izx7SSrKffkU0yKkZZ5isa/xOMBR7k0AMS1hjb90VJ6Yft+NY3jeJl8G66QqRr9hnyd2Qf3bcVV1jxlZwyva6X/AMTW8Ay2xSqR+5boce1eceIjfato+qatquoCG2SJ0j3ErG8m04iiHViT+A6mgD6F/a41OfRvAegahaNtnt9dhdT/ANsJ64Xw/rll4w0X7Vp0wScrie3z80bev0rq/wBtX/klmlf9hmL/ANET18e6BrV9oOox3umztDMh6joR6EdxQB9E3jT2pKuh3jrkfeqg80D5zBkE9R2qz4O8c6J40t0s9SVbTU8Y2M2BIfVD/StW/wDDFxDlrYefHjIXow/xoAxStksRMiMfdabA1muCEZhjGG9KkaEo7K6srDqr8GpIkVQDJESP5UAMe4gK7YxIvbDDiomkd8BcbR0q00UPBDMCex5pFhj3AIDz1NAFQRksC3HPJNPWDD71c7uoIOK0FiGMMqkfWo2iw2UBwe1AFuz1nUNPjO2fzEHGyUZrY0/UdK1Tb5o+wXR/iX7rVzyRM7AEcg49RTltkYkEfhQB2osbiECSJ47qIdSoya0tLNi04nWIJc425bt9K4vTLy4sJQ1vKyEDG0ng11Fhfw6qr4iFvqMa7mQfdlXuR70AauvpbQQQyTvhmbYm0cnNVNStXlgR3B2mIA1p2RWXyhOiyFCGQsP1q/IomMsajCMCceh9KAPCtdjc3TKowYn27vYVzs/m/ahscrEV7evrXUeJ3li1MbRu+Y7x9O9YjK7bQFVkJY8dR3oAhtkfBkJyG46dKtK8iSbIz8u3B4pg8yK23NyCMjHU1YaQb4cLhpV+fPtQBnmMNqESSSBsj5R2Fer+GNPWG1ReCcDJx1rze3tFlvAyqSiZXkdM17F4chEenPJwAq4GaAKuuXb24jjCbf8AaPAIrNvdZH2NHQnkYx3zUmtXgmgYy/Mg4RD6+tc9PbuGiSNGZ5GCgf3mPpQBRupJ7u4Aw0jucLGo5JrYsfB7Eedq1zHaxD/lmnLfiau7V8PsYIlWXUGX99Mf+WZ/urVKWSaVCsrMyHkjOT+NAEV9qGl2Q8nR9P8AOK8GWXpmsa61W8mXy2mZFI5EIxj2q1cmIIQsY3d8VnyIqt0yfagCkYMcjLSdyxyfzqBl+dhgZHXjNXmz5m4DkdKJZycB41C99o5oAzZMg4LZx+VPj3kHYIyBzk9qkmeKQFNoj9OMk1WkjwNsf3vUmgB0wTad8WSOQQeaqXCbEEjhEDdFByc091Cr++l2jPJ7n6Vf07Qrm7+dIvs8B586X7xHcgdqAKdn50rLbWoZXbhmA5FZ/wARPGY0a2Oi6TKXvQmyWbOfJB6gH+9/Km+LvHNjoFvLpvhplnvT8sl31CHvj1P8q8dlkaWRpJGLOxyzE5JNAH37+y6c/ArwyT/09f8ApVLRSfsuf8kJ8M/9vX/pVLRQBZ+On/Hl4Uzx/wATk9s/8uV1XFg4Udc+5ziuj/aUuLi18N+G57IZnTWQV+XP/Lpc54+ma8o0/wAZsUX+07PyVP8Ay0th5gP1HUUAdn5iFtuzLn+/ycU5TEDjKbv7q+vvVKy1ayuoQ1pNHOzcAB8EH6HkVaSIs2+SFQewHJ/SgCfYxwW2A/7R6Cp1AEfAVs9yMAfhTBI/ASNYx3AHWmzMcgvIvmDnb6UAThXCjyzgDjdSxnJyVDH1IzUBQnaxZnYnkEmpSQmB0HsDnPtQAl5awX8JivIIpkxyjgcL9a5O88FwPKH0qX7Gq/dEUh249wa6ueXaAu3B9uppEUKcleh5Y8gUAeda1oPiq1UG3EV/F02xnJI9wa5m8vYXZk1nRvKkGVbymMbj8D1r283AZisZXJ7nIrI8TaPaa1avbXUSG7AzHKPvoexJ9PagDzDw3YaBca9aGHUJoyGDCOWLG5uy7s/nVzxXYveajdXFhAc27ZZPLHzgdQB3FZWp2b6HPcMyzJFH8siIMEg9GDHt71Poskll9mvI3b7NJvjZ85ZR6j8T0oA7jwnrLakIpLqOOIEARRp1Hrj/AArrFkeJJHdk2rknIzn2/CvEdPvr7Tbi50+KQrcW8v2gM5xvHfn6YrfPjDUNbRLdILe1YMnmyhz86k4IUUAUPG3iu7sHn02wkEV3dIXvLlR8yo/3Yk9CV5J64IFebjAUAYVR2Hat/wAexXMXjTWvtUEkRa6bbuUhWGBjaTwRgA8VgEZ9efXsf8KAO6+DCyyeNZEAPktZSGdfXGNh/Bj+tb2p3M/g3xC7WkbNBNmQI7YDg9QTiuR8IeJb6y163h0bTLa4ubgxwSRop8yQA8ndn5fX0GK9h8Y2Ftf2w+2orGJgEkAGVycZ54PbrQByWseP3nEA02ARTR5ZgTuKnHfsR71zemXN5rwaAobid5QZmYjKjPbvisnXbC40u/ns5TiRCQeQAfcY9a0vBySWkV3qmANq+TDz1c9T9AKAOx8JSPDB4jvzcF4raLZCq5UKBnBp/g3xDdatpFyqxMswYRrLtGNx6kGqvhC4keKaJI/IguxsZmXiQdCce/rXZ2dnb6VZpZ6dbRwR9SirhR6knuTQBT0XSLfRIJWaUtLO26SRuWZv8fetcHzEyC5J/gc81BOYzIkYjZ1Q5II4HvUwkZ0GSGx0Gev0zQAqtMnMqZ56YpWO7G5VU44J7U1m6fezjoPSkDAnlG29znn8qAEMZ6pIykjIA71EI0TIMsuT0BPFSXLwRwl3uYIUXndIQAPzri9b+INhYlodKiOpyAAmQf6pfx6mgDsYsocBWYd/X61R1XXdM0+N2u72NWUcoG3OfoorynV/FniHVk2CR7a3b5dlqMfmeo+lY9lp81zcJFbLJe3bHAiiUsyn1JoA7XVPiDdF3TSbFkjx9+dQW+pHTFYCHXfEV8Uurqe4A+d4g2yIKO7noF9zVfUJtM8OuH8R30d1exEFNP099xH/AF0f7q/Tk1xnibx1qOs272VusenaUTn7HbcK3++3Vz9ePagDq9S8TaJodrNapINXumPMNsPKtEYHuw5k/DANeeeINf1DXrsT6jOZCo2xoBtSNf7qKOFH0rKJyeaSgD7V/bV/5JZpX/YZi/8ARE9fFVfav7a3/JLNK/7DUX/oieviqgB8btG4dGKsDkEHBFer+BPi/faWsdlr4a9shgCUf62P3z3ryWloA+z9G1DRPFdgJ7KW3vo+M4+WRPqOtLL4YsLksscs0LdMGvj/AEXWdQ0W7W50y6lt5l/iRsZr27wX8cI5Wit/FUG1gNv2qEdf95f8KAPQbnwfep89tPHOo9Rg1nT6HqFuTvt5FI4+XnNdzoesafrFos+j3sN3HjOA3I+tbMUo+7L8h9GoA8kMEgPzofyxSGHaTtLYr1yfTbS7UCeFG9GXg1haj4PdwXsCso67CcEfSgDgcENuBI+lTqN+CykfSrd5Yy2spjuoZImHGHB/nQtuGJCnbnsaAHQwqwCkcj1q1aIYLyCeDiWFt2P7w7j8qiiUo3zA4q/FCDhlP0NAHSaVcRSYiO4Sqfk/2l6/pXULCJYMpjJXKsO5rkdMNtdbEuHaCdDksONw9RXQafJNpzNHd4Fr95ZM8AHvQB5r8QNIFtq4mXIiuF3BgOjfxCuQa1UDeSE6gL619Aa7oltrumSRSMMH5kkQg7W9a8p1Lwlq9lKy/ZWuYe0kQz/+qgDjjaA3AQuAAmFz05pllbMHQSgttzt/OujXw1qsjqr2ksa4yHYdK0bPwpqDyp8jOu37xXH+RQBnaRZma8jihXPckf1r0XVIhY6LFAnL8A49TU3hfw5FpKvLIQ8xx07VZ1dYTI8krxny+kW4ZLUAcLf2TyfIikso3knsPWptGZnn/tK7j8lLcFIE7s/TdW7EIorCZbobrm6cOSOhUdAPQVmX0plx8gCjAUAcAUAZtynmzNcSnAY5J96z5kPmFwxVM/d7n61rSoyAZxntx0qjJEACxI/GgDMeHc+Sp25zgVFLAjZAcIM9B/jV58nPPyVbs/DeoakN1vamOLvLNwPyoA554EQExsCO5HXNUmDA4I+Xrjqa9Cg8DQxkG8vXkPdY+BWjDpum2C7be2Qkdz8xNAHl0Wk39zhoLOZs9yMCtG38I3bKXu5o7VPblq7zULtLK2ee6mitoFHLyMFArybxl8XtM09ng0RP7RuR0lfiNT6j1oA6e4ttB8MWhvbxkUD/AJb3B5J/2RXk3xF+Jn9sWradoQlhtmP76dvlaQf3QOwrg/EXiHUvEN4bnVLl5n/hXoq+wHasigBSc0lFFAH3/wDsuf8AJCfDP/b1/wClUtFH7Ln/ACQnwz/29f8ApVLRQBz37Yd/c6Z8OtFvLGZ4LmLWoikiHBGbe4B/QmvmfR/iS7ssfiGyiu424aeECKYD/eHB/EV9H/trf8ks0r/sNRf+iJ6+KqAPcZIrO6tEv9PZrrTpDtFwnyyxN/ddfX36HtVzTfEOt6avlWly1xbqMhJPmA/rmvGvDviHUdAuTLp85VG4kiYbo5B6MvQivS9H8XaHrqpFLs0HUOzrzbsfr1T9RQB3ll4/gK4vrWSBz95ozuz+Haup0/W9Jvk/0W4gkY4O1+CPzry2/wBCuLYCSZRJAw3LcQkPE/0I4NZc1vkJ5LxTE8ARffH1FAHvBcMQQ2TjqGzipl8tVO7G9h0Gc/nXhum6re6TcrJBvdQP9VLnbnvmu60v4h2LoqX9u9pIeGkUb0z9euKAO4JjOCwB/wBk9qZK7ODkH22/54qtZXtreRobS4hmBGf3bjP4ipn+Vdw3MT90ZzQBGFWPoxHuTyPp61OSCmGA9Rg8n3JpkR3bg0WH7gjpS7EG4kAZ54GBQBka7pa3sQkQKLyMYQsAwZT1Vh3U/pXPWVhpwsp7G4jWxkd9wQElUfH8B9D6V2cwWJVd2wx9f4vYVRuLK21aII0eJP8Aa/pQB534m065RYZ0jJvrNTjHPnR+3sB2p91a6Zpljut2EsV5GskE4GTE+PmAA6iuyutNljtfKuXdtv3XXqD6g1heIPh34psLWPWNLto9R09h5oSFt0kannPl9cH2oAXTdY/tbS20bxXZifRZE2wzyH/USDo6nqG561XX4f8AhibV0u7bVJDoyqN9nI2WZgMHMmcgE84/DpUOieH9T8bwRwadZG2uRIVlaUlIkHdsHkD+teiaL8FI7drgavrUN5HIgSNI7Ygxn1GTg/lQBWsrzRdFEWnaSLS1RVIEcAGCDzy3f3yazPF2tIdOuII/MZSmWkXCnH+yD1rorn4K+GjbulvrV/auWz5m5GxgcjBOPeuf1b4RtpFpJqmj6jLr7qmzym+VsnuOSMfSgDzPUY7rUbb+0nS2eKSQQgrIRITjjK10Wg6UdUZIJmit7K3UNMyjHmE/wj144zXa+APhK0M66344NvBaRDfDYeZtXI6NK3HA9OprU1Wx02XWZG0FY4NNUDBT7rN3ZQe3pQBh6TaxSancXSoPs0I8qFMkBQB6f1rYDbGwWZ2/56DsfQ0/7OEVY4lVVBx8vFCRFVBwBnnkcGgBqh8Z6oeu319ajuC/y5UbSeCRzT5A6ldsbM57KelVdY1Wx0eFWv7lVkIysS/M7fRaALTPtjLEiIAZbzDwB61yGv8Ajyz092t7ONrubH30wFX3z3rnPE/iLU9ctXjVP7P077ww2WkX/a7/AICsHS9FlvVRNPtpbiNBmQ/ciT/aeQ8YoAravqWp65NIbp5rmMNkJtwE98dqbp9hLdSrFHBc3k2MiCFc4H+0R2q1q+reGdEXyr27OrToP+PLTT5duD/tSdz9M1xmueP9X1G2NnZMml6b0FtZZQEf7Tfeb8TQB3Go3GkaBn+29RXzAM/2VppDtn0eT7q/qa4vXfHt7dQSWeiwRaNpz8NFak75B/tyH5m/QVxhYnrSUAOZixyTTaKKACiiigD7V/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKKKKACiiigDQ0nWNQ0i4E+m3c1vIO8bEV6x4Y+PGsWSxw63bRahEuAXPyvj614vRQB9ieGfi34Q1xUVrt9MuT/BPwv59K9J06+hvI1eyuLe7TpuikFfnnmtTSPEGraPIJNNv7i3YHPyORQB+g0wini8u7gDqeMSLkfnWJe+DLC7TzLGV7dzyVzuWvmDw38fvFelbUvHh1CLPImXk/iK9V8M/tFeHrtVTWrCeykPVojuWgDsLnwpqVkCXiWaP+9Gc/pTLbTJlYIEdc9Aw4rp/D3xD8KavEGsNdtcnokrbT9MGuxt0iuYw8QimQjhkIYUAedroVyxRJUKN2bqKNXS6TTHtblGkA5A3feHpmvR/s6BcY2jsKp3ulxXKMjAEHqCKAPLtNuvIurdbC0uLGN12yxtKTvb1UelaE9+Li5MKXdyDjEsaHBrfvvDIWRZYZTHIhyjbcsp9q4nxdYawbuS50vTmedyC7ltmWAwSKANTzdMPyyatcJLjG2dtrAH2qrdXcqtmx1WaZSu3p8oFeWeJPDms63cQQX9/aLc2ozGhP7xu5yatTDxDstkuogjY8rMLYjcDufTigD0C71MLbGC2vWklbqytwT6ZqjJcW6qIU0uWO5UDMzybiT3NU9O0ryNGtbBII4ljHA3Z3N1yWroNO8O3rkFom2465zQBHESyKRlmwAST29KlEIA3soLe/Ra67TfCsgx5rRonXplq1G8NRPhfNZIx2QDJoA8ymgZnztJB7nj9Kt6f4T1DUSHaNbeDP35PT2FenW+jWOmoZVijD4x5s7f1Ncn4n+JPg/Qiy6l4gtmlXgxW53n9KAJdP8ADem6T8/li5mHSSXnH0FT3buyFiMKOSXO1R/9avDfGH7R9pEZIfC+mGQ8gXF1x+IUV4v4r+J/irxMXXUNTlWBv+WMR2L+lAH0d41+Jnhrw7IYp737dcLkGC15wfc15Fr/AMdNQmDR6Fp8Fkh6O/zt/hXjTMWOWJJPc02gDX1zxFq2uTGTVL6e4JOdrN8o+g6VkUUUAFFFFABRRRQB9/8A7Ln/ACQnwz/29f8ApVLRR+y5/wAkJ8M/9vX/AKVS0UAcr+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFLmkooA29B8U6zoLg6ZfTRJnmPOUP1U8V3GnfEXS77auv6OkFx/wA/mn/I2fUoeD+GK8sooA96tXtdVw2ha9a3ykZFtckQzD2IPX8DVXVdLmtpALuwuLWfGWIUmPHr/wDqrxFWKnKkiun0Hx74j0RQllqUxgH/ACxmPmIf+AtmgDuIrWW3b7TY3cYYHgo+1/rius0XxzqlnC0WpRi54ysp+Vj6DcOK4S1+JtheqU8Q+HbeVmOTNZOYWz645FbNhrPhC/A+ya3daY7DBivYNyfiy8UAd7p3j/TrohLiKazPT5+R+YrbTxDo8oXy72CVpMEKrZ2/WvPG0Fr6Lfp91o99x8rwXShm/A45qpJ4Z1CyiZptG1BZM58yIBh+FAHq9wjzwERssy55zxgegPrUVo80W5HTgD5QyYIHsa8lt7zV7SNV+3XECn5UjlVlzn36V0ekeMbqBPs1ykF44bAKzYcn1OR0oA9KDRyqMqSDwQ3QYq9p/iLUtJ2mGT7TaoMC2f8Ah/3W6ivNV8YWMsjC/smiduF8ucHp6+lR6l4ss5HWO0Z2kQAhWfp+VAHu/hXxNp/iMMYIvsmpqv760mAEuAeox99femaxrul2niCPTtSsr8XOwMlwkJaPB9wa+fh4jSa7juliaKSKPKTRoS3XoD169+9XYPGuq3SB1juLghiCDubK/X60Ae26nrWh6fE1yljdX8uMbIYsnHr8xArbv9StNI0gXt0scEflh44chS7EZCD19yK8Y0rS7jVbdbmWWeGd84jGTt/OsnXdP8TfaY1keSezgXajIdzH/gJ6H6UAb/iG91LV72F9SlhlZjveNc7EH91Qewq1bXJKcPEOcZwAAPp6Vxt7BqsssZh07UiFA2jg9ulFxofiS4UOtgAPvbJJdoUeh9KAOyNzHHva5vYFUDkhhwPasq/8WadYo5haS6kxyQMKfxNcne2EWmWz/wBv+INL0yLHyJG4lfP+6Oa5TVPHfhXSSRo2mz6zeAY+03zFIc+ojHJ/GgDqr3xre38LpEtxC8h+Q2qZ+X6nqfpWTcaJc7Df600VjG/W61KfD49QvUn6CuAv/ih4puSwh1AWcZ6R2sSxqo9sDP61yV/f3eoTma+uZriU9XlcsfzNAHpN94x8N6VIx0+zudbu1yonvm8uA+4jHJ9skVxviHxhrWvDy727ItR9y1hHlwr9EHH55rnqKAFJJ60lFFABRRRQAUUUUAFFFFAH2r+2t/ySzSv+w1F/6Inr5F8GeHLvxb4msdD06W3hurtmVHuCwjXCljkqCeinoDX11+2t/wAks0r/ALDUX/oievmf4FX9ppnxX0C81K5t7W0ieUyTXEgjjUGJwMsSAMkgde9AGVrng6bTvDseu2Oq6ZrGkm5+xvPYmUeVKVLBXWWNGGQCQQCOOtcvXqGsappPiL4VLbaJ/Z3h+5027N1faOszBL4sNqTxPKzOzKCVMZY4BJHUivL6ACiiigAooooAKKKKACiiigCaC4mgbdDIyEehrptE8f8AiHRmBstSuYwP7shFcnRQB7fon7Q/iqyRUuLx5lHXzFDn866u3/adv1Q+dZ2sh28fu8EGvmWigD6Iv/2ndedSLayslPqYzxXI698efF+qxugnitwwwTEmD+FeS0UAbE3iXV5b0Xb30xuQ24SFuc10Vn8UfEtuFV7lJ0H8MiZzXC0UAeuaf8cNXtyon06ymQfw4Irs9I/aXubWNUl0aEgf7Rr5wooA+pJP2oJmjxFpdrG/qwY1zus/tJeI7hGWzmht8jrDAAfzNfPtFAHY+KPiL4j8RyMdQ1O7lVuzykj8ulci8jyEl2JJ9TTKKACiiigAooooAKKKKACiiigDa8S+Hbvw8ukm9kgcanYRajD5LE7Y5CwAbIGG+U5AyPesWvVvH2kP4l07wbc6RqOgyR2vh61tZ1l1qzgeOVTIWQpJKrAgMO1eU0Aff/7Ln/JCfDP/AG9f+lUtFH7Ln/JCfDP/AG9f+lUtFAGt8a/h1/ws3wra6N/an9meRepeed9n87dtSRNu3cuPv5znt0rxT/hkb/qdv/KT/wDbq+qqKAPlX/hkb/qdv/KT/wDbqP8Ahkb/AKnb/wApP/26vqqigD5V/wCGRv8Aqdv/ACk//bqP+GRv+p2/8pP/ANur6qooA+Vf+GRv+p2/8pP/ANuo/wCGRv8Aqdv/ACk//bq+qqKAPlX/AIZG/wCp2/8AKT/9upf+GRv+p2/8pP8A9ur6pooA+V1/ZJZTlfG5B9f7K/8At1a+nfs265ppBsfiXewEdNtg2Py8+vpGigDxGz+D3i2ABZviJFeIP4brQkk/9rZqaT4M30rB5tX8Ou4/iOgSA/pdCvaKKAPGIvgzewsWh1Tw4hJzxoEh/ndUL8G79WJXVvDgLdSPD78/+TVez0UAeQp8KtdiBFv4j0KDjGU8Pt/W5NRyfCzxawIj8d2MK+kfh9Rj/wAjV7FRQB4NqvwQ8V6nC8Nz8TZlhfG5IdJEYOOeqzA1EvwL8XqioPitf7VGBnTc4/8AI1e/UUAfPk3wE8VzDEnxV1Aj0/s8j+U1ZV3+zHqt4c3XxIvJif79gx/9r19MV5r+0fqV9pHwY8Q32lXlzY3sX2fy7i2laKRM3MQOGUgjIJH0NAHkB/ZIJJJ8bkn1/sr/AO3Un/DI3/U7f+Un/wC3V4roXiP4p+IPP/sHWfG+p+Rt837FdXU3l7s7d20nGcHGfQ1q/wDF7/8AqpP/AJPUAeq/8Mjf9Tt/5Sf/ALdR/wAMjf8AU7f+Un/7dXgt34+8fWd3Na3nizxTBcwu0csUupXCvG4OCrAtkEEEEGov+Fj+OP8AocvEn/g0n/8AiqAPf/8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq8A/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8AiqAPf/8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq8A/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8AiqAPf/8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq8A/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8AiqAPf/8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq8A/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8AiqAPf/8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq8A/4WP44/6HLxJ/4NJ//iqP+Fj+OP8AocvEn/g0n/8AiqAPun41/Dr/AIWb4VtdG/tT+zPIvUvPO+z+fu2pIm3buXH+sznPbpXiv/DI3/U7f+Un/wC3V4B/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB7/AP8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdXgH/Cx/HH/Q5eJP8AwaT/APxVH/Cx/HH/AEOXiT/waT//ABVAHv8A/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1eAf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAe/wD/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V4B/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB7/AP8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdXgH/Cx/HH/Q5eJP8AwaT/APxVH/Cx/HH/AEOXiT/waT//ABVAHv8A/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1eAf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAe/wD/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V4B/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB7/AP8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdXgH/Cx/HH/Q5eJP8AwaT/APxVH/Cx/HH/AEOXiT/waT//ABVAHv8A/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1eAf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAe/wD/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V4B/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB7/AP8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdXgH/Cx/HH/Q5eJP8AwaT/APxVfb/7OGpX2r/Bjw9fareXN9ey/aPMuLmVpZHxcygZZiScAAfQUAeP/wDDI3/U7f8AlJ/+3Uf8Mjf9Tt/5Sf8A7dX1VRQB8q/8Mjf9Tt/5Sf8A7dR/wyN/1O3/AJSf/t1fVVFAHyr/AMMjf9Tt/wCUn/7dR/wyN/1O3/lJ/wDt1fVVFAHyr/wyN/1O3/lJ/wDt1H/DI3/U7f8AlJ/+3V9VUUAfKv8AwyN/1O3/AJSf/t1H/DI3/U7f+Un/AO3V9VUUAfKv/DI3/U7f+Un/AO3Uf8Mjf9Tt/wCUn/7dX1VRQB8q/wDDI3/U7f8AlJ/+3Uf8Mjf9Tt/5Sf8A7dX1VRQByvwt8I/8IJ4E0zw39u+3/YvN/wBI8ryt++V5Pu7mxjfjqelFdVRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVftR/wDJCfE3/br/AOlUVeq15V+1H/yQnxN/26/+lUVAHiv7It3d2HhX4n3mmRmW/t7KCW3jAzukVLkqMd8kCvafgzDbX3hHwn4gu/E2qXWrXsBEyz6pJJFcylSWj8l2KApgn5FU/JknGc/K3wL+Ln/Cq/7b/wCJJ/av9peR/wAvfkeX5fmf7DZz5ntjHvXfWH7SWg6fqkmpWHwu0u11GQEPdQ3caSsD1y4t8nOB3oA8X+LH/JU/GX/Yavf/AEe9cpWt4s1f/hIPFWs6z5H2f+0b2a88nfv8vzHL7d2BnGcZwM+lZNABRRRQAUUUUAFFFFABRRRQAUVc07TbzUbhILG2lnmc4VI1LE/gK9c8H/s/+K9ZhW5v7ZNPtmG7dcybSB/uDmgDxeivrnRf2bNLhRTqOrM7EciCEdfq1dJD8APB0SYke9kJPDblGB+VAHxFRX3C3wE8DBceTe5/veaP8Kr3f7PvgySLbE19E5Hyyblb9Mc0AfE1FfYN9+zX4YkX9zq9/G2eSYk/Liuf1D9mK2CZsfEGSTjbNCRj8RQB8vUV75q/7NHiK3DNpuo2F2M/KpYoSMe9ee6/8KPGeiAtd6HcvGM/vIR5i/pQBwtFSz281u5SeJ43HVXUg1FQAUUUUAFFFFABRRRQAUUUUAFFFWtKsLnVdTtNPsYzLd3cyQQxjqzsQqj8yKAKtff/AOy5/wAkJ8M/9vX/AKVS18O+OPDV54P8WanoOpYNzZSmMuowJFIBVx7MpB/GvuL9lz/khPhn/t6/9KpaAPVaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8q/aj/5IT4m/7df/AEqir1WvKv2o/wDkhPib/t1/9KoqAPgCiiigAooooAKKlht5pyRDG7kcnaM4rodN8F6zfGPbbiISZ2eYcbsDPFAHM0V7z8GfhLo+v6xrVn4jc3X2OCFiLaUp5Tuz8EjqcIav+KPBHgbwD45isby0v9Qs5rBZ9s8qsImMjKDwFPRD615Uc5w8se8uV/aJX202vv6Gns3y8/Q+eQrMcAEmtGy0HVr4A2em3cwPQpExB/SvsDwTa+Cr6xlbQtMsBEp2yGOIFlP485ru9PhtdyQxOYkP3QEC5+n4V6pmfGnh34QeMNaljC6ZJaxM20yXHyBffB5r2Lwf+zlp0UaS+ItRknnAy8cA2xr/AMCPJ4r3ImaOCKS1RHxwUkPBUHkg+tSzXaXRVIVV7bIKluFJ759aAKnhnwvoHheAJoWnW1qDz5ijc7e+481viQFflJJPWqJjmWDNuYCeyt0/Cobi51C2RZJFt5MtjagIOKANXzlUbdwDYppkdiNrfLjp3NYZvbthJO6RxwbTjcvP+fSvMNQ8e6zc38llpF4zEOVC/ZmLn/dPTFAHtYfYQWzgHFRS3EPnhjdBEwQsZIxkdx7+1ed6RB4o1O1uvtt9PDJMp8o+WEMLD+9680y98G6vc6ooPiWZAqCWPEQIVuhH1PXNAHo0cq7FImBJBzuI5psku1C24HHIB6YrzvW9C1ez0lY7K6dVtjlDnfJP2OT2Jz+Vebf8J5qejTxSXUiyzRuVeIEhRn2PXj8qAPoppMsG8sbTwcGo/tRSQo0cpAHTg8eted/DrxhqXiUO4sGt4QcOztw3oV9q7E3hW3cShRcKQ4wffnH4UAZniLw3oPiOLy9e0u2ugg2BvL2kD+9uHIavEPG37PsTI914M1DcTlhZ3TDJHor9/wAa+kL3V7ew0w3Uh2iRtqgc89s1jG4s70/adJKxiGLfNF/CecbfY0AfCniDw5q/h67a21nT7i0lH/PRCAfcHoayK/QDVbO11CzNrqlrDcwvjdDMgZa828UfA3wpc3RjtoLrT5pAZA1tJ5iBR1OD0FAHyRRXvWofAONiP7N19QzfdW5hI3emMVzGpfA/xTbbjamyvEHdJdpP4GgDyyiui1zwX4h0SaWPUdKuY/LxuZV3LyM9Rx3rAkjeNsSIyH0YYoAZRRRQAV23wh8UaT4L8YxeINYsJ9QeyidrO2iKqGnPALsegALHIBOdvFcTRQB7D+034o0nxR4+uGs7Cez1XTJ59MvCxVo51ikKxyKRzk/NkEcDaMmvp79lz/khPhn/ALev/SqWviv4sf8AJU/GX/Yavf8A0e9fan7Ln/JCfDP/AG9f+lUtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVftR/8AJCfE3/br/wClUVeq15V+1H/yQnxN/wBuv/pVFQB8AUUVf0PTptV1W2srdC8kzhAo70AN0rTLzVbtLawgeaZuioM16Zp/w9sdBh+2eKLqJpEAYWiHJP1/lXUytYeBLFNP0eAPr0qL5pIyEHXn244FcS8kuoXDyTysZ33GSSQ9+oH9MUAehadbeC49JLxaxHa4UMqqmGV+wcYyQCaZ8TLrUYbey1nTLy3OkXsaRbYFH+s2kEg+jc8D0rzTaVfJ+R17Hrn0roIfFd3aeHU0u3VV2SCeOReDDIGDIy+hDKDSd7abges/srQBtK8R36kt5tzFAXPOSiFuv/bSuf8AjBpU2v8AxVvS11BbWttBBZmaUFtjbTIAB7+ZxXuXw+8SweLfCdjq0O1ZZV23Ea/8s5l4dfz6eoINeP8AxqvdA1nxHJo2nWdml+rBtT1eOEechQDbEHHJbAAJJOBhepOPzDJcZWxHENStOk1J3TV/htZXb00Vvnc7akUqSSZU8D3/AIQ8N6nHHYX93dXl5HsknlBRFIJGCOgJJ4r0ybU5ZxbpZwzbZgVd1I/dhe5Pb0r5av2kW7l3SzHcc75By57Gva/hv4gvdW0O4sPLtdyKBHGJMGQ45k+nqPWv1A4jv9M1CCWU2wvpFlyQ0fVAR147Vo/ahBd+VHMJbRRksmP3Xsa810Pw2sd3eXjW95ZFiIHzLuVMHOVb0NdNqGmTedp6aJNHDczkOfPyUl2HLxn6qeDQB1za1ZyK0dmZFuBwVdcYPrUcZuEniae5kkZ1ySw/Ij0qPyIEUmWIwuxAVWOT9M+lTXU8KafEnmqzJJ1Poex/GgC95ykb9pc42qp/maaWaBC8VtGrZ4IQClsWiAyMs7Y/A1pxgNk9SaAMZ9QuPJkke2eKPadp6sW7celMe8ZFaVbaUfKDID/Cw6keoroVjQHJHNGxBxgYoA5hfECPIQ9uxCdlU7gD396r30eh6uFj1LTLS5DEhDIgBz/Q11UkMTHJjXP0rJ1TRobgNhAN3Jz60AULextdPsjBYwR28EZyqx9FPt61kwSPeF5rjcGZzgJ2I/xpZLuTR5Vi1LK2kp2r/dHfO7tirs9u6ygQGGWKJy42nBdWHU+hoAURWtxCq38Pmw55YnlSOhrL1eGy0J2mgZzPcfKtvF85fvnHYY5yavSW11K5SaZIgPmRU5CL6+5rKWzkuIru7jK29snyhv43/wB4/wBPegB+m+IoZi+yDcy/KZLpwm1vpV601FLmeN4ZoJmuATHFbvkAg45PpntXk/i3w5DqUlqgnuPtdyxykY/1oBBzj27fWqWi2kmjNY6jrkjaLY6fcOv2lJs/ahyPKCL165LdyKAPUbuY3Egunvka4tnZGjtgCgYHBXPbHrXCfFPU/EViLWPQ7a5ltbuN2kuY1Em49wMcqQOc15p4r8XXWrBrbTlNhpCFl8qFsGbLE7nPXJ649SawLTU9QsWi+xX95b+U26MRzMFU+oGcUAX28Va8djHVblljCpsZ8ggEkbgep9c1QuNVuZ5ZJbsw3HmZ3ebGpGDyR7Va0+5ttV8Q2beJ7l1sZJQlzcQqFdF/vEAeuM16r4c8I+HNMubi5iurbVbq2doVdj+7343ozDp90igDzjw/4UtNbshLqGiXlrYur/8AE2tTmOMg43FD1GeDisTxr8NtZ8MRtcjy9Q0zPF5bAlR/vDqK2Y/HHiGDUbu5h1EfvZd7RogMIweNi9lx+daWj/EjV7XWZbjU1ju7G6UR3NoqBF2+qDoD/OgDxyivS/iB4MtX00+KPCZ87RZSTLEBhrc98jsPbt9K82RGd1RFLOxwqqMkn0FAFnVtQutX1W91LUJfOvbyZ7ieTaF3yOxZjgAAZJPAAFfen7Ln/JCfDP8A29f+lUtfFf8Awrjxx/0JviT/AMFc/wD8TX21+zPbT2fwU8P2t5DLBcwPdxyxSoVeN1u5gVYHkEEEEGgD0+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKv2o/+SE+Jv8At1/9Koq9Vryr9qP/AJIT4m/7df8A0qioA+Aa9Y+FNjHomj3via9gLyAeVaDHO4nGR+JA/OvNdCsjqOr2loDjzZApPtX0N4h0hG0DTrZLy20yC3ZZQZxjPZcAdxz9aAPOL57m4vZZ753lu5fmkeRtp3H39uKuWtrA+lL5k++R5W3JEnMRUcMze5NacF7pmgTSx3unR61qYbBeZsW8anqFHc+9ULLxBe21hNp9rDax28kvnMHjzhRzs+nT8qAMKRHjYrMpWQdQev41PplpFeapb288v2eCR8PJ1KjHb3PQV2WmW3hzX2js1a4s72T55ZZTuMrHr+XYVV0nwrDqXjNtKjnk/s61/fXM8Qy/kj72Pc9AffPagDqvA0XiTQI9RsPDoW2stYKKhmk8y5tX6GYRgYyycAE8FVJ4By/X9D03wpLa+fBdWYZgss05MvnxgksM9N5JznvzXrHh7ULO10S3XSNOt7Gw24j2HdI8fTczdcmma/fadf6PPY3GlPdxS/cjlHBPbBNc9LC0aVSdWEUpT3feysNybVmfKzxXV7fNDB506M7mHf8A3Mk59hjk+la3hiwk/ti1WLUxaX0LmeIJyoKDJyR13LwPXmqV5PDYalqtvAsiwSB4ozICJIOeR/MH2xUWjz2VpcpLN9rklUjyzBgBD646n6V0CPZfh18Rn1LxFPp/iDYmlajGQoRf+PRlPBPtzye3Fema3o3kWsMiOu6znW4jYNjPuPYg18y6P4a8RXN095p9ndwEMzI7DY7Z5IAPqPwr07Wb7xTqOjafZW8b2dzAFWZWIKOp6bfT6dqAPRNUuohbO8vyynggnIOeh9q5jU/E6xafHabEGo/aliKDnOPusPY9a5uytNaRpZdTu+QpG0ch8f3vatPwDp0V9BPqVwJpNSmdolaQcRRq3CAenfd3oA9J8OQSCBJZWJkftXRphB15qlp2Vto3zklcZA6+9WN/OP50ASmQg+1N3/8A1qjZs+1RsRnJBxQBY8zB5/GkDkcMcgj0qDJPUkGgMB0fI9KAMnxLaLPZSI8aTwup3RuPlf2NeZ+HfERm0AtKssctpdfYijDJ2nJTB/iHH4Yr0Xx9PPaeFLyezZFnGApbpk9j9emfevOtLs2udOj0NLZI7yAme6eA5i3sC3yN6/yoA3v7YjWzuI5l/eqo+SM/MFrft5rXV/Cm23uYooN29pCcAhepP+eTXjdmt5dx3VgNQBdXMfmDBmGOzkdsEgGl0nRNVs9VhmnvJ5rGFMRwtnaWXO0FR1HPfqaAMv4heK0i1Ux2au0gOxCr7WiiB+bkdGf9BiuL+1XmtavLHpNmc3amOOz80usS4/h3dD7+pNbep/D3VWNxdJLFLNJI0nlZO4gnPX8cVykM50i9KT2syXcbfMrkoycEcfnnNAFK6tprad4riExSISpVuxHUfUVC2OwOatrPJFEscgW5gbnbIc8nvnqGquEBDMGUYIByeQfp3oAhPStO1vrvSJ2SCU4ZQzxuPlzt4JHqBUEcrwAT27INpCYYAn8j61b8uSS5bVG02S4syxZ41yVHGOSOgz/KgDK3EFwpwGHIA4xVqGzuri0nuYoZDZQMonmxlYiemT2zT9HbTk1OL+14pZNPYlZPKba6Z6N749K6m48T6dYQ61pel2Pm6Lf2y24lU7HMiDHm4PXJoAg+GmuRaVrj2F8y/wBkaoPInWTlVY8K3oPQ+1cP410OTw74wu9Nti5McoMBTO7B5XHfPIq7LDL9h8wxlojkh1HGR2z2rV+LbTXes6JqUTvLPeWMLiaMEGRwMAjHfpQB2Hw9/wCFw/8ACfeGv7X/AOFgf2b/AGnbfavtX2zyfK81d+/dxt25znjGc19a/DT/AJFy8/7DWrf+nG4r5K+Hv/C4f+E+8Nf2v/wsD+zf7TtvtX2r7Z5Pleau/fu427c5zxjOa+tfhp/yLl5/2GtW/wDTjcUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlX7Uf/JCfE3/br/6VRV6rXlX7Uf8AyQnxN/26/wDpVFQB8RfD54U8YaabiMyIZQu1Tzk8A/gcGvRvHWpTXurCJ5/MNqPLO3kBgev1rzTwTDJN4p01YgWfzlIA+tdnqrM+q3rZDM8rMxB5PPSgCtcSBySM/MAQCc7TWhaWvlWDaheeaqZAhIGRJkHj8cGoNOt1u5yHBFunMhUZOPb3/pWokNxrl5Dp8ANvp8TEiQDhV7tju2AcUAa/ga2ttP0zVfEerbRbQt5Ecajc0jN1Vf0Ga7n4a3Om6N4Y1DxTrM8dqdQbzFhj58uFcqka9zkkkivK9W1JdRntNHtHNto9r+7QEEMwHJZvU9ce5rqdI8MrrohmuknXTox5UVvvwsQHoPXuT70AbB+JImkktdD0aScL8sbA4jHcgD8agu/FPje7tlg/syzSMZ8sqSWU+o/pXVWGnWOm26RWcUUcK/3V5z3zVpmBwhVQh4GDgkUAfPmsR373U1zrKzC6c5Z2jxuPTntniuz+DumW11qVxeXDhJLcgRgniTPUEelejahZ219E0c8aOhB3KwzjtXL6VDaeGLi5RbFjbSESeYvzGJRgEfQZzQB6pYOgd1kwCOpPXnpUdzh7obSBt4Y/hwawrudor2yaOUTW84IRwfvMACAPXNaltO7ZYjMjggEDj2oAyPEaS32lt5RihsFuEtrmQEmR2PSOMD+Ijkk1veHtGa21QpZq0Vvcxo0qtyVwMY9uMHFc74Mdb2zv7iAllgmLzI3O6YsVG30yBnNem6eGgs8IBv6yN+lAFlpfL2pEAFAx/hSCXK5K7ST0NRGQttjTbyCST/nrUm9fvEHI4oAkBYn0pGcAEnn14oYkkYPNI0oBIA4H3qAIpFZgTjnrwaiCBQXR8gHBGehp7yn1GewH8qiZFZS0ZRueQDjmgBmpWkeqaTc2Fx9ydCoJ7HqP1rz7StNn0kXOlpsilKHyiW7AfePtng/WvQEkDOCwK85B9PasjxTaRXESSqxjuk+aGVeo74PqDjkUAeZ32kwaSYtcs4JIreVh9vt1GWifoHUdx149811emFcBw+/yxy3Zgelc540vLpfBtxPp7+RcsY3G84ZTk5H6H8KZ4B1Ce+8L29+ZBNLI7icdBGQcAf1/GgDodQfYWbaMsQoRRya4r4g2ml6ho889+jGW3G7z4wBIo7hT/EPauztJ2j1ESXZXyFRiid8j3rx/x7rR1u+kFmYxayMSgU/dPuO3SgDl5IdPjcC2+0sjjcFdQXUe/bPetrRbvw7MEs9UtElgZcG5K+XKp6g8e/FLpOiidY2A3wkZdJDtJHfn071rT+HopFcukflkfu2j+8McY98UAZeoeA3njlu/D1zHd2+Nyw5+dG7oT61n+G/EWqaLa3+kWitDPPlFDRZdX6Fdp7n9K7PwpZHRNUL2kjfZWxG0TNkOT/H/AE9sVlfGTTms9e07VrfKC6TY0iHkyp0OfXbj8qAPOmQoWV9yyKSGUjkEUh646gjNSzFpmeZjukZiz/U96vRQ21xoakMVvIZTkt0KHsPp1oAqWkkwPlQySIZGAKqeD9RXR+IDJ4m8INNbqIr/AESYfLGNu5X6bMc9egrmIyyyFlOSD1B5+orV0TUv7NvXe7CvaSgRXC5x8gOcjuCPWgDsPh7/AMLh/wCE/wDDX9r/APCwP7N/tO2+1favtnk+V5q79+7jbtznPGM5r61+Gn/IuXn/AGGtW/8ATjcV8o23iPXLT4xeE7bTPHmqapo17qlnuiXWZJ12tMgaN13nIwcYbqDX1d8NP+RcvP8AsNat/wCnG4oA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKv2o/+SE+Jv8At1/9Koq9Vry/9pqFrj4JeIYU+9I9og+puoRQB8d/DHTJvLudVgXMsbpbQsBkpK5wpx3FbN5axDW71UuFjiSV9rsMkMOMH6nNdH4YtYtAj0HS4VDPLd+dNL90SAfcOfY9q5S6i/4nFyQrNEbluVHXDe/vQBraNPa2uqxrcrJHZ8Kzp905GQG9ya6vxDcmys5E0lY1gERRSgBHzDsfWuc0XS5JXuhfws9uWA82Mcy89E9x6/WniFdM1orbxSS2ytkQK+VOfvZB6YGaAOe0KKeTWUtFkEU9x+5ZpF3Fc8n8eK9+iiW2tIYUHyogUkcdu/1rw3W5YdP1eC/sQ5kictJC/DKynOM+hWvc4J1u7GCeM/LPGsiLjjBHT8OlAFWZsBgxwenTH+TVcSlWCh1yO5HOR2x61LOjuoJwSV2gVnzwyITgk8iTP90/X14oA1IyMnqXzuA9KyfEF/Hp5Rl/1czbHb+HPofStG3mBjJZfvEk+v1rkviLcBbSG1SLfLcyqkYA+UFiAC349KAF0yVrnwo0Rlke50S5LosZ2lFLZX69wDXf/wBriHQ7m/ZcYhMiqpAKkjIU+4ritO8K6h4Rlmt9aiQRXDmFJFO5TGwyVb1weR6VU+IRlsPAdlYRlnEs4UyscMyD5ufrQBv/AATlN9oviC83LHFFcxzuue23t+Oa9at7iNotkbALt6E8nvXh37PU8U+rappc7bormJZmGMAbOOT2xxx3r1620SSVPtNwxDqSkSA/eUn7x9zQBsqYG/1Trl/vH0+lPaSEPguGbAzk4rOk0aaO4WWIBXbKnLfdPqBWfdWU0MnkM+4Hc7P6N6UAbbXlsCwVst061DNqqjcI0+5yQeua5Z7xbcugXc+Que3PY1SnnuJQvmSCPaccGgDo5dfkQkRqWOf4F4XNO/t67hLo9oqsh6Feo9foe1ZdlcWjvHFMwjP8R759K6238q7thI6ICwwmOy0AYw15XR5rq0aNM5yfu/T2NY93rqalPDaWEcjm4LRwNt5Ujhs/TNdgNOt/tDC2YNIykSq3K4PfHr6VyljHa2mphrUH7MsjGVG4eOcHk/jwaAPM/i9e/ZLA26N8rzrEDjlhH1P6mqHwh1MLaappku7yfOE8Rx1LZB/DgVQ+NN80ur2dgz7miWSZyFwWZ24OfcD9KyvhNOy+M44AMpPBIHUngEAEEUAeu63bP/Y091uMcrRtFA4+6GPcj/PWvCtIFxb6sBKQJpGwyIPlznv7dxXvXiG5EugeTHhriM5CjjA7mvDbBprbX5GukYSO+PXigD0aygjhhUsmTwB6A+v0qbYrOw6ekmeFPofT2qvp9xFLGcKzqASCxxu9RVlUVImKgpHu3c8jA9fXtQBnbY7CRWUsY0bLAHgZ7t70vxdSCTwFZSpgmK5iMZz93cCD+YqTUkdj5aojSt0289epP9K5X4nXyw6fp+im5Es6t50igf6tMYQN6sev0oA4hrRooS7kbmUSLtbI298+/tRDDcT2byW0TyRQ/O7RrkJ/velaOiaRdaveCDTlidrUK0iyNtR8tgY9SfSu48VSyeGtOuLOKMQ3V1iSVkiAjk7Hjt9KAPNrOJZJo45GILH7oGMHtUcm+B2LkJJCevBKkH+mK3bX7Ro+jvMbZGvJwUWT7zJEwzk+hz09qztOhie/s4ZZVijklUtKWGYxnOTnjPHegD3Xwx8T9ZvW8LFvHT3d/falYwT2BSxO6OSZVkGEiDrwT3yK91+Gn/IuXn/Ya1b/ANONxXgOifFXX5ta8HwJ43fUJdS1C0gubUR2TDY8yq6kJEGX5Se+RXv3w0/5Fy8/7DWrf+nG4oA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPPj9EJ/hZqMLEASXdghJ6DN7AK9Drgfjmof4bXakZBvtPGP+36CgD5n8ZW1zHrNn5LsEhhi8qQj+PO4HHqSBmsHV2S71i5N+J7VpZC0hK8o+35vl+tdp8VtPY6jZSW7YLW+3bnooIwR71yVwl5PGsV+kkgnjURST8FyvdW/vAZ470Adv8ADvULa+8MmCZQbm2kY7c/M2eAw9OKw/FwhKz3FoS8bsAZEG1o+MEN688fjWP4b1W40LVHM8arDcQLDkjhQD8pz+ea6a5vdC1lGWLUYLS9jbcfNOI5SB0HquaAPP8AWblJvLIiAkkiRpQT0kGR+WP516N8LPEcU9uujXczG5TJtGc/ejA5Qn1HOPUfSuD8QaPqNk7teW8jRZ3LPGN0bg+hHQ+1Ye5opVdHaNx02nawoA+lJI1J3Z2qOfl6ms69tYpIXgdWK85AODz0INeYeH/iLqenqsGpr9rthwJMYkHpz0aty9+JFkV4tpiwBGRja/09KAOtTdboBIwIjAy3t61zmp6pBa+ILSXypb+5jk8+3s48ESOB8pb0AzmuM1bxne3ziOCMxEkbFRizMewP+FdR4K8LXkdw17qErJeyruMucsnP3fxoA7yG61TWkhuNeEPmqTsiiOUUn+Z964X43T+XcaNCNy4ikfcB8pzgY/SvSIQIlYIqg4xj+tec/G+CWa30q7A/dxbopMnBUnkUATfs47pPGeoIpX7LJZMJY26t83GPpz+de3+Grz7e11NHl41kAjOfujPAr5x+C19Pp3jywkgKsJ0kjYei7cg/nX0P4cs2sL69s4TiERK6sD3Jz/31QBt3d2VlkO9Qigjkd+3Neca/4vjt7S5uZZWC5KoFHzDb3/GrXji6vH0S7awkP2lSxCDuVPp6V4brsWpashN3bX9tOreVawquUmccuXPYjpigDqtJ8WWE4ubrUrvbZPJ+78xsOe2cdeexrKufEthpZt7i3vLjUoJ4yY4XODHhsMX+gzxXBQ6ez3Eb6gNgZ/K8rOJMDqcdgKpSXLrPiIAKo8pe5K9PzNAHqJ+Iyx25tVQteLOw3quY9n8LZ+nUV6x4F8X6brWmQNZys0i/Kdw2nf6V84WVtHay2EcTPHJPGHNxEPN2SNwsbDoo9/evWvCtzaJYQpGsVnO7IrgD5VYZ+ZT6cH86APb7e5BMaupjkfj5hwQPeuJ8QN5fjS6iRCrzQrLcH+HoQv4mt/TdZE2n75sSsRtXZ/e7Vzl2v2u4kujI73N7JsYn+CNB2+pNAHiXxmBXxDYEIVLWSlie+GYY/CsH4eyFPHGjsrYk8/A56/KQR+Vdt8ebQrd6NctG4i8t4C/fdwQD+tc38J4Y38UpJOARDGWjO3OGPGT6f/XoA9nu7dmjdQF54IPUj615n4z0GFkku7NPJuDwxDds/dA969VDmZGLow7bSOT9fas7ULCG5TZImQ3JyOTxQB4vZa7HZr5E6F3T5fMDZ2v2NbNp4kS4byo2MRJCyPnKqPU59T2qfxf4VhtbWa9mmjhjGFUBdu9j/D9B61wbQxSrJGt9i2gTzG8xdpZvRfU0Advq3iSG0t9tu5nkTmeReFM3aND3x3PYV57NM8txcXFx800pLMT/AHj6U+yt3u/Kt0lI+bKB/wDVqx7k9s10XhXSrW41GVt6m7t086OF+Q5U87fX/CgCLQdck8P2TmG2R53+dJJRn8x6g1qarr9x4k0YX91NA91ZSqWiJCOwxg8dx6Vk62Bqb3N8mYZULJL8v7tnxlSvoD0HrWfqzaPK6tYWV1YyLt+WWQSbxt5J9Dnt6UATX+rteaTb6fLa7JIpGlMitgucYH144qhCxhhluFI3YCwvjoc8n6gUunWsUzmW/me3tIsFjjLvk/dQetMuGkuXZo1RoIzvVdmUAznBHvQB9E6B4z8ZSweEtQm8U3txFqGoWcU8D2loEeOW4RGXKwhl+VjyDmvaPhp/yLt5/wBhrVv/AE43FeFWd68Npbaxo+gfDnzUCT28sXhoxsjggjDCfKsD3HIIr2D4E311qfw0sr/UEjjvbq91CedIgQiyNezswUEkgZJxkmgDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4X414/4V9Nnp/aGm/+l0Fd1XC/G1PM+Hs6Yzu1DTl/O+goA8D+J5D3GmxCVUmdW/ekcA7hgew/xrA0SG5htw76lYjSz+5dJm8wI3P3R1Dcnmux8Y6JHq3kyPcTWlzbOY9yruBU8nI/DiuJn8Maj9mBTT7aSQEkywP8+3PUr3FAFyDw/wDus2+vadcWueVZcu+OwHvXLXekRTzvHaQtEQ20Encr+/qMVMLK4sZVaaymZz8yuybdpz0U/SqM3nqJFlhmEqsUYqGJ/Md6ANKx8O66I8R3LQWpbb/rTyM9lra1bwt4egttMaXVZYJ2jcXMl4vEsuRtI9F68fSue0zS9Q1B2SA3m2N9puJNwRM9/qMV3Hh7Rfs7udfu/wC0Y5MfLszFE3TPPtQB59q/h2+so2eHF3a5OZIfmRPfPbtWDINvyupVwep4r0vVodC0G5ZtHa/i8wH/AEdX/dSEd8H61y6eImEpNxZWk0eQzRuuGPqM0AP8Harb6TdG6eweaIrtkkiTey+49K9T0/xVoMkRlF/HEudpaZShBIyBzXJ6NrnhqeaF5BJps2Apwu2PcB6jg12lrDd3A+0xx6Xq2nKMhUjHmjHQ+hNAFuLWdMuNptr+2YlQ/DjJHc/hXNfEW8tbvw7cWZ2veOokQlgQCDxz61szT6G8v2e6sLa3lzhhNBtwT2Bx3qzP4Y0K+CoLGFoxjKliAuDnH0oA5T4KeHo0u7vUtWtWSZUAs5O6Nk5ZR6/0r1uyuzBEssccjNBJmQr1MTHBf6qefpWFpFnK0k9rZRPBbQsEWSTuepx7CtjRWuP7bkimwY9hgG3pM4Gc/iP1oAg8QWqpbX2oCZRexSCUJn5GGMflXjuveIbqy0i8ukEx+3SedbOqZWOQfK2/+7xyPU103xg8TnTZGsbOCRorlPMe4HAjwcD/AMe4ryW+1KfVLC5LR3jwwRjf5T4jiy3BcdwTxQBgz3E08nmSO7u3VmPJpkc0keVjfAJBIx3HSm8kAKDjvz3prYydmdvagDuP+EP1Kz8B23iy31WOK21AiN7dW2OctgEHPzcjOOtdt8MNe0u4jNvqEkJljtyqWwXlWBw2313ZB/OvI77ULqfSbDTrss0FijfZl3fKpc53Y+mRmuv8LeBr6+8Nt4i0O9Z9QiIe1iixkODhkbP8XJIoA91sQoEc0JbbKpUgcYGOnsanZEl1aBEMayW9v5aRucbXHLAepPFY3ga/k1LRIJLlFW5lG507DHBBP1Ga0NXit7yZ4dhezkjAw2VZm7tu6joKAKOsW9hrML297EszS5XZIOQf6H3ryi1a80LWbv8AsPSJVtojg7kJaRM4Yj8a9N1O4ttMhaeS62xhNv7zke3PrXmGqeOHnlZIPMmkMhI2HYEUD17k/wBKAOol8d2lvbiW6W7DIwV4xEckkZGD0Irl9W+J965caXYR25PG6Zt7Y7EAd8Vzcut6rqe20ieW6K87LeLd1OQcDp3FbekeBfE9w6G1sI7eRDk3F0QEAYdfXI9KAOX1XWLvVriN9Ru7u8YHDK/CqOwVR2qvOFwsk32aGMOdi7txJ/3evNd+/hPwzoEWfFfisTXEhxLZaWMEn03DLfyqgPEWn6YrN4S8LwWm4lVu71fOlcdiBQBlaPo3iTVJDFp+lXLRt8/zx+SjqONvze/Srz+D/Gdvex6iulXMN1alZVkYphSOAAAefpViHx9rEk3k62018mxjlWEJDHjIx6elW5/El09sH8N+INYmmTbuS5cPlv7u0jmgDlLixvtN+0/2vPLDFcuDMoUkSsp3AenB6VnxQR3QaGxtJpnYgho1aRj7Yxwa7N/E/jO3Uvc2sckWMFZ7YOobPVcelT2PxJ1+2LRi20xCVzIYoNjAjn86AOXbQLu2iE+pwvZQBWVhdPg5HcL196khNtbyOhu0eMnaZIl2qy45JHr3Hoa15viNd3c27UNNs5XY/KwXLRjPvWrpradrl2w1iyitpbxT5EcQ/eMf72OwoAd8LHkfw1q0ClnilukFpCzY2s3Dtn0HXFfSPwJkWX4aWUkbB0e91BlYHqDez8185eNdUsfDPgq4trVIYppY/IQQ8eZKfvOp9AOp9a94/ZdOfgX4aJ6n7Uf/ACaloA9UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzD9pe5ls/grr9zbsUmhktJEYdmF3CQfzFen15V+1H/yQnxN/wBuv/pVFQB4x4G8dWPjSwWx1B1t9VCBXBOPOI6lff2qv4n0zU9FIuLS6uEhDD5wCcL6v6AZ/Gvneyu57G6iubSRo5omDKy9QRXtHw++Lu6KPTPFJymNkd5jJHPRx3HvQBPFrGr70jW4EpOWUOA6bR1/OnL4y1gRf6MbaLB3mJYNwI9c13lz4U0bVLeO70mZbaGbLJPandGx9COwrmdQ8I63bROFCyq/AktBkew29eMcn3oAyz4r8QpCJo5DHHxuK225Hz0wOx65rE1XV9S1S3Zru4eQQryoPlqQT12jqRW21zd6WWhW7uY4JHBKyw7VkbuMnpyOvvUF1qyXkz/ZtOt2JOwTqvzFyMEAdxigDmIY5bxXO2aZAN27JPTqR71M0FxbxwyzWAltmiLAjklc/ePoa07e7Ek3kuP3a/J5UY2D5fu/8CPP5VMb6O3jk+zW0qZOHSU5Dr16+x5oAxYkjVvKlR0JAQx8FVzz+B6c0lrcXNhdx3Gk3E9oQRuCy4yfXHQjI71J5MN/InkzK0jfNh8oWHXj1qWwS3YyLdou3O7BXliB0B9x1oA7nQ/iAksCxeLrVJRkAXMaghW/21/qK63Q4dPvVe88NXy3EX3ShOSR2K57V45FPBFNH58aJNIpETOuUVCMgA981ryDUbB4YxtimHzxtbHy2BI4x2x6igD2/TtRaV1jkAyp2MBwUP8Atjt9a0NRivoNagtoI4/Is1ju5ZAcswb7yj3HWuF8M+IRrNsGujt1exAgvX27TKpOAxHcZ5BrvNJneK4iIYiXu7c/TNAHnvxhkg03SYJSv2pLkeVGNvylc7y7fTGRXhKTLHFqMUDSgXCBVAbAZQwY7h34FfT/AMRNHur7wZe/Z7aOW5gka6hiZcowU7in4gHFfMF2kMck4Te4DHZIpwDn1H6UAZ7YJ6YHpTeRyM5HepJMHJwAeOB0pEcxyJIuCUIIzyOKAHujmGKR4v3bKY4nU8Hb1/LNbOjavqGnWlxY2bTmO4KzFLeQoyFf4wfccVnXV7NdrGl0qiGEYVI0ChcnJP1Ndl4I0eHWJLWFmE88MkcsiRHBWLJyrHvnjigD2/wxpy/2RaGAOIZUCKDxzjOT+JNc344mvNGaa8OrRiKGRFYBNyz9sKPXnr7V1urXkdvoQtIXZSp3qqjB2/xD6YxXFa/I9xq2gWa24FrNbSSxuCCM8AgZ9Bg/jQB55461j+0JWAnEcML7fIGcn39+vSu18GeAtFtPClzfeOI5t1wyi2tUyGjjHJZ8chienoPrVH4aaHBJcar4jv4UnWykeLTxNgoXXO6RR3PQA/WqFjdavqOr3J1G9uHglU7rENtLP1wD64wT7UAdJrPjbSdBsT/wiukxR7U8mMImCidi568HnHfmvL9c17W9QuwdQ1K8naX5/JGYoh9EHbuK6ySSGVWk02Z47q1bi3VBs91J/iHPHpXI36XczTs4madGJd5BjC+gPoKAMyJWVZJZQk2eSCMHJPU9zW5aaJqWtWJm0dnup1VlkjEgUIinhVB6msJ0MZby5AzJ8jMjZ3Z7e/pirOFtcSiS7SVogcRP5fPQgEf5NAF2+8N3tk0dusTzXOB5ghBcIT/Du9fWsiQNbzyxTxnz0bDODgo3fkflWvba7rMWmyQWd3IlovJaIYOR0LMeaqT3rXsnmXljCrMuHaEne5P8WPWgCOG9e1QiC8uYpkbDMshIP0zRNqU96LeO4lIjUnawQFlXOT9Se5psq2wCbUmkd/uoWAbb3XA75710mi+Eta1YF4oI9M051x5tz95168jrQBy0iSfa1jYMd7bQFGWlB9B711un248JWD+IfESvHckbYIC+XckY2j8OSewqbVb3QfhypeKI3+tyfNGsx5jUj7x/ug+g5NeReJfEOoeIr9rrUpy552IOFjHoo7CgBPEeu3mvXxub1+BlY41GFjXPRRX3T+y5/wAkJ8M/9vX/AKVS18AV9/8A7Ln/ACQnwz/29f8ApVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlX7Uf/JCfE3/AG6/+lUVeq15V+1H/wAkJ8Tf9uv/AKVRUAfAFLSUUAdN4R8a614Wn3aZdMIWYM8L/Mj49RXvfgf4qaJrywwXjrpWosSoyf3ZP17Z96+XqUEg5BwaAPuORUnixcxxTp/CxUNkev0rMu/B+hXsiuLAIyncPJbbz+HvXzH4T+JXiLw1GkFpd+baK4fyZhuH09hXsvhn4xeH9XaGLVEm025Y8kcxg/X0oA1774b28kUrWF1JFK2QzON29Sf59ea5jUvh3qdhA5gP2lYlYoEPJHXBH517BY3630Ik0+eC9hIyHicEgfSrAmCyMjoYwRyT0zQB823+nXXlxgQSkS5YNtyARjp/dFV0d9s5JMjr+9UqedvQkCvpHUvDemaxGWuISHwR5kDbSM/SvPtX+Fl7EJJNJuYbkgggOuyRR7EdR7UAebAwPLDHLIRD8qr5n3Y2PT8K0o5bq5IunuPPit2ZShHK9st7elSXOnT2FwltrUXmJHmMSzJsIz29CB61oHT3060iurCUxxgjNuUz8vfnuMUAX/C9uBOCzBZ5MK5z/rV7x/nyK9O067mhhhW6O+Zdn3VwHQHGfY15hZmG5jSRA6XDHcP7ydiMfqDXZ6F4i8u2j03WCZ0b91JMV2mRScDPoTQB6hY3MTwhosMpkEkZxkZ6FT+Ga+a/i34Bm8KalJdafEDoNy7GOfdnyXJJ2P6Hrg9+le3R3kmm3CxaZaT38UzbsBgCAOhGf4h+tao1S21CwkjltNwY+XcWl0gYp3wy9/rQB8XPGfTimOEDZYAKT03Yr6X1DwR4Bu7uCZ7O9s7UMRLJZhgsZJ6EAHgn24q1pngjwnaXMjWkbWoEjRl5IfM2x8YK56k9SaAPnTT9Om1iGC1sLe7kvizn5UHkkcAHd2PqT0r3/wAAfD9PDCSXcix+fLAuZeemMsB6jPf6V0enQ6Tp0Ie38u4eRm3xhNmzHt6ng1rX+rrd28NtDbTy4TKqvyl/8AKAOA1pXe4kvzcNBbxQH5m447gerdAP96m+K/D1vrGmaNHcO8DW0PmJOjGNoy2Mrj3HBrS16cLPaxarZR20aSfIpfflsdQO9Z7as00Uk0w2qxZEWcZIQDHP+0aAMTUrxFW20i0K2mmxLsMcQwRjuT2Ge3es3UJLcwT2ouFislQzlV4mc/3geo5H5VPqFkImNxmSKx2q0Qc5YPjBGO4xg5rkdaj8rUrdpXjQM2ASctj1Ht3x60AVtQuLg2tvNFbLYW2chVkzHIfXPUGlXVGGx1VpRCp2lm/dnA5PuQas6jp8l3qENtp7iVo48LGqFxIfUKOhYH867fQPhfqN2kN5qMo0i2K4khADzN/Rc0AefSajZQ3KNJpUVvKQ2yRRhdxGNyr3PvVS00a71O4P9k6feSCRsL5aluR0YseACa+hNI8HeHdDMYttPWSaMDbPdt5jr9Ca0mmOJUtoF2qcbUGwfnQB45Z/C7VZHD3d7FZW7IPM/wCWjt68dK2Ifhno0WDqF5eXbZ2qN3l4X3x3rrtb8RaXpELyavqVpbJyGQPlz6YHXNeUeKPjVZQfuvDVi8zgHNzd8c9iFoA9HWy0LwxbS3cFtY2kUYHmXU/8S+xPJIryfxp8YGFzLb+G0SRBwLudec+qr/U15h4j8Tat4juvP1e8knIOVToifRRwKxaALep391qd9LeX8zz3Mp3O7nkmqlFFABX3/wDsuf8AJCfDP/b1/wClUtfAFff/AOy5/wAkJ8M/9vX/AKVS0Aeq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V+1H/yQnxN/wBuv/pVFXqteVftR/8AJCfE3/br/wClUVAHwBRRRQAUUUUAFLSUUAaOk63qWkTrNpt7PbSKcgxuRXp/h747a9ZRpFqtvbagi4+Zxtb9K8fooA+p/D3xs8K6gUGoxXOmzkYY/ej/ADFejaT4h0rWol/sfVrK6dhlVMgDKc/nXwnUkE8sDh4ZHjcdGUkGgD9CLm2gvrdU1KxiuIhgMGQMMVz974A0a7fzLCR7bnIgDHap9q+SNC+KPi/Rdi2mtXLRooUJKd64HQc16Pof7SGrQeUur6VaXaqeWTKMaAPbrT4frBJ87R3EPbP3vfBq3L4Jtobd4wDNGRuQSDLAjnr6iuP0L9ofwfdqq31teWL/AO7vA/Ku+0z4l+DdRWMW2tw5kXO18jH196AOS1PR7m1Z5IjcuN27MTlXj4wcD+VZ/hS8lW4uIL4fZr2QkwSKSwuCAT8zHoxA4Femy+JfDFwFxrOnv83H7wZBrmfEGteFREyS65ZwKx5VSOvv6UAc1qHieDSbVbnVLp7K4dlVWtmBJB7MvpgEk+1c/Y/FqJ9fk025ltIrff5cd7G+5H9OCOM5rmfFeufDXS5ri4tYf7VvjuCR72ZAxHXnjGa57RPiL4blRbTWdBto7ZQFRoowevUmgD1a+8V3ga3i0yyS71JphGVuJFjXaTgvnvgfpUPijWbiwuJY2t5bwFSjyRTeWLY46j1HPauW0fVPAs2qf6JNaYzx9qLDyR6xk/yr0G0u/DGtRB5NQ065gLCP55AG3jnA/LNAHmttNqTTi4i+13+U/d+YfnCdDtJ9zXQaZpN/dNI8w8yZkVWZnJSNeeD7+9er6ZaeE4TGU1KwC4ICecuOTzjn1refXfC9jAYv7U0yKNQchXUjHvigDxddL1G9vlWzVrlmURtLHbs5YDhgc8KDW7a/Cg3TxTa3JFbReYpMJbc5UDhcjpySTXV3/wAW/AmnI6rq6ykD7lvEfm/HpXnnij9ovRbRWGi6S13OCQrTvhcEDnj+VAHp+j6DpehQeTotjtZQQ0jLlmH1NVdf1Ox0mPz9V1G2sYwN26Rxux9K+Z/E3x/8X6wrx2slvp0TDGLdPmH/AAI15ZqWp3up3DT6hdTXEzdXlcsf1oA+kvFnxt8PaYxTRYZdXuhkea/yRj+p/CvGvEnxQ8Ua5JJv1B7WBiSIbf5AB6Z6muHpKAJJppZ3LzSPIx6ljk1HRRQAUUUUAFFFFABX3/8Asuf8kJ8M/wDb1/6VS18AV9//ALLn/JCfDP8A29f+lUtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVftR/wDJCfE3/br/AOlUVeq1V1TTbHV7CWx1Wytr6ylx5lvcxLLG+CCMqwIOCAfqBQB+WtFfpV/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE0AfmrRX6Vf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0AfmrRX6Vf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAH5q0V+lX/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNAH5q0V+lX/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTQB+atLX6U/wDCuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNAH5rU9JZE+47r9Div0m/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoA/Nr7RNnPmv+dI80jk73Zs9cmv0m/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4mgD81qSv0q/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JoA/NalDsOjH86/Sj/hXHgf/oTfDf8A4K4P/iaP+FceB/8AoTfDf/grg/8AiaAPzZWaVfuyOPxqT7Zc7SvnSbT1Ga/SL/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mgD812dmOWYn6mm1+lX/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TQB+atFfpV/wrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATQB+atFfpV/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E0AfmrRX6Vf8K48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE0AfmrRX6Vf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAH5q0V+lX/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNAH5q19/8A7Ln/ACQnwz/29f8ApVLXV/8ACuPA/wD0Jvhv/wAFcH/xNdBpem2OkWEVjpVlbWNlFny7e2iWKNMkk4VQAMkk/UmgC1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Soft tissue window computed tomography (CT), axial pelvis. Note the cystic, low attenuation mass immediately anterior to the right femoral head (arrow).",
"    <br>",
"     (B) Proton density-weighted magnetic resonance imaging (MRI), axial pelvis. The area of decreased attenuation on the CT study displays homogeneous low signal intensity on MRI (arrow).",
"     <br>",
"      (C) T2-weighted MRI, axial pelvis. Observe the homogeneous hyperintense signal intensity in this localized fluid collection (arrow). These findings are consistent with iliopsoas bursitis.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37110=[""].join("\n");
var outline_f36_15_37110=null;
var title_f36_15_37111="Cystic thyroid nodules";
var content_f36_15_37111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic thyroid nodules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37111/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/15/37111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid nodules are common, and a large proportion has mixed cystic and solid components. In some studies, a nodule is called a cyst only if it is predominantly cystic on ultrasonography, but in others the term is applied to nodules that are predominantly solid but have small areas of cystic degeneration. Thus, depending upon the criteria used, up to 50 percent of solitary thyroid nodules are cystic. Most recur after fine needle aspiration. The appropriate evaluation and management of patients with cystic thyroid nodules is an area of controversy.",
"   </p>",
"   <p>",
"    This topic review will focus on the unique challenges presented by patients with cystic thyroid lesions. The general approach to thyroid nodules is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like most thyroid nodules, cystic thyroid nodules often come to attention when noted by the patient or as an incidental finding during a routine physical examination or radiologic procedure such as carotid ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) of the neck (so-called \"thyroid incidentalomas\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients develop symptoms, and cystic thyroid lesions (not subacute thyroiditis) are the most common cause of thyroid pain. As an example, sudden hemorrhage or hemorrhagic infarction of a solid thyroid nodule can result in a predominantly cystic and painful neck mass. Even relatively small hemorrhagic cysts of only 1 to 2 mL may be associated with considerable neck discomfort and dysphagia. More extensive hemorrhage may cause hoarseness and vocal cord paralysis and may compromise the airway, especially if the nodule is located within or below the thoracic inlet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=see_link\">",
"     \"Clinical manifestations and evaluation of obstructive or substernal goiter\"",
"    </a>",
"    .) In addition, chronic intermittent degeneration of a thyroid tumor can result in intermittent neck discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;True simple thyroid cysts lined by benign epithelial cells are rare. As an example, in one ultrasound study of 1985 patients with 3483 nodules larger than 10 mm, there were only seven completely cystic nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/3\">",
"     3",
"    </a>",
"    ]. Most cystic nodules are partly solid structures that have undergone cystic degeneration (mixed or complex nodules). Complex nodules are common. In a review of 1128 patients with 1458 thyroid nodules who underwent ultrasound-guided fine needle aspiration (FNA), 53.5 percent were partially cystic, with 13.7 percent described as &gt;75 percent cystic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thyroid adenomas and cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cystic thyroid nodules are benign degenerating thyroid adenomas. Autonomously functioning thyroid adenomas are more likely to undergo cystic degeneration than nonfunctioning adenomas. Purely cystic lesions rarely contain cancer, but the likelihood of cancer in complex (cystic and solid) nodules approaches that of solid nodules (5 to 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/3,5-9\">",
"     3,5-9",
"    </a>",
"    ]. The likelihood of cancer being present decreases as the proportion of the nodule that is cystic increases. In the ultrasound study described above, cancer was present in 5.8, 2.3, and 0 percent of mixed solid and cystic (25 to 74 percent cystic), predominantly cystic (&gt;75 percent cystic), and completely cystic nodules, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/3\">",
"     3",
"    </a>",
"    ]. In another report of 360 thyroid cancers, only nine (2.5 percent) had a cystic component that was &gt;50 percent of the volume of the mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/10\">",
"     10",
"    </a>",
"    ]. All nine of these cystic nodules showed other ultrasound features that suggested malignancy (microcalcifications, prominent mural solid component, irregular wall, increased vascularity).",
"   </p>",
"   <p>",
"    Among the thyroid cancers that are associated with cysts, papillary thyroid cancer is most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5\">",
"     5",
"    </a>",
"    ], although cystic areas have been found in all types of thyroid cancer. In one surgical series of 71 cystic nodules of the thyroid, the following distribution was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4 percent were simple cysts",
"     </li>",
"     <li>",
"      82 percent were degenerating adenomas",
"     </li>",
"     <li>",
"      14 percent were cancers, all papillary cancers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In assessing these figures, it is important to note that surgical series have selection bias. In this series, 23 percent of all nodules were cancers, about four to five times higher than in unselected patients with thyroid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. If this correction is applied to the preceding results, the risk of cancer in unselected patients with cystic nodules can be estimated to be about 2 to 4 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroglossal duct cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thyroid gland originates in the fetus in the foramen cecum at the base of the tongue and migrates caudally in the midline to its normal position in the anterior neck below the cricoid cartilage. This migration results in formation of the thyroglossal duct, which initially connects the floor of the pharynx to the thyroid gland. The thyroglossal duct normally disappears, but persistence of the duct can give rise to cystic masses. Over one-half of these cysts come to clinical attention during childhood and adolescence, but some first appear in adults.",
"   </p>",
"   <p>",
"    Over 90 percent of thyroglossal duct cysts are midline, but some may be displaced slightly. Most occur below the hyoid bone, but they can occur anywhere along the thyroglossal duct. Cysts in the upper tract may move when the tongue is protruded.",
"   </p>",
"   <p>",
"    Thyroglossal duct cysts may drain into the pharynx, become infected because of continuity with the pharynx, form sinus tracts to the overlying skin, and may rarely be malignant (usually a papillary thyroid cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/13\">",
"     13",
"    </a>",
"    ]. For these reasons, symptomatic thyroglossal duct cysts should be excised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25864?source=see_link\">",
"     \"Thyroglossal duct cysts and ectopic thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9693355\">",
"    <span class=\"h2\">",
"     Hydatid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary echinococcal cysts of the thyroid have been reported, but are extremely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9693402\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neck cysts, which may be confused with thyroid cysts, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parathyroid cysts &ndash; Parathyroid cysts are rare. Aspiration of clear, watery fluid from a neck mass is virtually diagnostic of a parathyroid cyst, which can be confirmed by finding a high concentration of parathyroid hormone in the cyst fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40387?source=see_link\">",
"       \"Parathyroid cysts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystic hygromas &ndash; Cystic hygromas develop when the jugular lymph sac fails to communicate with the thoracic duct. These cysts usually present in early childhood. Unlike thyroid and thyroglossal duct cysts, cystic hygromas do not move with swallowing.",
"     </li>",
"     <li>",
"      Branchial cleft cysts &ndash; Branchial cleft cysts develop from the first, second, or third pharyngeal pouches, and are usually located in the upper lateral neck (",
"      <a class=\"graphic graphic_figure graphicRef81013 \" href=\"mobipreview.htm?25/23/25972\">",
"       figure 1",
"      </a>",
"      ). They do not move with swallowing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11608?source=see_link&amp;anchor=H4#H4\">",
"       \"Differential diagnosis of a neck mass\", section on 'Branchial cleft cyst'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical importance of the cystic thyroid nodule evaluation is primarily related to the need to exclude thyroid cancer. As noted above, purely cystic lesions rarely contain cancer, but the likelihood of cancer in complex (cystic and solid) nodules approaches that of solid nodules, in the range of 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. It is the nature of the solid component associated with the \"cyst\" that is of primary clinical importance. The solid component may comprise more than one-half of the nodule, be just a small mass of cells along the wall of the cyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66403 \" href=\"mobipreview.htm?41/16/42254\">",
"     image 1",
"    </a>",
"    ), or be just a thickening of the cyst wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with thyroid nodules in general, the diagnostic evaluation of cystic thyroid nodules includes measurement of serum thyroid stimulating hormone (TSH), assessment of the sonographic features, and, if indicated, fine needle aspiration (FNA) biopsy. Features of the evaluation that are unique to patients with cystic nodules are reviewed below. The diagnostic approach to thyroid nodules in general is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31602767\">",
"    <span class=\"h2\">",
"     Serum TSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cystic thyroid nodules are nonfunctioning, and therefore the serum TSH is typically normal. Rarely, hemorrhage into a thyroid nodule can result in transient thyrotoxicosis in patients with previously normal TSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, some cystic nodules are hyperfunctioning thyroid adenomas that have undergone cystic degeneration. In these settings, the TSH may be below normal. If the serum TSH concentration is low, indicating overt or subclinical hyperthyroidism, the possibility that the nodule is hyperfunctioning is increased and thyroid scintigraphy should be performed next. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Thyroid scintigraphy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8000999\">",
"    <span class=\"h2\">",
"     Thyroid ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasonography should be performed in all patients with a suspected thyroid nodule on physical examination or with nodules incidentally noted on other imaging studies (carotid ultrasound, CT, MRI, or FDG-PET scan). Ultrasound can identify predominantly cystic nodules. In addition, there are several ultrasonographic findings that are suspicious for thyroid cancer (",
"    <a class=\"graphic graphic_table graphicRef68199 \" href=\"mobipreview.htm?20/17/20763\">",
"     table 1",
"    </a>",
"    ). The predictive value of these characteristics varies widely, and we do not rely on thyroid ultrasound to diagnose cancer or to select patients for surgery. However, ultrasound findings can be used to select nodules for FNA biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fine needle aspiration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8001087\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that the presence of suspicious ultrasound features is more predictive of malignancy than nodule size alone. The decision to biopsy a thyroid nodule should be based upon a combination of ultrasonographic features and nodule size. This approach is consistent with the American Thyroid Association guidelines (",
"    <a class=\"graphic graphic_table graphicRef70513 \" href=\"mobipreview.htm?2/6/2157\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mixed cystic-solid nodules without suspicious features on ultrasound, we perform FNA biopsy if the nodules are &ge;2 cm (",
"    <a class=\"graphic graphic_table graphicRef70513 \" href=\"mobipreview.htm?2/6/2157\">",
"     table 2",
"    </a>",
"    ). In the presence of suspicious ultrasound features, we perform FNA biopsy of mixed nodules &ge;1.5 to 2 cm, or if the solid component exceeds 1 to 1.5 cm (0.5 cm for high risk patients). Purely cystic nodules (no mural component) do not require a diagnostic FNA biopsy. Diagnostic biopsy usually requires tissue obtained from the solid component of the nodule, but occasionally, malignant cells are present in the cyst fluid. A complete discussion of thyroid biopsy techniques is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8001195\">",
"    <span class=\"h3\">",
"     Ultrasound-guided FNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of FNA performed by palpation is reduced in nodules with &gt;25 to 50 percent cystic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Thus, we suggest ultrasound-guided FNA for predominantly cystic nodules. Thyroid cyst fluid may contain diagnostic follicular cells, macrophages, blood,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colloid. Thus, the cyst fluid should be assessed for cellular material. When ultrasonography shows a solid component that is either small or posteriorly located, ultrasound-guided fine needle aspiration directed at the solid component or the cyst wall may reduce the risk of a non-diagnostic result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31814?source=see_link\">",
"     \"Ultrasound-guided thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8001202\">",
"    <span class=\"h3\">",
"     Non-diagnostic FNA results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyst fluid may be acellular, or the cellular material may be degenerated and uninterpretable by the cytopathologist. A finding of no malignant cells in the cyst fluid may be reassuring if the nodule is primarily cystic and decreases in size after aspiration. However, if palpation-guided FNA is performed and is non-diagnostic, and the nodule remains palpable, we suggest repeat aspiration under ultrasound guidance.",
"   </p>",
"   <p>",
"    In a series of 112 cystic nodules with surgical confirmation, malignancy was found at surgery in only 1 of 70 nodules (1.4 percent) that resolved after aspiration versus 4 of 37 nodules (10.8 percent) that remained palpable after aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/21\">",
"     21",
"    </a>",
"    ]. After an initial non-diagnostic FNA, repeat FNA with ultrasound guidance will provide a diagnostic specimen in 50 percent of cystic nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the results of ultrasound-guided fine needle aspiration of a complex cystic nodule are non-diagnostic, and the nodule remains palpable after aspiration, repeat aspiration under ultrasound guidance is indicated.",
"   </p>",
"   <p>",
"    Several caveats should be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For non-diagnostic hemorrhagic nodules, it may be helpful to wait four weeks for the nodule to organize and the blood to be resorbed before attempting a follow-up biopsy.",
"     </li>",
"     <li>",
"      Atypical cells may be present in aspirates of thyroid cysts. The cytologic features of reparative epithelial cyst-lining cells may include nuclear grooves and granular cytoplasm, but these are distinguished from papillary cancers by their spindled cytomorphology and other characteristic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nature of the fluid may be helpful. The fluid from nodules that contain cancer is usually hemorrhagic or pink-colored [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/23\">",
"       23",
"      </a>",
"      ]. Chocolate-colored fluid suggests hemorrhage that occurred at least one week before aspiration. Straw-colored fluid is less likely to be associated with cancer (although the fluid was straw-colored in one cystic papillary cancer in the series noted above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5\">",
"       5",
"      </a>",
"      ]); furthermore, cysts containing straw-colored fluid are more likely to resolve after aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Colloid cysts may contain viscous yellow-brown fluid that cannot be aspirated through a 25-gauge needle, but may be slowly aspirated through a 22-gauge or larger needle. The cytology of cells from the solid component of complex colloid nodules is usually consistent with a benign macrofollicular or colloid adenoma; if the cyst fluid is acellular but composed predominantly of colloid in such a lesion, it is likely to be benign.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thyroid scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid scintigraphy should be performed in patients with a low serum TSH concentration. Predominantly cystic nodules and the cystic component of complex nodules do not concentrate radioiodine or technetium, and will appear hypofunctioning (\"cold\") on radionuclide scans. However, some cystic nodules are degenerating, autonomously functioning thyroid adenomas. A thyroid scan may demonstrate that the solid portion of the nodule is autonomous in a patient with a low serum thyrotropin (TSH) concentration and a complex nodule, or a patient with a complex nodule in whom the aspiration cytology shows microfollicular cytology (\"follicular neoplasm\"). A nodule that is hyperfunctioning on radioiodine imaging does not require FNA because autonomous nodules are rarely cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Thyroid scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches may be successful in managing patients with cystic thyroid nodules. Fine needle aspiration alone may be curative in a minority of patients. Cancer is uncommon in cystic nodules that are no longer palpable after aspiration or substantially resolve on ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/21\">",
"     21",
"    </a>",
"    ]. If the nodule remains palpable after aspiration, or persists on ultrasound, however,",
"    <strong>",
"     treatment depends upon the cytologic results obtained from FNA",
"    </strong>",
"    . There are six major categories of results that are obtained from FNA, each of which indicates different subsequent management. The management of cytologically benign and non-diagnostic cystic nodules is reviewed here. The other diagnostic categories and subsequent management are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link&amp;anchor=H11#H11\">",
"     \"Thyroid biopsy\", section on 'Diagnostic categories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroxine (T4) therapy was not beneficial in a small randomized trial of patients with cystic nodules (recurrences occurred in seven patients (70 percent) in both the placebo and thyroid hormone-treated groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, we do not recommend suppressive therapy in patients with cystic nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16071313\">",
"    <span class=\"h2\">",
"     Benign cystic nodules",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16071360\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologically benign cysts do not require re-aspiration unless it is to alleviate compressive symptoms. Up to 25 to 50 percent of predominantly cystic nodules disappear after aspiration, but fluid reaccumulates in the majority due to either recurrent hemorrhage or slow accumulation of fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5,25\">",
"     5,25",
"    </a>",
"    ]. Repetitive aspiration is preferred over surgery by some patients, and some cysts do not recur after several aspirations. Cysts that are tense and hard on physical examination are more likely to refill after aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16071321\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite benign cytology, many patients opt for surgical excision of cystic nodules if the nodule recurs after one or more successful aspirations, or if there is continued enlargement or pain associated with fluid reaccumulation. Size (&gt;4 cm) of the cystic nodule may also be used as a criterion for surgery, although we do not use size as an absolute criteria for surgery if the patient is not bothered by the nodule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ethanol ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol ablation generally involves removing as much of the cyst fluid as possible under ultrasound guidance, and then instilling an amount of 99 percent ethanol equal to 50 percent of the aspirated volume into the thyroid cyst cavity. In some series the ethanol is removed after five minutes, and in other reports the fluid is allowed to remain in the cyst cavity. In randomized trials, ethanol ablation effectively reduces the size of benign cystic thyroid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. As an example, in a randomized trial of fine needle aspiration (FNA) of the cyst fluid versus FNA followed by percutaneous ethanol injection in 281 patients, median reduction in cystic nodule volume after one year was significantly greater in the ethanol group (85.6 versus 7.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/28\">",
"     28",
"    </a>",
"    ]. Compressive and cosmetic symptoms were also significantly improved in the ethanol group. Another randomized trial compared flushing with 99 percent ethanol versus saline in 66 patients with recurrent thyroid cysts (&ge;2 mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients had subtotal cyst aspiration prior to flushing and subsequent complete fluid aspiration after flushing. After six months, cure (defined as a cyst volume less than 1 cm) was obtained in a significantly greater proportion of patients treated with ethanol (82 versus 48 percent). Six patients required more than one ethanol ablative procedure. The results of observational trials are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In one prospective study, only 6 of 92 patients who responded to ethanol injections relapsed after a nine-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain during and immediately after the procedure is the major side effect of ethanol ablation. In the study cited above, 21 percent of patients had transient moderate to severe pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/27\">",
"     27",
"    </a>",
"    ]. Recurrent laryngeal nerve palsy also has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/32\">",
"     32",
"    </a>",
"    ]. As a result, ethanol should always be administered under ultrasound guidance. The use of ethanol sclerotherapy has gained much more acceptance in Europe and Japan than in the United States because of concerns regarding complications. Where ethanol ablation is performed routinely, it is an alternative to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8000655\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound-guided radiofrequency ablation has also been used to reduce the volume of benign cystic thyroid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one study, 20 patients with predominantly cystic nodules and incomplete resolution of symptoms after ethanol ablation underwent radiofrequency ablation (RFA). RFA after a single session of ethanol ablation significantly reduced mean symptom score, cosmetic score, and nodule volume (mean nodule volume decreased from 11.3 to 0.9 mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37111/abstract/35\">",
"     35",
"    </a>",
"    ]. Two patients required more than one RFA session. The major side effect of RFA is pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a burning sensation in the neck radiating to the head, shoulders, teeth, and chest. Hematoma and transient voice changes have also been reported. As with ethanol ablation, RFA is not commonly performed in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16071305\">",
"    <span class=\"h2\">",
"     Non-diagnostic cystic nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologically non-diagnostic cysts with a significant solid component require repeat diagnostic ultrasound-guided FNA. Repeat aspiration may also be therapeutic. If repeated ultrasound-guided aspirations of a predominately cystic nodule are",
"    <strong>",
"     non-diagnostic",
"    </strong>",
"    and the nodule remains palpable or persists on ultrasound after aspiration, or rapidly accumulates fluid, ultrasound monitoring or surgery are management options. Ultrasound monitoring is typically performed every 6 to 18 months and then possibly less often (three to five years) if the nodule size is stable or smaller. We prefer surgical resection if the cytology is non-diagnostic and the size of the solid component is greater than 1.5 cm (greater than 1 cm with suspicious ultrasonographic characteristics) (",
"    <a class=\"graphic graphic_table graphicRef68199 \" href=\"mobipreview.htm?20/17/20763\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23618?source=see_link\">",
"       \"Patient information: Thyroid nodules (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/16/18691?source=see_link\">",
"       \"Patient information: Thyroid nodules (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8000727\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic thyroid nodules often come to attention when noted by the patient or as an incidental finding during a routine physical examination or radiologic procedure, such as carotid ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) of the neck. However, some patients have symptoms, such as neck pain and dysphagia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cystic thyroid nodules are benign, degenerating thyroid adenomas. However, thyroid cancers may be cystic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with thyroid nodules in general, the diagnostic evaluation of cystic thyroid nodules includes measurement of thyroid stimulating hormone (TSH), assessment of the sonographic features, and, if indicated, fine needle aspiration (FNA) biopsy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mixed cystic-solid nodules without suspicious features on ultrasound, we perform FNA biopsy if the nodules are &ge;2 cm (",
"      <a class=\"graphic graphic_table graphicRef70513 \" href=\"mobipreview.htm?2/6/2157\">",
"       table 2",
"      </a>",
"      ). In the presence of suspicious ultrasound features, we perform FNA biopsy of mixed nodules &ge;1.5 to 2 cm, or if the solid component exceeds 1 to 1.5 cm (0.5 cm for high risk patients). Purely cystic nodules (no mural component) do not require a diagnostic FNA biopsy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fine needle aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspiration alone may be curative in a minority of patients. If the nodule remains palpable after aspiration, however, treatment depends upon the cytologic results obtained from FNA. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H24#H24\">",
"       \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytologically benign cysts do not require re-aspiration unless it is to alleviate compressive symptoms. If the nodule recurs after repeated aspirations and there is continued enlargement or pain associated with fluid reaccumulation, we suggest surgical excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ethanol ablation effectively reduces the size and recurrence of benign cystic thyroid nodules. Where ethanol ablation is performed routinely, it is an alternative to surgery. (See",
"      <a class=\"local\" href=\"#H16071313\">",
"       'Benign cystic nodules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Ethanol ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If repeated ultrasound-guided aspirations of a predominately cystic nodule are",
"      <strong>",
"       non-diagnostic",
"      </strong>",
"      and the nodule remains palpable or persists on ultrasound after aspiration, or rapidly accumulates fluid, ultrasound monitoring or surgery are management options.",
"      <br/>",
"      <br/>",
"      Ultrasound monitoring is typically performed every 6 to 18 months and then possibly less often (three to five years) if the nodule size is stable or smaller.",
"      <br/>",
"      <br/>",
"      If the size of the solid component of a complex cystic nodule is &gt;1.5 cm (&gt;1 cm in the presence of suspicious ultrasound features) (",
"      <a class=\"graphic graphic_table graphicRef68199 \" href=\"mobipreview.htm?20/17/20763\">",
"       table 1",
"      </a>",
"      ), and one is unable to obtain a benign cytology, we suggest surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery is also preferable for patients with painful nodular enlargement due to recurrent fluid reaccumulation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/1\">",
"      Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/2\">",
"      Massoll N, Nizam MS, Mazzagerri EL. Cystic thyroid nodules: Diagnostic and therapeutic dilemmas. The Endocrinologist 2002; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/3\">",
"      Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006; 91:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/4\">",
"      Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/5\">",
"      de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, Mazzaferri EL. Cystic thyroid nodules. The dilemma of malignant lesions. Arch Intern Med 1990; 150:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/6\">",
"      Cusick EL, McIntosh CA, Krukowski ZH, Matheson NA. Cystic change and neoplasia in isolated thyroid swellings. Br J Surg 1988; 75:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/7\">",
"      Hiromura T. [Ultrasonography of cystic thyroid nodules: sonographic-pathologic correlation]. Nihon Igaku Hoshasen Gakkai Zasshi 1994; 54:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/8\">",
"      Lee MJ, Kim EK, Kwak JY, Kim MJ. Partially cystic thyroid nodules on ultrasound: probability of malignancy and sonographic differentiation. Thyroid 2009; 19:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/9\">",
"      Lin JD, Hsuen C, Chen JY, et al. Cystic change in thyroid cancer. ANZ J Surg 2007; 77:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/10\">",
"      Henrichsen TL, Reading CC, Charboneau JW, et al. Cystic change in thyroid carcinoma: Prevalence and estimated volume in 360 carcinomas. J Clin Ultrasound 2010; 38:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/11\">",
"      Werk EE Jr, Vernon BM, Gonzalez JJ, et al. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/12\">",
"      Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992; 93:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/13\">",
"      Ewing CA, Kornblut A, Greeley C, Manz H. Presentations of thyroglossal duct cysts in adults. Eur Arch Otorhinolaryngol 1999; 256:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/14\">",
"      Deane SA, Telander RL. Surgery for thyroglossal duct and branchial cleft anomalies. Am J Surg 1978; 136:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/15\">",
"      Majumdar, P, Ghosh, DP. Hydatid cyst of thyroid. Indian J Surg 1970; 32:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/16\">",
"      Ginsberg J, Young JE, Walfish PG. Parathyroid cysts. Medical diagnosis and management. JAMA 1978; 240:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/17\">",
"      Simeone JF, Daniels GH, Mueller PR, et al. High-resolution real-time sonography of the thyroid. Radiology 1982; 145:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/18\">",
"      Onal IK, Da��delen S, Atmaca A, et al. Hemorrhage into a thyroid nodule as a cause of thyrotoxicosis. Endocr Pract 2006; 12:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/19\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/20\">",
"      Redman R, Zalaznick H, Mazzaferri EL, Massoll NA. The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid 2006; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/21\">",
"      Melliere D, Massin JP, Calmettes C, et al. [The risk of malignancy in cold thyroid nodules. 607 operated cases]. Presse Med 1970; 78:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/22\">",
"      Faquin WC, Cibas ES, Renshaw AA. \"Atypical\" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. Cancer 2005; 105:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/23\">",
"      Rosen IB, Provias JP, Walfish PG. Pathologic nature of cystic thyroid nodules selected for surgery by needle aspiration biopsy. Surgery 1986; 100:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/24\">",
"      McCowen KD, Reed JW, Fariss BL. The role of thyroid therapy in patients with thyroid cysts. Am J Med 1980; 68:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/25\">",
"      Miller JM, Zafar SU, Karo JJ. The cystic thyroid nodule. Recognition and management. Radiology 1974; 110:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/26\">",
"      Del Prete S, Caraglia M, Russo D, et al. Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid 2002; 12:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/27\">",
"      Bennedbaek FN, Heged&uuml;s L. Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab 2003; 88:5773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/28\">",
"      Valcavi R, Frasoldati A. Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract 2004; 10:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/29\">",
"      Yasuda K, Ozaki O, Sugino K, et al. Treatment of cystic lesions of the thyroid by ethanol instillation. World J Surg 1992; 16:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/30\">",
"      Cho YS, Lee HK, Ahn IM, et al. Sonographically guided ethanol sclerotherapy for benign thyroid cysts: results in 22 patients. AJR Am J Roentgenol 2000; 174:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/31\">",
"      Zingrillo M, Torlontano M, Chiarella R, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid 1999; 9:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/32\">",
"      Ryan WG, Dwarakanathan A. Minor complication of thyroid cyst sclerosis with tetracycline. Arch Intern Med 1986; 146:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/33\">",
"      Jeong WK, Baek JH, Rhim H, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol 2008; 18:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/34\">",
"      Sung JY, Kim YS, Choi H, et al. Optimum first-line treatment technique for benign cystic thyroid nodules: ethanol ablation or radiofrequency ablation? AJR Am J Roentgenol 2011; 196:W210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37111/abstract/35\">",
"      Jang SW, Baek JH, Kim JK, et al. How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: role of radiofrequency ablation. Eur J Radiol 2012; 81:905.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7850 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.22.229.50-9BE3393297-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37111=[""].join("\n");
var outline_f36_15_37111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8000727\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thyroid adenomas and cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroglossal duct cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9693355\">",
"      Hydatid cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9693402\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31602767\">",
"      Serum TSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8000999\">",
"      Thyroid ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fine needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8001087\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8001195\">",
"      - Ultrasound-guided FNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8001202\">",
"      - Non-diagnostic FNA results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thyroid scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16071313\">",
"      Benign cystic nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16071360\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16071321\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ethanol ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8000655\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16071305\">",
"      Non-diagnostic cystic nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8000727\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7850|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/16/42254\" title=\"diagnostic image 1\">",
"      Cystic thyroid nodule US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7850|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/23/25972\" title=\"figure 1\">",
"      Branchial cleft cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/17/20763\" title=\"table 1\">",
"      Ultrasound features associated with thyroid cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/6/2157\" title=\"table 2\">",
"      Indications FNA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=related_link\">",
"      Clinical manifestations and evaluation of obstructive or substernal goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11608?source=related_link\">",
"      Differential diagnosis of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40387?source=related_link\">",
"      Parathyroid cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/16/18691?source=related_link\">",
"      Patient information: Thyroid nodules (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23618?source=related_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31814?source=related_link\">",
"      Ultrasound-guided thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37112="Clinically isolated syndromes suggestive of multiple sclerosis";
var content_f36_15_37112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinically isolated syndromes suggestive of multiple sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37112/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/15/37112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinically isolated syndrome (CIS) is a single attack compatible with multiple sclerosis (MS), such as optic neuritis. An episode of CIS can create a diagnostic and therapeutic dilemma. Over 80 percent of patients with a CIS and magnetic resonance imaging (MRI) lesions go on to develop MS, while approximately 20 percent have a self-limited process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Identifying those 80 percent may have particular importance, since accumulating evidence suggests that starting disease modifying therapies early in the course of MS improves outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Interferons'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A radiologically isolated syndrome (RIS) suggestive of MS is defined as a presentation without overt clinical symptoms but with MRI findings highly suggestive of MS based upon location and morphology within the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the evaluation and treatment of CIS suggestive of MS.",
"   </p>",
"   <p>",
"    Optic neuritis and other aspects of MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29944?source=see_link\">",
"     \"Optic neuritis: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with a CIS presents as a young adult with a single episode of central nervous system dysfunction followed by at least partial resolution. In contrast, a radiologically isolated syndrome (RIS) is defined by incidental MRI findings highly suggestive of MS in an asymptomatic patient lacking any history, symptoms, or signs of MS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinically isolated syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIS most often presents with either long tract",
"    <span class=\"nowrap\">",
"     symptoms/signs,",
"    </span>",
"    optic neuritis, or a brainstem or spinal cord syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. While CIS is by definition isolated to a single attack in time, it is not necessarily isolated in space, as approximately one-quarter of patients present with multifocal abnormalities.",
"   </p>",
"   <p>",
"    There are no clinical findings that are unique to MS, but some are highly characteristic of the disease (",
"    <a class=\"graphic graphic_table graphicRef63940 \" href=\"mobipreview.htm?21/53/22363\">",
"     table 1",
"    </a>",
"    ). Common presenting symptoms of MS are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"     table 2",
"    </a>",
"    ). Any of these may present as a CIS. These symptoms are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .) They are summarized here.",
"   </p>",
"   <p>",
"    The following are among the more common types of presentation with a CIS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory symptoms are a common initial feature of MS (",
"      <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"       table 2",
"      </a>",
"      ). Symptoms are commonly described as numbness, tingling, pins-and-needles, tightness, coldness, or swelling of the limbs or trunk. Radicular pains also can be present, particularly in the low thoracic and abdominal regions. An intense itching sensation, especially in the cervical dermatomes and usually unilateral, is suggestive of MS.",
"     </li>",
"     <li>",
"      Optic neuritis is the most common type of involvement of the visual pathways. It usually presents as acute or subacute unilateral eye pain that is accentuated by ocular movements. This is followed by a variable degree of visual loss (scotoma) affecting mainly central vision. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9464?source=see_link\">",
"       \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Motor symptoms present as leg weakness more commonly than arm weakness due to the frequent occurrence of lesions in the descending motor tracts of the spinal cord. Physical findings include spasticity, usually more marked in the legs than in the arms. The deep tendon reflexes may be exaggerated, and extensor plantar responses may be observed.",
"     </li>",
"     <li>",
"      Diplopia may result from lesions in the brainstem or in cerebellar pathways.",
"     </li>",
"     <li>",
"      Coordination problems include gait imbalance, difficulty in performing coordinated actions with the arms, and slurred speech. These may occur as a result of impairment of cerebellar pathways. Physical examination may reveal dysmetria, decomposition of complex movements, hypotonia, or an intention tremor. Ocular findings of nystagmus, ocular dysmetria, and failure of fixation suppression (square wave jerks) suggest cerebellar or cerebello-vestibular connection dysfunction. Speech can be scanning or explosive in character.",
"     </li>",
"     <li>",
"      Vertigo is a reported symptom in 30 to 50 percent of patients with MS. It is commonly associated with symptoms reflecting dysfunction of adjacent cranial nerves such as hyper- or hypoacusis, facial numbness, and diplopia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiologically isolated syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A radiologically isolated syndrome (RIS) suggestive of MS is characterized by incidental brain MRI findings highly suggestive of MS in the absence of signs or symptoms of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed diagnostic criteria for RIS are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of incidentally identified central nervous system (CNS) white matter anomalies meeting the following MRI criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ovoid, well-circumscribed, and homogeneous foci with or without cerebellar involvement",
"     </li>",
"     <li>",
"      T2 hyperintensities measuring &gt;3 mm and fulfilling at least three out of four Barkhof criteria, which are 1) nine or more lesions or one or more gadolinium-enhancing lesions, 2) three or more periventricular lesions, 3) one or more juxtacortical lesions and 4) one or more infratentorial lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The CNS white matter anomalies are not consistent with a vascular pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No historical accounts of remitting clinical symptoms consistent with neurologic dysfunction",
"     </li>",
"     <li>",
"      The MRI anomalies do not account for clinically apparent impairments in social, occupational, or generalized areas of functioning",
"     </li>",
"     <li>",
"      The MRI anomalies are not due to the direct physiologic effects of substances (eg, drug abuse, toxic exposure) or a medical condition",
"     </li>",
"     <li>",
"      Exclusion of individuals with MRI phenotypes suggestive of leukoaraiosis or extensive white matter pathology lacking involvement of the corpus callosum",
"     </li>",
"     <li>",
"      The MRI anomalies are not better accounted for by another disease process",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to white matter abnormalities, demyelinating cortical lesions have been identified in some patients with RIS using double inversion recovery MRI sequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGRESSION TO MULTIPLE SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of those patients with radiologically isolated syndrome (RIS) or CIS who are likely to progress to multiple sclerosis (MS) is a major goal of current research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     With a radiologically isolated syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a radiologically isolated syndrome (RIS) are at risk of developing CIS and MS, but data are limited and the magnitude of the risk is uncertain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort study evaluated 44 patients (median age 39 years, range 16 to 67 years) with incidentally discovered MRI findings meeting strict radiologic criteria for RIS developed by the study investigators (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Radiologically isolated syndrome'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"       3",
"      </a>",
"      ]. The brain MRI studies were performed for various reasons (eg, headache, head trauma, spells of uncertain etiology, curiosity). The following observations were noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among 41 patients with imaging follow-up, MRI progression (new T2 foci, gadolinium enhancement, or enlargement of preexisting lesions) occurred in 24 patients (59 percent). The presence of gadolinium enhancement on the baseline MRI scan signifying RIS was associated with an increased risk for new lesions on subsequent brain MRIs.",
"     </li>",
"     <li>",
"      Among 30 patients with clinical follow-up, either CIS or clinically definite MS developed in 10 (33 percent). The time to the first clinically defining event (ie, CIS) ranged from 1 to 10 years (median 5.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subsequent retrospective study from the same investigators evaluated 71 patients with an RIS who had MRI of the cervical spine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/8\">",
"       8",
"      </a>",
"      ]. There were 25 patients with asymptomatic T2 hyperintense lesions in the cervical spinal cord, and among these, a CIS or a diagnosis of MS developed over a median follow-up of 3.3 years in 21 (84 percent). In contrast, among 46 patients who had no cervical cord abnormalities, a CIS or MS developed in 3 (7 percent). These findings suggest that spinal cord lesions in patients with an RIS are a marker of high risk for clinical progression to MS. However, prospective data are needed to confirm this finding.",
"     </li>",
"     <li>",
"      Another study with prospective data collection reported a cohort of 70 patients (mean age 36 years, range 16 to 48 years) with an isolated demyelinating lesion on brain MRI (performed for various reasons) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/9\">",
"       9",
"      </a>",
"      ]. Over a mean follow-up of 5.2 years, conversion to CIS occurred in 23 patients (33 percent). The mean time from first brain MRI to onset of CIS was 2.3 years (range 0.8 to 5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger prospective studies are needed to better define the risk of MS associated with RIS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     After isolated optic neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Optic Neuritis Treatment trial (ONTT), the cumulative five-year incidence of clinically definite MS was 30 percent following a first episode of idiopathic demyelinating optic neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/10\">",
"     10",
"    </a>",
"    ]. The cumulative incidence increased to 40 percent at 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/11\">",
"     11",
"    </a>",
"    ]. The presence of characteristic demyelinating lesions on brain MRI is a strong predictor of developing MS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81188 \" href=\"mobipreview.htm?36/46/37606\">",
"     image 1",
"    </a>",
"    ). In the ONTT, the risk of MS after 10 years was 56 percent among those with one or more lesions on MRI versus 22 percent among those with no lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/11\">",
"     11",
"    </a>",
"    ]. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29944?source=see_link\">",
"     \"Optic neuritis: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21504293\">",
"    <span class=\"h2\">",
"     After acute transverse myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute transverse myelitis is a rare inflammatory disorder that presents with the rapid onset of weakness, sensory alterations, and bowel and bladder dysfunction.",
"   </p>",
"   <p>",
"    Patients presenting with acute complete transverse myelitis (complete or near complete clinical deficits below the lesion) have a generally cited risk of MS of only 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/12\">",
"     12",
"    </a>",
"    ], although some reports suggest a higher conversion rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/13\">",
"     13",
"    </a>",
"    ]. However, partial or incomplete myelitis with mild or grossly asymmetric spinal cord dysfunction is a much more common clinical entity and bears more relevance to MS. Patients who have acute partial myelitis as an initial presentation and cranial MRI abnormalities showing lesions typical for MS have a transition rate to MS over three to five years of 60 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In contrast, patients with acute partial myelitis who have a normal brain MRI develop MS at a rate of only 10 to 30 percent over a similar time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/16\">",
"     16",
"    </a>",
"    ]. Cerebrospinal fluid (CSF) studies suggest that patients with monosymptomatic disease and positive oligoclonal bands (OCBs) have a higher risk of evolution to MS than those without OCBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/17\">",
"     17",
"    </a>",
"    ], although CSF results do not help further in prognosis when compared with MRI alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders affecting the spinal cord\", section on 'Transverse myelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     McDonald diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The McDonald diagnostic criteria, revised in 2010, incorporate clinical and MRI findings for the diagnosis of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'McDonald criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The core requirement of the diagnosis is the objective demonstration of dissemination of lesions in both space and time, based upon either clinical findings alone or a combination of clinical and MRI findings. For patients with one attack who have objective clinical evidence of one lesion (ie, a CIS), the criteria require evidence of dissemination in both space and time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dissemination in space",
"      </strong>",
"      is demonstrated on MRI by one or more T2 lesions in at least two of four MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a further clinical attack implicating a different central nervous system site. For patients with brainstem or spinal cord syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count.",
"     </li>",
"     <li>",
"      <strong>",
"       Dissemination in time",
"      </strong>",
"      is demonstrated on MRI by the simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or a new T2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan,",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a second clinical attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, some patients with a single clinical attack &ndash; a CIS &ndash; can be diagnosed with MS at the time of presentation if a single MRI obtained at any time shows dissemination in space and, as evidence for dissemination in time, at least one or more asymptomatic gadolinium-enhancing and nonenhancing lesions (",
"    <a class=\"graphic graphic_algorithm graphicRef57030 \" href=\"mobipreview.htm?15/26/15790\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. An MRI that shows dissemination in space but either lacks any enhancing lesions or shows all lesions enhancing would fail to confirm dissemination in time. In such cases, a follow-up MRI would be required in order to demonstrate new T2 or gadolinium-enhancing lesions as evidence of dissemination in time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Applying the MRI criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The McDonald criteria for the diagnosis of MS apply to patients with clinical syndromes that are typical for CIS, such as optic neuritis, a brainstem syndrome, or transverse myelitis (",
"    <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The utility of these criteria for atypical CIS is unknown. In addition, the performance of these criteria in patients younger than 15 years and older than 49 years has not been studied.",
"   </p>",
"   <p>",
"    In patients with atypical syndromes, appropriate investigations should be performed to seek alternative diagnoses or to find other features of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/20\">",
"     20",
"    </a>",
"    ]. Multifocal or ring enhancing white matter lesions on MRI are particularly suggestive of MS. Identification of spinal cord lesions on MRI adds specificity in differentiating MS from other inflammatory or vascular central nervous system diseases. Evoked potentials and CSF examination for oligoclonal bands should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Oligoclonal bands",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CIS, the presence of oligoclonal bands in cerebrospinal fluid may be an independent risk factor for progression to MS. Supporting evidence comes from a study of 415 patients with CIS, that found that the presence of oligoclonal bands was associated with a significantly increased risk of developing clinically definite MS (hazard ratio 1.7, 95% CI 1.1-2.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/21\">",
"     21",
"    </a>",
"    ]. This increased risk was independent of the number of lesions on baseline MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antimyelin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum antimyelin antibodies have been studied as potential markers of disease activity and predictors of progression to MS. Although data are conflicting, most of the available studies have found that these antibodies are not associated with an increased risk of progression from a CIS to MS. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Antimyelin antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials in patients with CIS have shown that early treatment with beta interferons,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , and intravenous immune globulin can delay conversion to clinically definite MS. However, it is unknown whether such treatments prevent or delay long-term disability.",
"   </p>",
"   <p>",
"    Currently, there is no indication for the use of disease-modifying treatment for patients with RIS (ie, asymptomatic but with incidental MRI findings suggestive of MS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Radiologically isolated syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early treatment with recombinant human interferon beta (IFNB) for patients with CIS delays the occurrence of a second attack, and therefore the onset of clinically definite MS, for up to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/23-30\">",
"     23-30",
"    </a>",
"    ]. However, early treatment in patients with CIS has not been shown to prevent long-term disability.",
"   </p>",
"   <p>",
"    The effectiveness of IFNB for patients with CIS was examined in a meta-analysis published in 2008 that identified three trials (ETOMS, CHAMPS, and BENEFIT) with a total of 1160 patients (639 treatment and 521 placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/27\">",
"     27",
"    </a>",
"    ]. The probability of converting to clinically definite MS was significantly lower with IFNB treatment compared with placebo both at one year (pooled odds ratio [OR] 0.53, 95% CI 0.40-0.71) and at two years of follow-up (pooled OR 0.52, 95% CI 0.38-0.70).",
"   </p>",
"   <p>",
"    The detailed individual trial results are reviewed next.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three randomized controlled trials (CHAMPS, ETOMS, and REFLEX) have investigated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     recombinant human interferon beta-1a",
"    </a>",
"    (Avonex and Rebif) for patients with CIS. One trial (BENEFIT) evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     recombinant human interferon beta-1b",
"    </a>",
"    <span class=\"nowrap\">",
"     (Betaferon/Betaseron)",
"    </span>",
"    for patients with CIS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CHAMPS trial enrolled 383 patients who suffered a first acute clinical demyelinating event and who also had evidence of prior subclinical demyelination on brain MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/23\">",
"       23",
"      </a>",
"      ]. During three years of follow-up, patients treated with glucocorticoid therapy followed by weekly intramuscular injections of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       recombinant human interferon beta-1a",
"      </a>",
"      (Avonex) 30 mcg had a significantly lower probability of developing clinically definite MS than those treated with glucocorticoids followed by placebo injections (cumulative probability 35 versus 50 percent).",
"      <br/>",
"      <br/>",
"      All patients in CHAMPS were offered weekly intramuscular injections of recombinant human",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Avonex) 30 mcg in an ongoing open-label extension study called the CHAMPIONS study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients initially assigned to recombinant human interferon beta-1a in CHAMPS were considered the immediate treatment group and those initially assigned to placebo were considered the delayed treatment group. At five years, the immediate treatment group continued to have a lower risk of developing clinically definite MS compared with the delayed treatment group (adjusted hazard ratio 0.57; 95% CI 0.38-0.86). Few patients in either the immediate or delayed treatment group developed major disability within five years (11 versus 14 percent).",
"     </li>",
"     <li>",
"      The ETOMS trial enrolled 308 patients and followed them for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/24\">",
"       24",
"      </a>",
"      ]. Significantly fewer patients developed clinically definite multiple sclerosis in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      group (weekly subcutaneous Rebif 22 mcg) than in the placebo group (34 versus 45 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, the time at which 30 percent of patients had converted to clinically definite MS was significantly longer in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       recombinant human interferon beta-1a",
"      </a>",
"      group compared with placebo (569 days versus 252). The number of new T2-weighted MRI lesions and the increase in lesion burden were also significantly lower with active treatment. A later analysis of this study population found that recombinant human interferon beta-1a treatment significantly reduced the rate of global brain atrophy compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The BENEFIT trial randomly assigned 292 patients with CIS to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       recombinant human interferon beta-1b",
"      </a>",
"      (subcutaneous Betaferon 250 mcg every other day) and 176 patients to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/26\">",
"       26",
"      </a>",
"      ]. At two years, significantly fewer patients treated with recombinant human",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      had converted to clinically definite MS, a primary outcome measure, than those receiving placebo (28 and 45 percent, hazard ratio [HR] 0.5, 95% CI 0.36-0.70) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/26\">",
"       26",
"      </a>",
"      ]. Similar results were found for the co-primary outcome measure of MS as defined by the McDonald criteria (69 and 85 percent, HR 0.54, 95% CI 0.43-0.67). Active treatment was also associated with significant reductions in the cumulative number of newly active lesions and change in T2 lesion volume on brain MRI.",
"      <br/>",
"      <br/>",
"      In two follow-up extension studies of BENEFIT, the patients initially assigned to recombinant human interferon beta-1b (ie, the early treatment group) were compared with those who were initially assigned to placebo with the option of starting recombinant human interferon beta-1b after a diagnosis of clinically definite MS or after two years (ie, the delayed treatment group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Blinding to initial treatment allocation was maintained. Compared with delayed treatment, early recombinant human interferon beta-1b treatment was associated with a statistically significant reduction in the risk of developing clinically definite MS at three years (absolute risk reduction [ARR] 14 percent) and at five years (ARR 11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. However, the benefit of early treatment for preventing disability was small at three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/29\">",
"       29",
"      </a>",
"      ] and was lost by five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The REFLEX trial evaluated 517 patients with a CIS and at least two clinically silent T2 lesions on brain MRI. At two years, the probability of MS diagnosed by the McDonald criteria was significantly lower with subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Rebif) 44 mcg dosed either three times a week or once a week (63 and 76 percent, versus 86 percent for placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/32\">",
"       32",
"      </a>",
"      ]. Similarly, for the outcome of clinically definite MS according to the Poser criteria, both doses of interferon beta-1a resulted in significant reductions (21 and 22 percent, versus 38 percent with placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glatiramer acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    delays conversion from CIS to clinically definite MS. Supporting evidence comes from the multicenter, blinded PreCISe trial that enrolled 481 adults with a CIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/33\">",
"     33",
"    </a>",
"    ]. The trial was stopped early because of benefit with a mean average exposure to glatiramer of 2.3 years. By intention-to-treat analysis, glatiramer acetate (20 mg subcutaneously daily) therapy significantly reduced the risk of conversion to clinically definite MS (hazard ratio 0.55, 95% CI 0.40-0.77), prolonged the time for 25 percent of patients to convert to clinically definite MS (772 days, versus 336 for placebo), and reduced the frequency of conversion to clinically definite MS (25 percent, versus 43 percent with placebo). Adverse events, mainly injection site reactions and systemic allergic reactions, led to withdrawal of 6 percent of subjects assigned to glatiramer acetate.",
"   </p>",
"   <p>",
"    As noted earlier, it is unknown whether treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    prevents or delays disability in patients with CIS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) may also improve outcomes after a first demyelinating event. This was illustrated in a randomized, placebo-controlled study of 91 patients, 15 to 50 years of age, who had a first well-defined neurologic event consistent with demyelination within 90 days prior to randomization that was confirmed by neurologic examination and brain MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/34\">",
"     34",
"    </a>",
"    ]. The dose of IVIG was 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    loading dose with boosters (0.4",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    given once every six weeks for one year. The cumulative probability of developing clinically definite MS at one year was significantly lower in the IVIG group compared with placebo (26 versus 50 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of these trials cited above support early disease-modifying treatment of suspected MS in patients with CIS who have additional clinically silent lesions in the brain or spinal cord detected by MRI. Early treatment beginning prior to the technical diagnosis of MS has a greater impact than later treatment on delaying disease progression to MS. However, the trials do",
"    <strong>",
"     not",
"    </strong>",
"    show that early treatment of CIS prevents long-term disability.",
"   </p>",
"   <p>",
"    Given the available data, we suggest disease-modifying treatment with one of the recombinant human interferon beta agents or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    (20 mg subcutaneously daily) for patients with CIS who have an abnormal brain MRI at presentation or within three to six months of the event. An alternative approach favored by some experts is to begin early treatment of CIS in patients considered at high risk for developing MS (eg, those with &gt;9 T2 lesions or the presence of a gadolinium enhancing T1 lesion on baseline MRI) while deferring treatment in those considered at lower risk until there is obvious active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The understanding of CIS is rapidly evolving, and treatment options continue to expand. The recommendations given here and below reflect those made by the American Academy of Neurology (AAN) on disease modifying therapies in MS published in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/36\">",
"     36",
"    </a>",
"    ], the European review of the role of MRI in the diagnosis of MS published in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37112/abstract/20\">",
"     20",
"    </a>",
"    ], and subsequent developments in therapeutics. Supplemental and updated information for the AAN guidelines on disease modifying therapies in MS can be found online (",
"    <a class=\"external\" href=\"file://www.aan.com/go/practice/guidelines\">",
"     www.aan.com/go/practice/guidelines",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/47/17138?source=see_link\">",
"       \"Patient information: Multiple sclerosis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinically isolated syndrome (CIS) is a single attack compatible with multiple sclerosis (MS), such as optic neuritis, transverse myelitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinically isolated syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A radiologically isolated syndrome (RIS) suggestive of MS is defined as a presentation without overt clinical symptoms but with MRI findings highly suggestive of MS based upon location and morphology within the central nervous system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Radiologically isolated syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who present with a CIS should have T2 and gadolinium-enhanced brain MRI studies as part of the initial evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The McDonald diagnostic criteria, revised in 2010, incorporate clinical and MRI findings for the diagnosis of MS. The core requirement of the diagnosis is the objective demonstration of dissemination of lesions in both space and time, based upon either clinical findings alone or a combination of clinical and MRI findings. For patients with one attack who have objective clinical evidence of one lesion (ie, a CIS), the criteria require evidence of dissemination in both space and time (see",
"      <a class=\"local\" href=\"#H8\">",
"       'McDonald diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dissemination in space is demonstrated on MRI by one or more T2 lesions in at least two of four MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) or by the development of a further clinical attack implicating a different central nervous system site. For patients with brainstem or spinal cord syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count.",
"     </li>",
"     <li>",
"      Dissemination in time is demonstrated on MRI by the simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or a new T2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan, or by the development of a second clinical attack.",
"      <br/>",
"      <br/>",
"      Thus, some patients with a single clinical attack &ndash; a CIS &ndash; can be diagnosed with MS at the time of presentation if a single MRI obtained at any time shows dissemination in space and, as evidence for dissemination in time, at least one or more asymptomatic gadolinium-enhancing and nonenhancing lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial brain MRI is abnormal (with a demyelinating lesion), the likelihood of developing MS is 60 percent, and treatment with a disease modifying agent is suggested. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the initial brain MRI is normal (no demyelinating lesion), the likelihood of developing MS is 20 percent, and a repeat brain MRI should be obtained between three and six months.",
"     </li>",
"     <li>",
"      If the three to six-month brain MRI is abnormal, treatment with a disease modifying agent is suggested.",
"     </li>",
"     <li>",
"      If the repeat MRI is normal, further scanning is not recommended in the absence of new symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with CIS who have an abnormal brain MRI at presentation or within three to six months of the event, we suggest disease-modifying treatment with one of the recombinant human interferon beta agents or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      (20 mg subcutaneously daily) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Among the interferons, we prefer treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       recombinant human interferon beta-1a",
"      </a>",
"      using injections of intramuscular Avonex 30",
"      <span class=\"nowrap\">",
"       mcg/week.",
"      </span>",
"      An alternative is recombinant human",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      using subcutaneous Rebif 22 mcg once a week. Prescribing information for Rebif in the United States recommends initial treatment with subcutaneous injection of 8.8 mcg three times a week, gradually increasing over four weeks to the final recommended dose of 44 mcg subcutaneous injection three times a week. Doses of subcutaneous Rebif should be separated by at least 48 hours. Another alternative is treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       recombinant human interferon beta-1b",
"      </a>",
"      using 250 mcg subcutaneous Betaferon or Betaseron every other day. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Interferons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no indication for the use of disease-modifying treatment for patients with a radiologically isolated syndrome (RIS) suggestive of MS.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/1\">",
"      Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/2\">",
"      Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/3\">",
"      Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009; 72:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/4\">",
"      Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/5\">",
"      Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/6\">",
"      Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 ( Pt 11):2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/7\">",
"      Giorgio A, Stromillo ML, Rossi F, et al. Cortical lesions in radiologically isolated syndrome. Neurology 2011; 77:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/8\">",
"      Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011; 76:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/9\">",
"      Lebrun C, Bensa C, Debouverie M, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009; 66:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/10\">",
"      The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997; 49:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/11\">",
"      Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/12\">",
"      Bruna J, Mart&iacute;nez-Y&eacute;lamos S, Mart&iacute;nez-Y&eacute;lamos A, et al. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/13\">",
"      Gajofatto A, Monaco S, Fiorini M, et al. Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. Arch Neurol 2010; 67:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/14\">",
"      Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116 ( Pt 1):135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/15\">",
"      Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/16\">",
"      Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler 2005; 11:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/17\">",
"      Bashir K, Whitaker JN. Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 2000; 6:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/18\">",
"      Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/19\">",
"      Montalban X, Tintor&eacute; M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/20\">",
"      Miller DH, Filippi M, Fazekas F, et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 2004; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/21\">",
"      Tintor&eacute; M, Rovira A, R&iacute;o J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/22\">",
"      Bourdette D, Simon J. The radiologically isolated syndrome: is it very early multiple sclerosis? Neurology 2009; 72:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/23\">",
"      Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/24\">",
"      Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/25\">",
"      Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/26\">",
"      Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/27\">",
"      Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008; :CD005278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/28\">",
"      Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/29\">",
"      Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/30\">",
"      Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/31\">",
"      Pittock SJ. Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurol 2009; 8:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/32\">",
"      Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/33\">",
"      Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/34\">",
"      Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004; 61:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/35\">",
"      Giovannoni G. The REFLEX study: a missed opportunity? Lancet Neurol 2012; 11:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37112/abstract/36\">",
"      Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1691 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37112=[""].join("\n");
var outline_f36_15_37112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinically isolated syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiologically isolated syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGRESSION TO MULTIPLE SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      With a radiologically isolated syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      After isolated optic neuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21504293\">",
"      After acute transverse myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      McDonald diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Applying the MRI criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Oligoclonal bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antimyelin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glatiramer acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1691|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?15/26/15790\" title=\"algorithm 1\">",
"      Diagnostic algorithm CIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1691|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/46/37606\" title=\"diagnostic image 1\">",
"      MRI of CIS presenting as optic neuritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/53/22363\" title=\"table 1\">",
"      Clinical features of MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/55/34684\" title=\"table 2\">",
"      Presenting symptoms in MS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29944?source=related_link\">",
"      Optic neuritis: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/47/17138?source=related_link\">",
"      Patient information: Multiple sclerosis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37113="Acute rejection airway I";
var content_f36_15_37113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77118%7EPULM%2F52040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77118%7EPULM%2F52040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway pattern of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph demonstrating a lymphocytic inflammatory response surrounding the airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway pattern of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph demonstrating an inflammatory response surrounding the airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37113=[""].join("\n");
var outline_f36_15_37113=null;
var title_f36_15_37114="Treatment of relapsed or refractory multiple myeloma";
var content_f36_15_37114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/15/37114/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/15/37114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with multiple myeloma (MM) who survive initial treatment will eventually relapse and require further therapy. Relapsed or refractory MM is usually identified on routine surveillance performed during treatment or after the completion of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluating response to treatment of multiple myeloma\", section on 'Response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options for patients with relapsed or refractory MM include hematopoietic cell transplantation (HCT), a rechallenge of the previous chemotherapy regimen, or a trial of a new regimen. Factors used to determine the choice of therapy include a risk stratification of myeloma (ie, high or standard risk disease), prior treatments used, and the duration of response to these treatments.",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory multiple myeloma will be discussed here. The initial treatment of multiple myeloma with chemotherapy and the use of hematopoietic cell transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION OF SUSPECTED RELAPSE OR RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing chemotherapy for multiple myeloma are evaluated before each treatment cycle and periodically after the completion of therapy to monitor their disease status. The preferred monitoring method is the measurement of monoclonal (M) protein in the serum or urine and serum free light chain (FLC) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/1\">",
"     1",
"    </a>",
"    ]. An increase in one of these measurements raises the suspicion of progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive disease (PD) is defined as a 25 percent increase from the lowest response value in any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum M-protein (absolute increase &ge;0.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Urine M-protein (absolute increase of &ge;200",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours)",
"     </li>",
"     <li>",
"      Bone marrow plasma cell percentage (at least 10 percent absolute increase) in patients who lack measurable M protein levels",
"     </li>",
"     <li>",
"      Difference in the kappa and lambda FLC levels (FLC ratio must be abnormal and absolute change must be &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PD is also diagnosed when new bone or soft tissue lesions (eg, plasmacytomas) are identified or there is an unequivocal increase in the size of previously existing lesions. The development of an otherwise unexplained serum calcium &gt;11.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is also a marker of PD.",
"   </p>",
"   <p>",
"    Refractory myeloma is defined as disease that is non-responsive while on therapy, or progresses within 60 days of last therapy. There are two categories of refractory myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relapsed-and-refractory myeloma",
"     </li>",
"     <li>",
"      Primary refractory myeloma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relapsed-and-refractory myeloma is defined as relapse of disease in patients who achieve minor response or better, and then either become non-responsive while on salvage therapy, or progress within 60 days of last therapy.",
"   </p>",
"   <p>",
"    Primary refractory myeloma refers to refractory disease in patients who have never achieved a minor response with any therapy, and includes two sub-categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who never achieve MR or better in whom there is no significant change in M protein and no evidence of clinical progression.",
"     </li>",
"     <li>",
"      Primary refractory, progressive disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relapsed myeloma is defined as previously treated myeloma patients who, after a period of being off-therapy, require salvage therapy but do not meet criteria for \"primary refractory\" or \"relapsed-and-refractory\" categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of their initial diagnosis, individual patients are stratified into high, intermediate, or standard risk MM based upon the results of FISH for specific translocations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deletions, and conventional cytogenetics. This evaluation helps to identify the 15 percent of patients with high risk MM who have a median survival of approximately two years or less with standard therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When progressive disease is identified, information on the initial response to therapy can be used to further identify patients with high risk disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who relapse less than 12 months from first-line therapy or relapse on therapy (ie, refractory disease) are considered to have high risk disease even if evaluation by FISH and cytogenetics previously classified their disease as standard risk.",
"     </li>",
"     <li>",
"      On the other hand, patients previously diagnosed with high risk disease by cytogenetics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      FISH who relapse more than two years from initial therapy can be considered as having standard risk disease at the time of relapse in the absence of new additional high risk cytogenetic abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These concepts are supported by retrospective studies that have demonstrated inferior survival among patients who relapse less than 12 months after initial therapy. As an example, a retrospective analysis of 102 patients with relapsed MM reported that patients who had a time to first progression &le;12 months had a significantly shorter median overall survival rate when compared with those who had a time to first progression after 12 months (20 versus 59 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with high risk disease at the time of relapse are best treated in the context of a clinical trial. These are the patients who will be the least likely to respond to conventional therapies and likely require more intensive treatment, which may include prolonged maintenance therapy, multi-agent combination therapy, autologous stem cell transplantation, or consideration for allogeneic transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transplant eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility for autologous or allogeneic hematopoietic cell transplantation (HCT) is primarily determined based upon the patient's age, performance status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of comorbid conditions. Given the potential role for HCT in relapsed disease, reassessment of transplant eligibility should be performed at the time of relapse. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for relapsed or refractory MM include hematopoietic cell transplantation (HCT), a rechallenge of chemotherapeutic agents used previously, or a trial of new agents. The best approach is unknown at this time and patients should be encouraged to participate in clinical trials. When a clinical trial is not available or a patient does not want to participate in a trial, we choose therapy based partly upon their eligibility for HCT, what agents have been used previously, how the disease responded to this therapy, side effect profiles, and patient comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENTS WHO ARE TRANSPLANT CANDIDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of relapsed disease in patients who are eligible for autologous hematopoietic cell transplantation (HCT) depends partly upon whether they have undergone HCT in the past.",
"   </p>",
"   <p>",
"    Prospective randomized trials have shown that autologous HCT results in superior event-free and overall survival rates when compared with combination chemotherapy in patients with previously untreated multiple myeloma. In addition, at least one randomized trial found similar overall survival rates among patients who underwent HCT as part of their initial therapy and those who delayed HCT until the time of relapse. As such, after initial chemotherapy and collection of stem cells, patients can either proceed to early (upfront) autologous HCT or can opt for delayed autologous HCT at the time of relapse. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H5#H5\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Timing of HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients who are eligible for HCT but did not undergo HCT as part of their initial treatment, we recommend high dose chemotherapy followed by autologous HCT at relapse. Support for the use of autologous HCT in MM and practical details on the performance of autologous HCT are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H12#H12\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Treatment of transplant candidates'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those patients who have already undergone autologous HCT, who have experienced a durable benefit with the first transplantation, treatment options include repeat autologous HCT or chemotherapy. Treatment of these patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H20#H20\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Treatment of relapse after HCT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are initially refractory to induction chemotherapy (primary refractory disease) can achieve a good response to subsequent autologous HCT, and lack of response to initial therapy does not preclude transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12216861\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse more than one year after chemotherapy will likely respond to a repeat course of the previous therapy. This is given to maximum response for up to one year of therapy, or until progression. Ultimately, this regimen will fail and the patient will develop progressive disease (PD), at which point other regimens will be needed. If PD is not accompanied by worsening clinical symptoms, (ie, the PD is only based on laboratory values) salvage treatment may be deferred depending on the speed at which the monoclonal protein levels are rising, and the clinical condition of the patient. There are a plethora of agents that have demonstrated activity in relapsed or refractory MM.",
"   </p>",
"   <p>",
"    Most patients with relapsed disease respond to further chemotherapy, but the duration and quality of response are usually inferior to those of the initial response, and become progressively shorter with each successive regimen. As an example, in our series of 578 patients followed for the course of their disease, median event-free survival rates for initial and subsequent treatment regimens were, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial regimen &mdash; 10 months",
"     </li>",
"     <li>",
"      Second regimen &mdash; 7 months",
"     </li>",
"     <li>",
"      Third regimen &mdash; 6 months",
"     </li>",
"     <li>",
"      Fourth regimen &mdash; 4.5 months",
"     </li>",
"     <li>",
"      Fifth regimen &mdash; 4 months",
"     </li>",
"     <li>",
"      Sixth regimen &mdash; 3 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in this study were treated before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    became available for general use. As these newer agents have been incorporated into the initial treatment of MM, median progression-free survival with the initial regimen has increased to approximately two years. In addition, a retrospective analysis of 387 patients with relapsed myeloma who had not received thalidomide, bortezomib, or lenalidomide in the past had significantly longer survival from relapse following treatment with one of these agents when compared with patients treated with older regimens (31 versus 15 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/5\">",
"     5",
"    </a>",
"    ]. However, patients who have progressed despite treatment with these novel agents have a poor prognosis. As an example, a retrospective study reported that 286 patients with disease that was refractory to bortezomib and who were refractory to or ineligible for an immunomodulatory derivative (eg, thalidomide, lenalidomide) had median overall and event-free survival times of nine and five months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who relapse after initial therapy and lose response to their initial regimen, we suggest combination therapy that incorporates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . The choice between these agents is made based upon the therapies that the patient has already tried and side effect profiles. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      are both immunomodulatory derivatives (IMiDs). For patients who fail to respond to a regimen that contains one of these agents, we would initiate treatment with a regimen containing the proteasome inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      since it has a different mechanism of action.",
"     </li>",
"     <li>",
"      Patients who have progressed despite initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      therapy can be treated with a regimen containing either IMiD. The choice between these agents may be based upon the side effect profile. As an example, we would use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      -based therapy for patients with a preexisting neuropathy because of the risk of neuropathy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      treatment.",
"     </li>",
"     <li>",
"      An alternative to substituting an existing regimen with new drugs is to add new drugs to the existing regimen. Thus, patients who progress on IMiDs may also respond to the addition of other active drugs to their existing treatment regimen. For example, patients progressing on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      may respond to the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (ie, VRD regimen). Similarly, patients progressing on bortezomib and dexamethasone may respond to the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (ie, VCD regimen).",
"     </li>",
"     <li>",
"      Patients whose disease progresses despite an IMiD and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      are candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      or multi-drug combinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    all have activity as single agents, but have higher response rates when given in combination with other active agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . The choice of therapy should balance the potentially higher response rates achievable as more drugs are combined with each other versus the likelihood for greater toxicity, and should be tailored to meet the clinical need. Thus in patients with paraprotein only relapse, a two-drug combination may be sufficient, while in patients presenting with aggressive relapse and end-organ damage, triple or multi-drug combinations need to be considered (at least initially) to get the disease under control. The following sections review the response rates, survival data, and toxicities associated with each of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been prospectively studied in the treatment of relapsed or refractory MM both alone and in combination with other agents. Treatment with thalidomide plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    results in overall response rates of approximately 46 percent. By comparison, single agent thalidomide has overall response rates of approximately 25 to 35 percent in this setting, with a median response duration of 12 to 14 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/7-16\">",
"     7-16",
"    </a>",
"    ]. Similar overall response rates are seen in patients with an initial partial response or better with thalidomide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy who undergo repeat treatment with thalidomide at progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/17\">",
"     17",
"    </a>",
"    ]. Response rates are lower (10 to 15 percent) in patients with disease that progresses while receiving lenalidomide therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many small prospective phase II trials have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (TD) in patients with relapsed or refractory MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. A 2008 systematic review included 12 phase II trials comprising 451 patients with relapsed or refractory MM treated with TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall response rate was 46 percent. Treatment-related toxicity was similar to that seen with single-agent thalidomide except for a higher rate of venous thromboembolism (5 versus 2 percent). Toxicities included somnolence (26 percent), constipation (37 percent), and peripheral neuropathy (27 percent). Other side effects include those related to high dose dexamethasone including edema, puffiness of the face, hypertension, hyperglycemia, muscle weakness, mood alterations, and osteoporosis.",
"   </p>",
"   <p>",
"    Prospective single arm studies have also suggested that the addition of alkylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ), anthracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ) or other agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) may increase the response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/7,22,25-30\">",
"     7,22,25-30",
"    </a>",
"    ]. However, higher response rates do not necessarily yield better survival outcomes, but may produce greater toxicity. As an example, a multicenter randomized phase III study compared TD alone with TD plus bortezomib (VTD) in patients with MM progressing or relapsing after autologous transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/31\">",
"     31",
"    </a>",
"    ]. When compared with TD, VTD resulted in a higher response rates and a longer median time to progression, but similar survival at two years. VTD was associated with higher rates of severe toxicity, including peripheral neuropathy, infection, and thrombocytopenia. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In initial studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    was given in doses ranging from 100 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, doses &gt;200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    cause greater toxicity without substantial increases in response rate. In general, we administer thalidomide plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    as it is given for initial induction chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link&amp;anchor=H4997000#H4997000\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'Thalidomide with or without dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constipation, weakness, fatigue, or somnolence occur in 25 percent or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/9,32,33\">",
"       9,32,33",
"      </a>",
"      ]. Some of these symptoms may be due to hypothyroidism since, in one report, serum thyroid stimulating hormone was elevated in 20 to 22 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A dose-dependent peripheral neuropathy (sensory more than motor axonal neuropathy) occurs in up to 80 percent of patients with prolonged therapy, and may not be reversible. Accordingly, patients with this complication should be told to reduce the dosage or stop the drug, depending on the severity of the neuropathy and the status of their disease. In general,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      should be avoided for patients with a preexisting grade 2 or higher neuropathy. While population-based genotype studies have identified single nucleotide polymorphisms (SNPs) that may be associated with a higher rate of thalidomide-induced neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/35\">",
"       35",
"      </a>",
"      ], it has not yet been determined which SNPs are most important and how this information may be used clinically. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H24#H24\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Thalidomide and lenalidomide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombotic complications are well described with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      therapy and can occur in up to 25 percent of patients treated with thalidomide plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . This subject, including recommendations for thromboprophylaxis, is discussed in depth separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"       \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Grade 1 or 2 leukopenia is rare at any dose level, while grade 3 or 4 thrombocytopenia or anemia has been described in less than 4 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unexplained and often severe hyperkalemia may occur in patients with multiple myeloma and renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Serial monitoring of potassium levels is advised in such patients.",
"     </li>",
"     <li>",
"      Dermatologic side effects have been noted in approximately 40 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lenalidomide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Response",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    has demonstrated activity both alone and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with relapsed or refractory MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/7,39-43\">",
"     7,39-43",
"    </a>",
"    ]. As described in more detail below, overall response rates improve from approximately 25 to 60 percent when dexamethasone is added. Responses are seen in approximately half of patients with an initial partial response or better with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or lenalidomide therapy who undergo repeat treatment with lenalidomide at progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two large randomized phase III studies (MM-009 and MM-010) compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO on days 1 through 21 of a 28-day cycle) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO on days 1-4, 9-12, and 17-20 for the first 4 cycles then on days 1-4 only for subsequent cycles) versus dexamethasone plus placebo in a total of 704 patients with relapsed or refractory multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Both studies were stopped by their data safety monitoring boards due to significantly better response rates and time to progression with lenalidomide plus dexamethasone compared with dexamethasone alone.",
"   </p>",
"   <p>",
"    Both trials had similar results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      had significantly higher complete response rates (approximately 15 versus 1 to 3 percent) and overall response rates (approximately 60 versus 20 to 24 percent).",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      had a significantly longer time to disease progression (11 versus 5 months).",
"     </li>",
"     <li>",
"      Median overall survival was significantly longer for patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (at least 30 months versus 20 months).",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      group had significantly more grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      neutropenia (30 to 40 percent versus 2 to 4 percent) and venous thromboembolism (approximately 11 versus 4 percent).",
"     </li>",
"     <li>",
"      In a post-hoc subgroup analysis of pooled data from these two trials,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      showed activity in patients previously treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      -based therapy demonstrated higher rates of overall response (54 versus 14 percent), longer median time to progression (8.4 versus 4.6 months) and progression-free survival (8.4 versus 4.6 months) when compared with those who received dexamethasone alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial in newly diagnosed myeloma found superior overall survival and reduced toxicity with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus a lower dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40 mg PO on days 1, 8, 15, and 22 of each 28-day cycle) compared with lenalidomide plus the standard high-dose dexamethasone (40 mg days 1 to 4, 9 to 12, 17 to 20 every 28 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/48\">",
"     48",
"    </a>",
"    ]. Although this study was done in newly diagnosed myeloma, it may have implications for relapsed or refractory myeloma and so physicians should consider lowering the dose of dexamethasone used in combination with new agents such as lenalidomide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities seen in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    include neutropenia (30 to 40 percent), anemia (9 to 13 percent), thrombocytopenia (12 to 15 percent), and venous thromboembolism (11 percent). Nonhematologic toxicities of fatigue (55 percent), insomnia (20 percent), diarrhea (21 percent), constipation (24 percent), muscle cramps (24 percent) and infections (20 percent) have been reported, but were usually not severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of an increased incidence of thromboembolic events in patients treated with the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"      lenalidomide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"      dexamethasone",
"     </a>",
"    </span>",
"    combination (11.4 percent versus 4.6 percent in those treated with dexamethasone alone), prophylactic antithrombotic therapy should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/44\">",
"     44",
"    </a>",
"    ]. Details regarding risk of thrombosis and options for prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H9#H9\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide analogues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are emerging concerns regarding an increased risk of second primary malignancy among patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -based therapy. This long-term toxicity was initially suspected when excess second cancers were noted in phase III trials in which lenalidomide was given as maintenance therapy immediately following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -based treatment. It is unknown whether second primary cancers are increased among patients who receive lenalidomide in the relapsed or refractory setting. A retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy that included data from 3848 patients with relapsed or refractory myeloma reported an overall incidence rate of second primary cancers of 3.62 events per 100 patient years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/50\">",
"     50",
"    </a>",
"    ]. The rate of invasive second primary cancers was similar to that expected in older adults according to the Surveillance, Epidemiology, and End Results (SEER) database. However, this study&rsquo;s ability to report the long-term risk of second cancers was limited because reliable reporting of second malignancies was restricted to the duration of lenalidomide treatment (median five months). The risk of second malignancies after lenalidomide maintenance is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H14#H14\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Use in renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is secreted via the kidneys and should be used with caution in patients with renal impairment. Two studies have evaluated the use of lenalidomide in patients with renal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 72 patients given",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"        lenalidomide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"      </span>",
"      for first line treatment of multiple myeloma demonstrated that patients with a creatinine clearance &lt;40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      had an 8.4-fold increased likelihood of needing a lenalidomide dose reduction for grade 3 or worse myelosuppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pharmacokinetics study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in patients with various degrees of renal impairment and in patients on hemodialysis reported impaired excretion of lenalidomide in patients with creatinine clearance less than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/52\">",
"       52",
"      </a>",
"      ]. While there was no change in the oral absorption, protein binding, or nonrenal elimination of lenalidomide in subjects with declining renal function, renal clearance of unchanged lenalidomide dropped substantially in those with creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      resulting in increases in the area under the curve and drug half life. They also noted that a 4-hour hemodialysis treatment removes approximately 30 percent of total body lenalidomide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As such, dose adjustments of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    are necessary for patients with creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H32#H32\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective, phase II trials and two randomized phase III trials have evaluated the efficacy of the proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in the treatment of patients with relapsed or refractory MM. Overall response rates for single agent bortezomib are approximately 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/53-62\">",
"     53-62",
"    </a>",
"    ]. Bortezomib has also been evaluated in combination therapy with overall response rates of approximately 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/63-71\">",
"     63-71",
"    </a>",
"    ]. Similar overall response rates are seen in patients with an initial partial response or better with bortezomib therapy who undergo repeat treatment with bortezomib at progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/72\">",
"     72",
"    </a>",
"    ]. Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The open-label, nonrandomized, phase II SUMMIT study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      included 202 patients who had received at least two prior therapies (median number 6; 64 percent had received hematopoietic cell transplantation or other high dose therapy) and were progressing on the most recent therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      could be added for patients with a suboptimal response. For the 193 patients with measurable disease, the complete plus partial response rate was 28 percent. For responding patients, median time to progression and median overall survival were 14 and &gt;23 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The randomized phase III multicenter APEX trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      to treatment with high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 669 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/57,58,73\">",
"       57,58,73",
"      </a>",
"      ]. Patients who had relapsed after one to three previous therapies were randomly assigned to receive one of the following two regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      40 mg by mouth on days 1 to 4, 9 to 12, and 17 to 20 every five weeks for four cycles, followed by 40 mg by mouth on days 1 to 4 every 28 days for an additional five cycles.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days 1, 4, 8, and 11 every three weeks for eight cycles, followed by 1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days 1, 8, 15, and 22 every five weeks for an additional three cycles.",
"      <br/>",
"      <br/>",
"      Following an interim analysis, which showed an overall survival benefit for patients taking bortezomib, the monitoring committee recommended that treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      should be halted and patients randomly assigned to receive dexamethasone be allowed to receive bortezomib. At a median follow-up time of 8.3 months, patients treated with bortezomib had the following significant findings when compared with those treated with dexamethasone:",
"     </li>",
"     <li>",
"      Higher overall (38 versus 18 percent) and complete (6 versus 0.6 percent) response rates.",
"     </li>",
"     <li>",
"      Longer median time to progression (6.2 versus 3.5 months).",
"     </li>",
"     <li>",
"      Longer estimated one-year survival (80 versus 66 percent).",
"     </li>",
"     <li>",
"      Higher rates of significant (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities (75 versus 60 percent, respectively). Nearly one-third of the patients discontinued treatment because of side effects.",
"     </li>",
"     <li>",
"      Superior health-related quality of life on multiple measures including less dyspnea and sleep disturbance over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/74\">",
"       74",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A subsequent analysis after a median follow-up of 22 months reported that treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      resulted in a significantly higher median overall survival (29.8 versus 23.7 months) when compared with high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      even though more than 62 percent of patients initially treated with dexamethasone subsequently received bortezomib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/73\">",
"       73",
"      </a>",
"      ]. Among those treated with bortezomib, there appeared to be an association between response and clinical benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/75\">",
"       75",
"      </a>",
"      ]. The relative superiority of bortezomib over dexamethasone was independent of prior therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized phase III multicenter trial compared subcutaneous versus intravenous administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 4, 8, and 11 of a 21 day cycle) in 222 patients with relapsed multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/62,77\">",
"       62,77",
"      </a>",
"      ]. When compared with intravenous administration, subcutaneous administration resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar median time to progression (9.7 versus 9.6 months) and rate of survival at one year (76 versus 78 percent)",
"     </li>",
"     <li>",
"      Fewer severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities (57 versus 70 percent)",
"     </li>",
"     <li>",
"      Lower rates of peripheral neuropathy (38 versus 53 percent) and severe peripheral neuropathy (6 versus 16 percent)",
"      <br/>",
"      <br/>",
"      This trial suggests that subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      offers similar efficacy, but less toxicity, when compared with intravenous bortezomib. Subcutaneous administration may be considered an alternative to intravenous administration in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a survey of studies that have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in combination with other agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DOXIL-MMY-3001 randomized phase III trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      administered on days 1, 4, 8 and 11 every 21 days), alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      administered as a one-hour intravenous infusion on day 4) in 646 patients with relapsed or refractory myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/67\">",
"       67",
"      </a>",
"      ]. Overall response rate was approximately 44 percent and did not differ between the two arms. Patients who received bortezomib plus pegylated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       liposomal doxorubicin",
"      </a>",
"      had the following significant differences when compared with those who received bortezomib alone:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Longer median time to progression (9.3 months versus 6.5 months), higher rate of 15-month survival (76 versus 65 percent) and longer median duration of response (10.2 versus 7.0 months).",
"     </li>",
"     <li>",
"      More grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      adverse events (80 versus 64 percent). Specific toxicities of note included myelosuppression, constitutional symptoms, and gastrointestinal and dermatologic toxicities. The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      did not increase the rate of treatment-emergent neuropathy, which was approximately 12 percent (3 percent grade",
"      <span class=\"nowrap\">",
"       3/4).",
"      </span>",
"     </li>",
"     <li>",
"      In a prespecified analysis, responses to therapy and toxicity profile were similar in patients who had or had not previously received immunomodulator therapy (either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter phase III study of 269 patients with MM progressing or relapsing after autologous transplantation randomly assigned treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (TD) alone or TD plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (VTD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/31\">",
"       31",
"      </a>",
"      ]. When compared with TD, VTD resulted in a higher rate of complete response plus near-complete response (45 versus 25 percent) and a longer median time to progression (19.5 versus 13.8 months). Survival at 24 months was similar (71 versus 65 percent). VTD was associated with higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      peripheral neuropathy (29 versus 12 percent), infection (14 versus 7 percent), and thrombocytopenia (17 versus 7 percent).",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial has shown significant activity for the 4-drug combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (BMPT) in 30 patients with relapsed or refractory myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/65\">",
"       65",
"      </a>",
"      ]. Overall and complete (ie, immunofixation-negative) response rates were 67 and 17 percent, respectively, with a one-year progression-free survival of 61 percent.",
"     </li>",
"     <li>",
"      In a phase II trial, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , intermediate dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and continuous low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in 50 evaluable patients with relapsed myeloma yielded overall and complete response rates of 66 and 16 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/64\">",
"       64",
"      </a>",
"      ]. Antiviral prophylaxis appears to be mandatory for patients receiving this combination.",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 53 patients with relapsed myeloma demonstrated an overall response rate of 68 percent (23 percent complete or near complete responses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/71\">",
"       71",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events included thrombocytopenia (62 percent), neutropenia (57 percent), infection (21 percent), and neuropathy (15 percent). Similar results were seen in another trial of the same regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common adverse effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    include anorexia, nausea and vomiting, peripheral neuropathy, cutaneous reactions, neutropenia, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenia occurs in 43 percent of patients but is rarely severe enough to postpone subsequent cycles. Platelet count nadir typically occurs at day 11 and drops to approximately 40 percent of baseline. Platelet counts typically recover before the start of the next cycle and there is no evidence that this toxicity is cumulative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peripheral neuropathy, often painful, develops in approximately 40 percent of patients who receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/83,84\">",
"       83,84",
"      </a>",
"      ] and in approximately 20 percent of patients who receive bortezomib 1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/85\">",
"       85",
"      </a>",
"      ]. It appears to be less frequent and less severe when bortezomib is administered subcutaneously rather than intravenously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/62,77\">",
"       62,77",
"      </a>",
"      ]. It is more frequent and severe in those who have previously received neurotoxic therapy and those with preexisting neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/86\">",
"       86",
"      </a>",
"      ]. Thus, it is important to avoid neurotoxic agents with limited single-agent activity, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , in the treatment of myeloma. Although certain single nucleotide polymorphisms (SNPs) may be associated with a higher rate of bortezomib-induced neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/87\">",
"       87",
"      </a>",
"      ], it has not yet been determined which SNPs are most important and how this information may be used clinically. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H25#H25\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Bortezomib and carfilzomib'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A dose adjustment algorithm for neuropathy is available within the full prescribing information on the US FDA website (",
"      <a class=\"graphic graphic_table graphicRef70033 \" href=\"mobipreview.htm?7/59/8123\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/82\">",
"       82",
"      </a>",
"      ]. The following is a summary of these recommendations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For grade 1 peripheral neuropathy (paresthesias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of reflexes) without pain or loss of function,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      therapy can be continued at current dose and regimen.",
"     </li>",
"     <li>",
"      For grade 1 neuropathy with pain or grade 2 neuropathy (neuropathy interfering with function but not with activities of daily living), the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      dose should be reduced to 1",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      For grade 2 neuropathy with pain or grade 3 neuropathy (neuropathy interfering with activities of daily living),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      should be held. Once this toxicity resolves, bortezomib can be restarted at the lower dose of 0.7",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly.",
"     </li>",
"     <li>",
"      For grade 4 neurotoxicity (disabling neuropathy),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      therapy should be discontinued permanently.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      therapy may be associated with an increased risk of herpes zoster (varicella zoster reactivation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. This has been demonstrated in a retrospective analysis of 282 patients treated with bortezomib and a post hoc subset analysis of patients in the prospective randomized phase III APEX trial of bortezomib versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in relapsed or refractory disease. As an example, the post hoc subset analysis of 663 patients included in the APEX trial found that patients treated with bortezomib had a significantly higher incidence of herpes zoster when compared with patients who received high-dose dexamethasone (13 versus 5 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/88\">",
"       88",
"      </a>",
"      ]. The majority of these herpes zoster reactivations were clinically mild. Retrospective studies suggest that antiviral prophylaxis may at least partially abrogate this increased risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/90\">",
"       90",
"      </a>",
"      ]. We suggest that antiviral prophylaxis be given to all patients receiving bortezomib therapy. We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg twice daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      500 mg once daily.",
"     </li>",
"     <li>",
"      Responses to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      may be associated with increased serum levels of bone-derived alkaline phosphatase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/91,92\">",
"       91,92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The FDA has received rare reports of reversible posterior leukoencephalopathy syndrome (RPLS), which can present with seizures, hypertension, headache, lethargy, confusion, blindness, or as other visual or neurological disturbances.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      should be discontinued if the diagnosis of RPLS is confirmed on brain MRI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"       \"Reversible posterior leukoencephalopathy syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a Japanese study, 4 of 13 patients treated with this agent developed severe pulmonary complications with respiratory failure, two of which were fatal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/93\">",
"       93",
"      </a>",
"      ]. In one additional case there was a rapid response of this complication to high-dose steroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Use in renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial results suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    can be used safely in patients with impaired renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Patients with renal impairment were included in the prospective, randomized phase III APEX trial described above that compared the use of bortezomib with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with relapsed or refractory MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/57,96\">",
"     57,96",
"    </a>",
"    ]. Of the 330 patients in the trial who had baseline creatinine clearance (CrCl) measurement available, the percentage of patients with CrCl &lt;30, 30 to 50, 51 to 80 and &gt;80",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    were approximately 5, 14, 43, and 39 percent of patients, respectively. Response rates and safety profiles with bortezomib treatment were similar across these four subgroups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Use in hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    is metabolized by the liver. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment. For patients with moderate or severe impairment of hepatic function (serum bilirubin &ge;1.5 times the upper limit of normal), we initiate therapy with a reduced dose of bortezomib (0.7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/97\">",
"     97",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22222487\">",
"    <span class=\"h2\">",
"     Carfilzomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     Carfilzomib",
"    </a>",
"    is a second generation selective proteasome inhibitor that has demonstrated activity in patients with multiple MM. The most common toxicities are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. Infusion can be associated with a hypersensitivity reaction immediately following or up to 24 hours after the administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H10520016#H10520016\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Carfilzomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    in MM come largely from three single arm phase II trials: two in relapsed myeloma, and one in newly diagnosed myeloma. Randomized trials are ongoing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single-arm, phase II trial, 129 patients with relapsed or refractory myeloma who were",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -naive received one of two dosing schedules of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/98\">",
"       98",
"      </a>",
"      ]. A partial response or better was seen in 60 patients (48 percent) with a median duration of response of approximately 13 months. The most common treatment-related adverse events were fatigue (62 percent) and nausea (49 percent). Peripheral neuropathy was mostly mild and seen in 17 percent. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In another single arm phase II trial, 266 patients with refractory myeloma who had at least two prior therapies, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      and either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      ,",
"      <sup>",
"      </sup>",
"      as well as an alkylating agent, were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/99\">",
"       99",
"      </a>",
"      ]. An overall response rate of 24 percent was found, with a median duration of response of 7.8 months.",
"     </li>",
"     <li>",
"      In the newly diagnosed setting, 53 patients were treated with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in a phase II trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/100\">",
"       100",
"      </a>",
"      ]. Stem cells were collected after the fourth cycle for transplant-eligible patients. After a median of 12 cycles, 98 percent achieved an at least partial response (81 percent very good partial response or better). With a median follow-up of 13 months, the estimated progression-free survival at 24 months was 92 percent. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were hypophosphatemia (25 percent), hyperglycemia (23 percent), anemia (21 percent), thrombocytopenia (17 percent), and neutropenia (17 percent). Mild to moderate peripheral neuropathy was seen in 23 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     Carfilzomib",
"    </a>",
"    is approved by the US Food and Drug Administration for patients with MM who have received at least two prior therapies, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/101\">",
"     101",
"    </a>",
"    ]. Carfilzomib is administered intravenously over 2 to 10 minutes, on two consecutive days weekly for three weeks (ie, days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (ie, days 17 to 28). The recommended cycle one dose is 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day,",
"    </span>",
"    and, if tolerated, the recommended dose for the second and succeeding cycles is 27",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (4 mg, administered orally or intravenously) is given prior to each carfilzomib dose during the first cycle and during the first cycle of the 27",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    dosing. Cases of shingles or hepatitis reactivation have been reported following carfilzomib therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/102\">",
"     102",
"    </a>",
"    ]. We suggest that antiviral prophylaxis be given to all patients receiving carfilzomib therapy. In patients with refractory disease, if needed, higher doses of dexamethasone such as those used in other regimens (20 to 40 mg per week) can be considered in a manner suggested in the phase II trial of carfilzomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349206892\">",
"    <span class=\"h2\">",
"     Pomalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     Pomalidomide",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analog that has demonstrated activity both alone and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with relapsed or refractory MM. As described in more detail below, overall response rates improve from approximately 7 to 30 percent when dexamethasone is added. Pomalidomide is approved by the US Food and Drug Administration for patients with MM who have received at least two prior therapies, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and have demonstrated disease progression on or within 60 days of the completion of the last therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"       Pomalidomide",
"      </a>",
"      plus low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg weekly) has shown significant clinical activity in patients with relapsed and refractory myeloma. The response rate is approximately 60 percent in relapsed disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/104\">",
"       104",
"      </a>",
"      ], 30 percent in patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      refractory disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/105\">",
"       105",
"      </a>",
"      ], and 25 percent in patients who are refractory to both lenalidomide and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II,",
"      </span>",
"      multicenter, randomized study evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"       pomalidomide",
"      </a>",
"      (4 mg daily for 21 of 28 days, until disease progression) with or without low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg once weekly) in 221 patients with relapsed or refractory multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Patients with renal insufficiency (serum creatinine &gt;3",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      or hepatic impairment (serum bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       AST/ALT",
"      </span>",
"      &gt;3 x upper limit of normal) were excluded. All patients received thromboprophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or another agent. Patients had received a median of five prior therapies, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      . When compared with pomalidomide alone, the combination of pomalidomide plus dexamethasone resulted in a higher overall response rate (29 versus 7 percent); there was one complete response. Median duration of response was 7.4 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (38 percent), anemia (21 percent), thrombocytopenia (19 percent), pneumonia (23 percent), fatigue (13 percent), and dyspnea (13 percent).",
"     </li>",
"     <li>",
"      Another phase II, multicenter, randomized open label study evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"       pomalidomide",
"      </a>",
"      at two different dosing schedules with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 84 patients with relapsed or refractory multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/109\">",
"       109",
"      </a>",
"      ]. Patients had received a median of five prior therapies. All patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for thromboprophylaxis. The overall response rate was 35 percent. At a median follow-up of 23 months, median overall survival was 14.9 months with 44 percent of patients alive at 18 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (64 percent), anemia (36 percent), thrombocytopenia (27 percent), pneumonia (13 percent), bone pain (11 percent), renal failure (11 percent), and dyspnea (12 percent). Three patients (4 percent) developed a venous thromboembolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these trials demonstrate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    is associated with improvements in markers of disease burden. Further study is needed to assess changes in disease-related symptoms and impact on survival. Given that pomalidomide is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analog and thalidomide is a known human teratogen, pomalidomide is absolutely contraindicated in pregnant and nursing women. Pomalidomide is only available through a restricted program known as the Pomalyst REMS program. A discussion of thromboembolism prophylaxis in patients taking immunomodulatory agents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other chemotherapy regimens that have activity in relapsed or refractory multiple myeloma include VAD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), alkylator containing regimens (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus dexamethasone, etc.) and high dose steroids alone. These regimens may be used for patients who have failed treatment with regimens containing newer agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . It is important to note that patients who have not been treated with standard dose melphalan or cyclophosphamide-based chemotherapy can still benefit from these regimens even if they previously failed autologous HCT which typically employs a single high-dose administration of melphalan. High dose steroids (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) can be useful in patients who have organ dysfunction, poor performance status, or low blood counts.",
"   </p>",
"   <p>",
"    The following is a survey of regimens that may be considered for patients with multiply relapsed disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The VAD regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [0.4 mg] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [9",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ]",
"      </span>",
"      given each day by continuous infusion for four days and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      40 mg PO daily given on days 1 to 4, 9 to 12, and 17 to 20 of each of the monthly cycles) and other similar anthracycline containing regimens can be useful in patients in relapsed refractory myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/110\">",
"       110",
"      </a>",
"      ]. Dexamethasone is usually given only on days 1 to 4 in even numbered cycles because of steroid side effects at this dosage. In the setting of relapsed or refractory disease overall and complete response rates are approximately 60 and 3 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/111\">",
"       111",
"      </a>",
"      ]. Bolus VAD is an acceptable alternative to infusional VAD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'Modified VAD regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapy with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"      </span>",
"      or other alkylating-agent based regimens (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus prednisone) can be effective in relapsed myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/112\">",
"       112",
"      </a>",
"      ]. Patients relapsing after an autologous hematopoietic cell transplantation have often not been previously exposed to these regimens, and may therefore respond [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 21 days of each four weeks), daily low dose oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (100 mg), and daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 mg tapering to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over eight weeks) has demonstrated activity in patients who are refractory to lenalidomide plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 21 days of each four weeks),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg weekly), administered on a 28-day cycle, demonstrated a partial response or better in 13 of 25 patients with multiply relapsed or refractory myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/115\">",
"       115",
"      </a>",
"      ]. Common toxicities included neutropenia (79 percent), thrombocytopenia (83 percent), anemia (59 percent), hyperglycemia (31 percent), and fatigue (45 percent). The median progression free survival was six months. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      can be given as the only therapeutic agent and probably accounts for over 80 percent of the effect of VAD. Intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (2 g IV three times weekly for a minimum of four weeks) is helpful in patients with pancytopenia and refractory disease. We find fewer side effects with this approach than with dexamethasone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58772948\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ongoing trials are evaluating traditional agents in new combinations and evaluating newer agents, such as new immunomodulatory derivatives (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/106\">",
"     106",
"    </a>",
"    ]), second generation proteasome inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/98,100\">",
"     98,100",
"    </a>",
"    ], and agents that target novel pathways (eg, histone deacetylase inhibitors,",
"    <span class=\"nowrap\">",
"     AKT/P13K/mTOR",
"    </span>",
"    inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/117\">",
"     117",
"    </a>",
"    ], heat-shock-protein inhibitors, and monoclonal antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/15/37114/abstract/118-122\">",
"     118-122",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with multiple myeloma who survive their original presentation and treatment eventually relapse, and a small percentage are refractory to initial treatment (primary refractory disease). When progressive disease is identified, information on the initial response to therapy can be used to further classify patients as having high or standard risk disease. Patients with high risk disease at the time of relapse are best treated in the context of a clinical trial. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment options for relapsed or refractory MM include hematopoietic cell transplantation (HCT), a rechallenge of chemotherapeutic agents used previously, or a trial of new agents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients with relapsed or refractory MM who are eligible for HCT but did not undergo HCT as part of their initial treatment, we recommend high dose chemotherapy followed by autologous HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H12#H12\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Treatment of transplant candidates'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those patients who have already undergone autologous HCT, who have experienced a durable benefit with the first transplantation, treatment options include repeat autologous HCT or chemotherapy. Treatment of these patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H20#H20\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Treatment of relapse after HCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who relapse more than one year after chemotherapy will likely respond to a repeat course of the previous therapy. This is given to maximum response for up to one year of therapy, or until progression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Patients who are not transplant candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If relapse occurs less than one year after stopping the initial chemotherapy regimen or if",
"      <span class=\"nowrap\">",
"       relapse/resistance",
"      </span>",
"      occurs while on initial therapy, we suggest the administration of a regimen that is different from the one used initially (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The main treatment options for relapsed or refractory disease are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , alkylators, anthracyclines, and corticosteroids, administered alone, or more commonly as part of two or three drug combinations (eg,",
"      <span class=\"nowrap\">",
"       thalidomide/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"       ,",
"      </span>",
"      <span class=\"nowrap\">",
"       lenalidomide/dexamethasone,",
"      </span>",
"      <span class=\"nowrap\">",
"       bortezomib/dexamethasone,",
"      </span>",
"      <span class=\"nowrap\">",
"       bortezomib/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"        pegylated liposomal doxorubicin",
"       </a>",
"       ,",
"      </span>",
"      etc). These regimens form the major treatment options for relapsed or refractory disease, with selected patients undergoing autologous or allogeneic HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these agents is made based upon the therapies that the patient has already tried and side effect profiles. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      are both immunomodulatory derivatives (IMiDs). For patients who fail to respond to a regimen that contains one of these agents, we would initiate treatment with a regimen containing the proteasome inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      since it has a different mechanism of action. Patients treated with bortezomib have a higher incidence of herpes zoster. We suggest that antiviral prophylaxis be given to all patients receiving bortezomib therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg twice daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      500 mg once daily. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have progressed despite initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      therapy can be treated with a regimen containing either IMiD. The choice between these agents may be based upon the side effect profile. As an example, we would use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      based therapy for patients with a preexisting neuropathy because of the risk of neuropathy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      treatment.",
"     </li>",
"     <li>",
"      Patients whose disease progresses despite an IMiD and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      are candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22222487\">",
"       'Carfilzomib'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/1\">",
"      Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111:4908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/2\">",
"      Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/3\">",
"      Palumbo A, Bringhen S, Falco P, et al. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/4\">",
"      Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/5\">",
"      Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/6\">",
"      Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/7\">",
"      Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/8\">",
"      Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/9\">",
"      Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/10\">",
"      Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/11\">",
"      Jaslow R, Kaplan G, Lyons L, et al. Thalidomide in multiple myeloma--from the clinic to the laboratory. Cancer Invest 2002; 20:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/12\">",
"      Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/13\">",
"      Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/14\">",
"      Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/15\">",
"      Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/16\">",
"      van Rhee F, Dhodapkar M, Shaughnessy JD Jr, et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008; 112:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/17\">",
"      Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011; 118:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/18\">",
"      Guglielmelli T, Petrucci MT, Saglio G, Palumbo A. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. Br J Haematol 2011; 152:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/19\">",
"      Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/20\">",
"      Hus I, Dmoszynska A, Manko J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer 2004; 91:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/21\">",
"      Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/22\">",
"      Offidani M, Bringhen S, Corvatta L, et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 2007; 78:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/23\">",
"      Murakami H, Handa H, Abe M, et al. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 2007; 79:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/24\">",
"      von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008; 81:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/25\">",
"      Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/26\">",
"      Ciolli S, Leoni F, Casini C, et al. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008; 141:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/27\">",
"      Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/28\">",
"      Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98:3846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/29\">",
"      Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/30\">",
"      Hovenga S, Daenen SM, de Wolf JT, et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 2005; 84:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/31\">",
"      Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012; 30:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/32\">",
"      Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002; 13:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/33\">",
"      Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/34\">",
"      Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002; 112:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/35\">",
"      Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/36\">",
"      Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004; 125:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/37\">",
"      Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/38\">",
"      Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003; 48:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/39\">",
"      Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/40\">",
"      Zangari M, Tricot G, Zeldis J, et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) (abstract). Blood 2001; 98:775a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/41\">",
"      Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/42\">",
"      Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113:4137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/43\">",
"      Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/44\">",
"      Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/45\">",
"      Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/46\">",
"      Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/47\">",
"      Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112:4445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/48\">",
"      Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/49\">",
"      Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/50\">",
"      Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/51\">",
"      Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na&iuml;ve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/52\">",
"      Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/53\">",
"      Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/54\">",
"      Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/55\">",
"      Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/56\">",
"      Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer 2006; 106:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/57\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/58\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/59\">",
"      Dispenzieri A. Bortezomib for myeloma -- much ado about something. N Engl J Med 2005; 352:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/60\">",
"      Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 113:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/61\">",
"      Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/62\">",
"      Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/63\">",
"      Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/64\">",
"      Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/65\">",
"      Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/66\">",
"      Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/67\">",
"      Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/68\">",
"      Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) 2007; 21:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/69\">",
"      Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26:4777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/70\">",
"      Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/71\">",
"      Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 2009; 144:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/72\">",
"      Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology 2010; 79:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/73\">",
"      Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110:3557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/74\">",
"      Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008; 143:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/75\">",
"      Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008; 143:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/76\">",
"      Vogl DT, Stadtmauer EA, Richardson PG, et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol 2009; 147:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/77\">",
"      Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012; 97:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/78\">",
"      Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/79\">",
"      Romano A, Chiarenza A, Consoli U, et al. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Ann Oncol 2013; 24:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/80\">",
"      Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/81\">",
"      Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol 2006; 55:897.",
"     </a>",
"    </li>",
"    <li>",
"     Available at: &lt;www.fda.gov/cder/foi/label/2006/021602s010lbl.pdf&gt;. Accessed on December 15, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/83\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/84\">",
"      Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/85\">",
"      Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/86\">",
"      Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/87\">",
"      Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/88\">",
"      Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26:4784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/89\">",
"      Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/90\">",
"      Swaika A, Paulus A, Miller KC, et al. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 2012; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/91\">",
"      Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/92\">",
"      Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/93\">",
"      Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107:3492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/94\">",
"      Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007; 25:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/95\">",
"      Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/96\">",
"      San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008; 22:842.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/98\">",
"      Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/99\">",
"      Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/100\">",
"      Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120:1801.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf?et_cid=29661884&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f202714lbl.pdf (Accessed on July 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/102\">",
"      Kortuem KM, Stewart AK. Carfilzomib. Blood 2013; 121:893.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf?et_cid=31038989&amp;et_rid=463648356&amp;linkid=www.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f204026lbl.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/104\">",
"      Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27:5008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/105\">",
"      Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/106\">",
"      Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/107\">",
"      Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013; 121:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/108\">",
"      Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (abstract 450). Blood 2012; 120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/109\">",
"      Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013; 121:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/110\">",
"      Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/111\">",
"      Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/112\">",
"      Rajkumar SV, Gertz MA, Kyle RA, et al. Current therapy for multiple myeloma. Mayo Clin Proc 2002; 77:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/113\">",
"      Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005; 80:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/114\">",
"      van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010; 148:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/115\">",
"      Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012; 119:4608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/116\">",
"      Gertz MA, Garton JP, Greipp PR, et al. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/117\">",
"      Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011; 29:4243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/118\">",
"      Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/119\">",
"      Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/120\">",
"      Benson DM Jr, Byrd JC. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol 2012; 30:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/121\">",
"      Blad&eacute; J, de Larrea CF, Rosi&ntilde;ol L. Incorporating monoclonal antibodies into the therapy of multiple myeloma. J Clin Oncol 2012; 30:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/15/37114/abstract/122\">",
"      Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6661 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37114=[""].join("\n");
var outline_f36_15_37114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION OF SUSPECTED RELAPSE OR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transplant eligibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENTS WHO ARE TRANSPLANT CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12216861\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Toxicities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Use in renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Use in renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Use in hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22222487\">",
"      Carfilzomib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349206892\">",
"      Pomalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58772948\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/59/8123\" title=\"table 1\">",
"      Dose mod neurotox Velcade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_15_37115="Clinically important anaerobes";
var content_f36_15_37115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically important and most frequently isolated anaerobes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gram negative bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteroides fragilis group: B. fragilis, B. thetaiotaomicron, B. distasonis, B. ovatus, B. vulgatus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmented Prevotella (formerly Bacteroides): P. intermedia, P. melaninogenica, P. corporis, P. denticola, P. loescheii, P. nigrescens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevotella (other): P. bivia (formerly B. bivius), P. disiens (formerly B. disiens), P. oralis (formerly B. oralis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyromonas asaccharolytica (formerly B. asaccharolyticus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fusobacterium: F. nucleatum, F. necrophorum, F. varium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilophila: B. wadsworthia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gram positive cocci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptostreptococcus: P. intermedius, P. micros, P. anaerobius, P. magnus, P. asaccharolyticus, P. prevotii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gram positive, spore-forming bacilli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clostridium: C. perfringens, C. difficile, C. sporogenes, C. sordellii, C. septicum, C. tertium, C. ramosum, C. novyi, C. histolyticum, C. bifermentans, C. innocuum, C. tetani, C. botulinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gram positive, non-spore-forming bacilli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propionibacterium: P. acnes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eubacterium: E. lentum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bifidobacterium: B. dentium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinomyces: A. israelii, A. naeslundii, A. odontolyticus, A. viscosus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37115=[""].join("\n");
var outline_f36_15_37115=null;
var title_f36_15_37116="Bioterrorism agents by category";
var content_f36_15_37116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential bioterrorism agents by category",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category A agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variola major (smallpox)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacillus anthracis (anthrax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis (plague)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clostridium botulinum toxin (botulism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis (tularemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Filoviruses (Ebola, Marburg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arenaviruses (Lassa, Junin and related viruses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category B agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii (Q fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucella spp. (brucellosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burkholderia mallei (glanders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. pseudomallei (melioidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia psittaci (psittacosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsia prowazekii (typhus fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alphaviruses (eastern equine encephalitis, western equine encephalitis, Venezuelan equine encephalitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ricin toxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epsilon toxin of Clostridium perfringens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus enterotoxin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shigella dysenteriae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escherichia coli O157:H7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio cholerae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptosporidium parvum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nipah virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hantaviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tickborne hemorrhagic fever viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tickborne encephalitis viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yellow fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multidrug-resistant tuberculosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     The United States Centers for Disease Control and Prevention has ranked various pathogens into&nbsp;these categories based on their potential to cause harm.",
"     <br>",
"      Category A agents are the highest priority. They can cause high mortality, can be grown easily in large quantities, and are resistant to destruction. They are also well suited to airborne dissemination and can thus infect large numbers of people.",
"      <br>",
"       Category B agents are the second highest priority. They are moderately easy to spread but generally cause less morbidity and mortality than Category A agents.",
"       <br>",
"        Category C agents include pathogens that could be engineered for mass dissemination and have significant potential morbidity and/or mortality.",
"       </br>",
"      </br>",
"     </br>",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37116=[""].join("\n");
var outline_f36_15_37116=null;
var title_f36_15_37117="Survival retransplantation";
var content_f36_15_37117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    One year survival after retransplantation is related to the transplant interval",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A review of 514 patients who underwent retransplantation found that the one-year survival after retransplantation is significantly lower when the interval between the initial transplantation and retransplantation is &lt;2 years (60 percent versus 75 percent for an interval &gt;2 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Srivastava, R, Keck, BM, Bennett, LE, Hosenpud, JD. Transplantation 2000; 70:606.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37117=[""].join("\n");
var outline_f36_15_37117=null;
var title_f36_15_37118="Apical 4 chamber effusion";
var content_f36_15_37118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82153/Apical_4_chamb_eff_movie.mp4?title=Apical+4+chamber+effusion\" style=\"width:496px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber view showing pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip shows a pericardial effusion as seen from an apical four chamber view.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37118=[""].join("\n");
var outline_f36_15_37118=null;
var title_f36_15_37119="Absence of pus in LAD";
var content_f36_15_37119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Absence of pus in leukocyte adhesion deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The absence of pus formation at the sites of infection is a hallmark of leukocyte adhesion deficiency syndromes. This elbow lesion shows the effect of a profound impairment of leukocyte mobilization into extravascular sites of inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_15_37119=[""].join("\n");
var outline_f36_15_37119=null;
